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Summary 
 
Treatment improvements for childhood cancer have resulted in high survival but the ardor of 
therapy and care experiences, physically and emotionally affects parents and patients. 
Relationships with clinicians play an important role for supporting them in achieving 
improved outcomes. Communication is at the center of building trust and also ensuring 
understanding of information for permission for treatment, both an ethical and legal 
requirement. However, processes are many times reduced to exchanges rather than sharing of 
information and there are shortcomings in physician training in efficient and empathic 
communication. This work discusses communication in medical encounters during cancer 
treatment and explores the importance of microethics, the everyday actions and interactions, 
for improving understanding and information sharing. A model of exploration of illness and 
experiences is proposed for daily use in the clinic to remedy difficulties in diagnosis 
disclosure and decision-making. This model can facilitate later communication for poor 
prognosis and discussions on research participation and end-of-life care. 
The doctoral thesis starts with a general introduction on issues in cancer care, normative 
aspects of decision-making in pediatrics, ethical suggestions for patient participation and 
difficulties of implementation in clinical practice. Subsequent chapters draw from two studies 
conducted in Swiss and Romanian pediatric oncology units to address issues related to 
parental and physician experiences during communication and in involving children and 
adolescents in their care. 
Chapter I offers different perspectives on communication in pediatric oncology and identifies 
diagnosis disclosure and the involvement of patients as particularly challenging. Attention is 
paid to analyze physician practices in relation to ethical principles and to identify professional 
duties. 
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Chapter II explores decision-making processes and the inclusion of patients in care in 
Switzerland and Romania. It starts with a theoretical analysis of legal and ethical aspects of 
capacity and then moves to provide empirical data on how parents decide for their children 
and what contribution they, their children and physician can make in the process. 
Chapter III is a theoretical exploration of ethical justifications for the involvement of minor 
patients in research that does not aim to benefit the individual patient, but to provide 
generalizable knowledge. The first article of the chapter argues that patients can have group 
interests and therefore contribute to promoting them without seeking personal benefit. Then, a 
phenomenological theory of children as body-subjects further highlights ethical reasons for 
allowing non-beneficial research in pediatrics. A study exploring minor patients’ views on 
cancer care adds to the argument that research with children is necessary for improving health 
care outcomes. 
A last Chapter summarizes a literature review on end-of-life decision-making and discusses 
sensitive issues in communicating with patients at the end-of-life by affirming the importance 
of including children’s voices. 
The general discussion brings all empirical and theoretical findings together to analyze 
communication in pediatric cancer care and proposes a model of exploration (EMICPO) to 
improve outcomes for parents and patients. Further implications for clinical practice and 
future research are presented. 
Although the results of this work focus on difficulties and failures to appropriately 
communicate in cancer care, its broader goal is to offer reassurance that with the help of 
physicians and through increased awareness of parental and child experiences, families and 
patients can get through cancer. 
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Introduction 
 
Few illnesses evoke for patients and their families so many fears and different scenarios 
dominated by uncertainty as a cancer diagnosis1-3. Normal daily-life routines are disrupted for 
the whole tribe and the consequences of living through the cancer experience are long felt3-8. 
Different portrayals of cancer, its treatment and what meaning they have for patients and their 
families permeate social discourses. Rebecca Dresser talks about a “public picture of cancer 
[that] is incomplete”1, usually oscillating between openness about one’s own cancer journey 
in the public sphere and avoidance. Similarly, media representations and therefore society’s 
views of cancer are many times shaped around the “battling” and “fighting” images which 
convey that rather than being patients, people suffering from cancer are or will eventually 
become heroes, survivors1,2,9. These depictions may stand in stark contrast with feelings of 
being overwhelmed, the isolation and anguish patients and their loved ones experience3,10-13. 
Even more, cancer for many equates with a less hopeful image - that of a dying patient - and 
symptoms or even suspicion of cancer trigger heightened anxiety and existential 
questioning1,14,15. 
Childhood cancer is particularly difficult, as the diagnosis comes at a time when life is just 
beginning. It challenges parents to confront an existential crisis defined not only by their own 
fragility, but also their child’s and poses a threat to their parenting2,14,16,17. Physicians caring 
for children suffering from cancer have a unique position as they can offer patients and their 
parents information about the diagnosis and treatment and help them navigate what is 
happening. As such, clinicians themselves become part of families’ intimate journeys through 
cancer and time and time again have to handle the delicate ways of communicating distressing 
news and sustaining hope18-22. 
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The good, the bad and the ugly in childhood cancer 
 
Prognosis for children with cancer has continuously improved in the past decades and 
currently childhood cancer survival is at approximately 80%23,24. A majority of those 
diagnosed today will survive as a result of significant advances in research in adults and 
children25,26. The pediatric oncology practice has always been characterized by a strong 
interweave of standard care and clinical trials protocols27. Medical recommendation of 
treatment is focused primarily on the likelihood of cancer-directed therapy to cure children 
and improve survival28. However, with continuous efficacy improvements treatments 
protocols have also become more intense, combining various forms of therapies: 
chemotherapy, surgery and/or radiotherapy. Cancer treatment regimens add to illness’ burden 
inducing a large spectrum of physical and psycho-social symptoms - mucositis, dyspnea, 
drowsiness, lack of appetite, depression, anxiety and fear29,30. Therapy itself induces a great 
deal of pain and many patients report this to be worse than cancer related pain, thus causing 
significant distress31-33. Even after remission is achieved, those children and teenagers who 
enter the survivorship phase find themselves at risk of developing short and long-term 
complications or other illnesses, including secondary tumors, as a late treatment adverse-
effect34-37. All the complications experienced either during treatment or in remission affect the 
quality of life of children and adolescents. 
Parents share many of the pediatric patients’ burdens. They are usually the first informed 
about the cancer diagnosis38,39. This communication has a significant impact on them and 
their reaction is described in several studies as a “blow” that leaves them “breaking 
down”38,40. After receiving the diagnosis and due to their main role as caregivers 
accompanying children, parents endure significant stress and emotional burdens. This can 
take a toll on their psycho-social wellbeing and expose parents to a series of posttraumatic 
symptoms which may linger in the post-treatment years41,42. The presence of symptoms in 
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parents at diagnosis time raises questions regarding parents’ wellbeing, adequate ways of 
communicating distressing information to them and the circumstances parents face when 
making complex decisions for their children41,43. This can directly influence their abilities to 
involve children and emphasize their own dependency on physicians, but most importantly 
highlights struggles to support patients’ participation in care38,40,44. 
Childhood cancer is therefore a stressful and sometimes traumatic experience for both patients 
and their families. It puts patients and families under considerable pressure: invasive 
procedures, long hospitalization periods, various treatment side-effects, loss of control and 
social disturbances45-47. On this background, parents, physicians and patients have to make 
various decisions regarding children suffering from cancer and their care. 
 
Decision-making in pediatrics 
 
Decision-making processes in pediatric oncology are complex due to the general uncertainty 
that accompanies cancer treatment and outcomes, but also as a result of choices made 
available by combining research and care48-51. Traditionally, decision-making regarding 
healthcare for minor patients rests on the assumption of children’s incompetence, therefore 
their lack of mental capacities and abilities to reason about choices, especially those of a 
complex nature52,53. Based on this presumption, the responsibility of making decisions for 
children lies with physicians, who provide information and medical recommendations, and 
with parents, charged with giving permission for treatment and care54,55. In fulfilling their 
responsibilities, parents and physicians have to take into consideration two ethical standards: 
best interest and harm. The principle of best interest of the child is the prevailing standard in 
making decisions about the course of treatment and is used both by parents and clinicians in 
promoting patient’s welfare28,56,57. 
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Decision-making processes are also influenced by the triadic relationships and 
communication between parents, the medical team and the patient45,58-60. In acknowledgment 
of the child’s position in the triad and as a consequence of the evolving recognition of 
persons’ right to self-governance54,61, the role of minor patients in healthcare has been given 
more weigh28,62,63. As a result, decision-making in pediatrics is increasingly complex and the 
triad’s actors may contribute in different and intertwined ways to the process of deciding for 
oncological treatment and care59,60,64. 
 
Physician role in decision-making 
Collaboration with patients and parents is fundamental to making decisions28. Physicians’ 
primary role is that of a medical expert, who can establish a diagnosis, propose a course of 
action, and offer information on the illness and possible choices of treatment59,60. In this 
process, individual treatment and care recommendations are subjected to physicians’ 
professional and personal judgment and, in some cases, decisions by the physician are 
warranted prior to discussions with families28,56,57,63. Oncologists can make use of therapeutic 
privilege and select a course of therapy to propose to parents and families without presenting 
all treatment options60,65. Levine and colleagues66 argue that this action is justified when 
physicians’ own assessment promotes best interest and lowers risk of harm to the patient66. 
For example, in the case of young children with brain tumors responsible treatment would be 
to abstain from the option that may increase chances of survival but leave the patient with 
significant brain damage and opt for another option that has significant, although lower, 
survival chances, but avoids undue risk of excessive brain damage to patients66. 
Oncologists’ secondary role in decision-making is to support parents and children in their 
participation in healthcare. This duty is fulfilled by providing information in a manner that 
can be understood by parents and tailoring communication to patients’ abilities, according to 
mental and emotional maturity, and age. Physicians must also assess parents’ and patients’ 
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understanding and willingness to participate in the decision-making process28,56. In these 
assessments, physicians should also ensure that parents can engage in voluntary decision-
making, free from coercion or extreme influences that may be external (i.e. pressure from 
family) or internal (i.e. psycho-social)28,67. These elements of information, comprehensiveness 
and voluntariness are fundamental to obtaining informed consent28,67. 
 
Parental role in decision-making 
Parents are generally viewed as possessing high interests in promoting their children’s best 
interests due to the emotional ties within a family, the common goals and mutual 
commitments of pursuing the wellbeing of all within the group and adults’ self-assumed 
responsibility to care for minors68. Including in healthcare, parents’ role is crucial in caring 
for and protecting their offspring’s rights28. In most legislations patients who are minors, 
therefore do not fulfill the minimum age of maturity, usually 18 years old, are generally 
presumed incompetent to make informed decisions in healthcare56,69. However, they still 
preserve the same rights regarding treatment like all other patients, including the right to be 
informed and to consent, which are exercised for them by parents or legal representatives who 
providing permission for care28,69. 
Child’s best interest is not the sole foundation for the decision-making process, as children are 
part of a family in which interests are tightly linked68. When parents are in a position to make 
a decision for which the best interest of the ill child is not obvious, they may consider other 
competing interests, like the wellbeing of the family as a whole56. Ross68 argues for this 
constrained parental autonomy that is intrinsic to respecting intimate families’ rights, which 
should not be overruled easily54,68. In liberal societies, parents are usually given wide latitude 
in relation to their values and child-rearing choices and as long as their actions are not 
neglectful or abusive the same leeway should apply for healthcare decisions70. 
 18 
Parental decisional rights are respected pending that they do not conflict with the harm 
principle and, consequently, the decisions parents make do not lead to serious injury, risk of 
death, disability or pain for their child28,68,71. When the contrary situation occurs and after 
careful consideration of potential risks for all parties, physicians can take legal measures to 
overrule the need for parental authorization of treatment28. This is particularly the case when 
parents’ religious or spiritual beliefs are the justification behind decisions to reject treatment 
and therefore endanger the child’s life or bodily integrity71. Physicians’ role in these situations 
increases and they become advocates for children and their best interests, while protecting 
patients from considerable harms. This position also comes in consideration of children’s 
developing sense of self and of the fact that they may not share parents’ values or are 
incapable of forming and commit to such strong beliefs on their own71. 
 
Children’s and adolescents’ participation in care 
 
Children’s involvement in care, including participation in decision-making, can play a 
significant role in ensuring the delivery of best possible care. This step is attuned to increased 
recognition of respect for children’s developmental autonomy28,62,72,73, as well as growing 
evidence of promoting minor patients’ wellbeing by supporting them in building resilient 
mechanisms through participation in care management and decisions74-76. As such, various 
medical associations require physicians to pay attention to and respect individual needs when 
informing families and children about the cancer diagnosis28,39,62.  
Professional recommendations regarding initial communication with children state that 
diagnosis disclosure should take place without extensive delays, while trying to honor 
parental wishes on how to inform children. Special consideration for each patient’s mental 
and psychological state equally should determine how the communication of diagnosis 
discussion is carried out and the extent of the information provided39,62. Parental and 
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physician agreement and mutual understanding in fulfilling this task is essential for assuring 
patients. It also is meaningful for building trusting relationships between clinicians and 
families39,62. Providing information regarding the nature of the illness and therapy to children 
is indicated in view of the benefit of reducing their anxiety, but also with the purpose of 
obtaining assent and avoiding forcing treatment upon children28. The American Academy of 
Pediatrics28 similarly emphasizes the relationship that physicians need to build with patients 
in order to support their participation to the greatest extent that their wishes and capacities 
dictate. Involving and coaching children and adolescents to participate in their care from the 
diagnosis onward, might result in increased abilities to deal with later and more serious 
decisions77. Particularly for patients for whom treatment fails, involvement is recommended 
when addressing care goals and choosing a caring plan no longer aiming at curing the 
patient28. 
 
Normative aspects of participation 
Legislations in different countries contain diverse prescriptions regarding underage persons’ 
rights to decide for themselves. North American countries and many European states regulate 
decisions for persons who have not attained the age of maturity, usually set at 18 years, by 
giving parents authority over child and adolescent care68,78,79. There are several exceptions to 
these provisions based on the mature minor doctrine, recognized the United States (US) and 
the United Kingdom (UK), and also in consideration of minors’ best interests when it comes 
to accessing care for mental or reproductive health28,55,78. Seeking patient assent is permissible 
under such legal provisions, but minor patients’ rights are strictly limited. Refusal to provide 
assent or the expression of dissent is not binding for medical care that would be significant to 
patient welfare, but is valid in the context of research participation28. 
Several European countries, such as the Netherlands and the UK, have more permissive 
legislations concerning minors who demonstrate sufficient mental capacities to make 
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reasonable decisions80. In these countries the approach is to award authorization for treatment 
to parents and recognize different degrees of capacity in children. As a result, laws formally 
acknowledge the power of assent and the transition to a more active consent by adolescents, 
giving them rights to decide, together with their parents or by themselves78,81-83. Age limits 
and a mandate for physician assessment of decision-making capacities are usually the 
standards for granting children and adolescents the right to consent81. Higher age limits alone 
can sometimes be used to declare a presumption of adult-competency for older adolescents82. 
However, even in the case of adolescents with capacity, their decisions can be overruled if 
treatment is considered to be in their best interest78,83. Therefore, different legal provisions 
shape the way in which physicians interpret their duties to inform patients and their parents. 
 
Participation and communication in practice 
Despite significant changes in acknowledging minor patients’ claim to be involved in their 
own care28,73, participation in practice is difficult to achieve45,49,84-86. First, as described above, 
involvement of children is subjected to legal provisions regarding decision-making powers 
and authority in healthcare, which in many countries is assigned to parents56,81. Second, 
children and adolescents may sometimes be deemed to have clinical decision-making capacity 
for certain treatment or procedures, but not for others55,78. Such assessments should be 
performed by physicians, but procedures to establish whether children are capable of making 
medical choices are not standardized54,81. There is not enough evidence on how to 
meaningfully determine which children or adolescents have capacity and for what decisions 
and judgments are more likely to be influenced by clinicians’ intuition, be guided by legal 
standards of maturity and constrained by parental attitudes81,82. Communication between the 
parties therefore plays a major role in assessing minors’ abilities and also supporting them to 
participate in care decisions54,81,82. 
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Challenges in physician, parent and patient communication 
Ambiguity of ethical and legal imperatives on parental rights and authority to decide for 
children influences physician-patient open communication82,87. Despite guidelines 
encouraging clinicians to fully communicate with minor patients, there is insufficient 
guidance on how to achieve this while respecting their wishes and those of their parents39,65,88. 
Patients have individualized preferences and some require direct and truthful provision of 
information, while others seek selective knowledge40,45. Additionally, patient involvement is 
subjected to parental and physician influences which can be both restrictive and supportive. 
Several studies report the impact that parental fears have on shielding children from 
information44,45,89,90. Oncologists may perceive parents’ reaction and efforts to limit 
information as impeding them to freely communicate with children, but sometimes adopt 
similar attitudes towards parents when discussing prognosis20,91. Physician training, both 
formal and through observation of senior clinicians, is often limited and inadequate regarding 
communication and emotional management upon delivering difficult news92,93. Therefore, it is 
particularly challenging for physicians to individually assess for each patient how much to tell 
and when40,45. 
While it is believed that open communication with children and families is morally 
appropriate, evidence on benefits and harms of complete truthfulness with patients and on 
how it affects parents is limited94-96. Particularly at the first discussions about their child’s 
cancer diagnosis parents struggle to absorb information and experience fear while trying to 
define their caring roles and to protect children12,90. Open physician-patient communication 
can be at odds with parental wishes to be informed separately and to have time to navigate 
their own emotions before having to comfort their children38,96. Patient presence in 
discussions can lead to parents suppressing their own emotions in an attempt not to scare or 
confuse patients and does not create an opportunity for parents to prepare themselves for how 
to tell children. It can also act as a barrier to parent inquiries about what they perceive as 
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inappropriate to discuss with children40,96. Parents’ need of emotional support and empathic 
communication vary and can change in time if treatment fails43,90. Although, parents 
recognize that child presence can psychologically benefit patients by showing them respect, 
they prefer limiting patient participation in communication that alludes to cancer’s severity. 
Discussions about prognosis or risk of dying are distressful for parents and increase their fears 
of psychologically harming children40,90,97. 
Communication is subjected also to cultural influences that operate on several dimensions: 
families’ representations of cancer and views on death and dying, diversity of values and 
possible tensions between physicians’ and parents’ beliefs, perceived roles and hierarchies of 
physician-parent interactions, stereotyping and judgment of ethnic groups, language barriers98-
100. The role of cultural beliefs perhaps is most evident and its significance the more important 
when healthcare professionals commit to deliver care that is patient and family centered101. In 
situations when cure is no longer achievable, providing such care is highly needed by 
families. Caring when healing is no longer possible is dependent on how clinicians adapt 
communication to ensure the provision of effective and compassionate end-of-life services 
grounded in respect and sensitivity towards patient’s and families’ wishes is91,102. 
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Research gap 
 
Considering the different legal provisions among states and the difficulties physicians face in 
implementing ethical standards of open communication and patient involvement in cancer 
care little is known about clinical practices in different countries. It is unclear how both 
physicians and parents experience their own participation in decision-making and how fears 
and assumptions influence these processes. Also, there is no consensus on how children’s 
involvement should be achieved and how to balance parents’ and children’s needs of 
involvement. 
 
Study aims 
 
The goals of the doctoral study are enclosed into the main aims of the Attitudes and motives 
concerning end-of-life decisions: Competency and autonomy of children and adolescents in 
pediatric oncology, a prospective 3 years project funded by the Swiss National Science 
Foundation (SNSF), Switzerland (National Research Program 67 “End of Life”, No. 
406740_139283/1): 
• to explore the ways in which a child or adolecent living with cancer can be included 
in her care and decision-making processes 
• to examine physicians’ and parents’ associated motives and attitudes behind their 
actions to include patients or not. 
Given this overarching framework, the doctoral work focuses on investigating the challenges 
that parents and physicians face in communication, as well as in the involvement of and 
decision-making for children suffering from cancer on the background of different norms, 
and diverse institutional and cultural contexts. The doctoral thesis is structured in two parts: 
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(1) one is based on research study’s results regarding diagnosis disclosure and practical 
attitudes towards communication and patient participation, and (2) the other is a theoretical 
analysis of parent-physician communication with children and of patients’ inclusion in 
particular aspects of care: research participation and end-of-life. 
The empirical data will be used to explore ethical concepts of open communication, fears, 
participation roles in making collaborative decisions for children and adolescents suffering 
from cancer and their involvement during different stages of treatment. The theoretical 
analysis will explore different ways in which children can be included in difficult decisions, 
particularly end-of-life, and what ethical justification can be offered for the participation of 
children in research without direct benefits. 
 
Within this scope, the following research questions will be addressed: 
• What challenges do physicians and parents face when communicating the 
diagnosis of cancer to patients and how can physicians ethically address them? 
•  How does parental and physician communication and attitudes shape the 
involvement of children at different stages of cancer treatment? 
• How does participation and communication in decision-making takes place in 
countries with different norms? 
• What benefits and harms should be considered when limiting information 
provision to patients, particularly regarding diagnosis, prognosis and end-of-
life? 
• What ethically relevant elements should be considered when assigning 
decisional priority and authority in decision-making in pediatric oncology? 
• Can children’s participation in research with low or no direct benefits (i.e. 
phase 1 clinical trial for incurable cancer) be ethically justified? 
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Contributions 
 
The doctoral work is based on empirical and theoretical analysis that resulted in 11 
publications – six articles drawing from the qualitative data from the Swiss and Romanian 
studies, one literature review, and three theoretical articles and one commentary on 
contentious ethical issues in pediatric practice. Results of these publications have been made 
possible through collaborative efforts with members of the research team of the SNSF study 
in Switzerland, as well as with partnering physicians involved in enrollment and data 
collection. Individual contributions for each publication are detailed below, highlighting 
Domnita Oana Badarau’s work as PhD candidate. 
(1) Domnita O Badarau, Tenzin Wangmo, Katharina M Ruhe, Ingrid Miron, Anca 
Colita, Monica Dragomir, Jan Schildmann, Bernice S Elger (2015). Parents’ 
challenges and physicians’ tasks in disclosing cancer to children. A qualitative 
interview study and reflections on professional duties in pediatric oncology. Pediatric 
Blood & Cancer, 62(12):2177-2182 
The article was conceptualized by D Oana Badarau in collaboration with Jan Schildmann and 
Bernice Elger. Together with Jan Schildmann, D Oana Badarau refined the coding of the data 
that was carried by the first author together with Tenzin Wangmo and Katharina Ruhe. 
Doctors Colita, Miron and Dragomir facilitated data collection and helped with participant 
enrollment in the study. D Oana Badarau took the lead in writing the manuscript and 
coordinating all authors’ input. The manuscript was reviewed by Jan Schildmann before 
being sent for comments and approval of final version by all authors. 
(2) Domnita O Badarau, Eva De Clercq, Tenzin Wangmo, Monica Dragomir, Ingrid 
Miron, Thomas Kühne, Bernice S Elger (2016). Cancer care in Romania: challenges 
 32 
and pitfalls of children’s and adolescents’ multifaceted involvement. Journal of 
Medical Ethics, 42(12):757-761 
D Oana Badarau conceptualized this manuscript with Eva De Clercq. Data for this paper was 
coded by the first author and Tenzin Wangmo, and checked by Eva De Clercq. Ms. Badarau 
wrote the article and all authors reviewed, commented on her work and approved the final 
content for publication. 
(3) Katharina M Ruhe, Tenzin Wangmo, Eva De Clercq, Domnita O Badarau, Marc 
Ansari, Thomas Kühne, Felix Niggli, Bernice S Elger; Swiss Pediatric Oncology 
Group (2016). Putting patient participation into practice in pediatrics – Results from a 
qualitative study in pediatric oncology. European Journal of Pediatrics, 175(9):1147-
1155 
The article’s topic was developed by the SNF research team composed of Tenzin Wangmo, 
Katharina Ruhe, D Oana Badarau and Bernice Elger. Katharina Ruhe and Tenzin Wangmo 
took the lead and wrote the manuscript. D Oana Badarau supported enrollment and data 
collection for the study, co-developed a coding map for the initial analysis of data and read, 
commented, reviewed and approved the final manuscript. Bernice Elger, Thomas Kühne, 
Felix Niggli, and Tenzin Wangmo designed the SNF study from which the paper was 
developed. All co-authors provided input during the writing process, reviewed and approved 
the final manuscript. 
(4) Katharina M Ruhe, Tenzin Wangmo, Domnita O Badarau, Bernice S Elger, Felix 
Niggli (2015). Decision-making capacity of children and adolescents - suggestions for 
advancing the concept's implementation in pediatric healthcare. European Journal of 
Pediatrics, 174(6):775-782 
Katharina Ruhe, Tenzin Wangmo and D Oana Badarau developed the idea of the manuscript. 
Ms Badarau identified key issues in defining capacity and competency from a legal and 
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ethical perspective. Katharina Ruhe drafted the article. D O Badarau supported the 
development of the legal arguments and critique. Together with all other authors, D O 
Badarau reviewed several drafts and approved the final article. 
(5) Domnita O Badarau, Katharina M Ruhe, Thomas Kühne, Eva De Clercq, Anca 
Colita, Bernice S Elger, Tenzin Wangmo (2017). Decision-making in pediatric 
oncology: Views of parents and physicians in two European countries. AJOB 
Empirical Bioethics, 8(1):21-31 
The idea for this publication was developed within the goals of the SNF study as a joint work 
between D O Badarau, Katharina Ruhe, Tenzin Wangmo, Eva de Clercq and Bernice Elger. 
D O Badarau worked on developing the analysis and themes for the paper in collaboration 
with Tenzin Wangmo and with the support of Eva De Clercq and Katharina Ruhe for the 
Swiss data. Ms. Badarau wrote the manuscript which was enriched by authors’ input and 
comments. The final product of this work was approved by all authors. 
(6) Tenzin Wangmo, Katharina M Ruhe, Domnita O Badarau, Thomas Kühne, Felix 
Niggli, Bernice S Elger; Swiss Pediatric Oncology Group (2016). Parents’ and 
patients’ experiences with pediatric oncology care in Switzerland – Satisfaction and 
some hurdles. Swiss Medical Weekly, 146:w14309 
The idea for this article was developed by K Ruhe and T Wangmo who worked on the draft. 
D O Badarau contributed to the discussion section, read and provided critical input for the 
whole manuscript, as well as reviewed and approved the final version for submission. 
(7) Katharina M Ruhe, Domnita O Badarau, Pierluigi Brazzola, Heinz Hengartner, 
Bernice S Elger, Tenzin Wangmo; Swiss Pediatric Oncology Group (2016). 
Participation in pediatric oncology: Views of child and adolescent patients. 
Psychooncology, 25(9):1036-1042 
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For this publication the idea was developed by the joint effort of Katharina Ruhe, Tenzin 
Wangmo and D Oana Badarau. Ms. Ruhe took the lead in writing the article and D O 
Badarau read drafts of the manuscript and provided constructive comments for the analysis, 
results and discussion. The final work was reviewed and approved by all collaborators. 
(8) Domnita O Badarau, Rebecca L Nast and David M Shaw (2014): The Vulnerability 
of the Individual Benefit Argument. American Journal of Bioethics, 14(12):17-18 
For this article D O Badarau and Rebecca Nast worked together on conceptualizing a critical 
analysis in reply to an article on research ethics with vulnerable populations. Ms. Badarau 
drafted the paper and worked closely with Ms. Nast on improving its content. Ms. Nast 
reviewed several versions of the manuscript and produced the final article in collaboration 
with D O Badarau. The manuscript was reviewed by David Shaw who commented on it and 
also gave permission for submission of the final article. 
(9) Eva De Clercq, Domnita O Badarau, Katharina M Ruhe and Tenzin Wangmo 
(2015). Body matters: Rethinking the ethical acceptability of non-beneficial clinical 
research with children. Medicine, Health Care and Philosophy, 18(3):421-431 
The idea for this article was conceptualized by Eva De Clercq who developed it further with 
the help of all authors. Eva De Clercq took the lead in writing the manuscript and 
coordinating the review process of all authors. D O Badarau and other co-authors commented 
and critically reviewed the paper and approved the final article. 
(10) Katharina M Ruhe, Domnita O Badarau, Bernice S Elger and Tenzin Wangmo 
(2014): End-of-Life Decision Making in Pediatrics: Literature Review on Children's 
and Adolescents' Participation. AJOB Empirical Bioethics, 5(2):44-54 
The literature review resulted from the four authors’ collaboration on the idea for the article 
and design of the search strategy. K Ruhe carried out the literature search. D O Badarau and 
Tenzin Wangmo supported in the appraisal of resulting publications and deciding on their 
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exclusion or inclusion. D O Badarau was also involved in the synthesis of the final results 
together with the first and last authors. The final manuscript was edited and reviewed by all 
authors who approved the final article. 
(11)  Domnita O Badarau, Eva De Clercq, Bernice S Elger (2019). Continuous Deep 
Sedation and Euthanasia in Pediatrics. Does One Really Exclude the Other for 
Terminally Ill Patients? The Journal of Medicine and Philosophy, 44(1) 
The article was conceptualized by D O Badarau in collaboration with Eva De Clercq. D O 
Badarau wrote the article, which Eva De Clercq reviewed and revised. All co-authors 
commented on the final version of the article and approved it for publication. 
 
Study methodology 
 
The doctoral work is part of a larger project on decision-making, competency and autonomy 
of children in pediatric oncology care conducted in two European countries: Switzerland and 
Romania. The project is a multi-center research that employed both quantitative and 
qualitative methods for data collection in order to achieve a comprehensive image of 
decision-making processes for children and adolescents suffering from cancer. Participants 
included in the doctoral study were enrolled in the SNSF study. Primary investigators for this 
project are Prof. Bernice Elger, Dr. Thomas Kühne and Dr. Felix Niggli, who also designed 
the study together with Dr. Tenzin Wangmo. In Romania, participants were recruited as part 
of the doctoral study funded by the Botnar Stiftung and the Hemmi Stiftung, Basel. 
Two countries with different normative systems in relation to children’s recognized right to 
participate in or be in charge of healthcare decision-making were selected for the purposes of 
the doctoral study. Swiss civil law does not make a distinction between patients’ right to 
consent to treatment based on age, but on mental capacities. As such, minor patients who can 
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be proven competent should be awarded the same authority to consent to treatment as 
competent adult patients1. In Romania, parents generally have the right to make decisions for 
their children, as long as they are not emancipated. Parental permission and for adolescent 
patient’s assent are customary. However, a refusal can be overruled if treatment is considered 
to be in the child's best interest2-4. 
Data from proxies and physicians caring for minor patients diagnosed with cancer was 
collected from eight of the nine independent units of the Swiss Pediatric Oncology Group and 
from three university-affiliated pediatric oncology centers in Romania. Among the 
participating centers in Switzerland, four are at university pediatric clinics and four are units 
within the cantonal pediatric hospitals. Participants were recruited from all Swiss regions, 
French, German and Italian speaking. Proxies and physicians in Romania were recruited from 
two distinct country regions where children from all over the country are treated for either 
solid tumors or oncological/hematological illnesses. For the purposes of the doctoral thesis 
only data obtained from qualitative interviews with proxies and pediatric oncologists in 
Switzerland and Romania will be presented and serve as the basis for the concluding 
discussion. 
 
Data Collection  
 
In Switzerland data collection started in August 2012 and concluded in April 2015, while in 
Romania it began in October 2012 and ended in August 2014. During these periods 
interviews and surveys were administered to physicians and proxies in Romania and 
Switzerland. Interviews with children were carried only in Switzerland as part of the SNSF 
study. 
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Qualitative methods 
Qualitative one-on-one, in-depth interviews were used to explore the experiences of parents 
and oncologists when caring and making decisions related to the care of children suffering 
from cancer. It was also investigated if and how children (8 to 17 years old) can be included 
in decisions related to their care. A qualitative study design is most suited for exploring 
sensitive topics and seizing genuine participant experiences5,6. A total of 37 patient cases, 18 
in Romania and 19 in Switzerland were discussed with proxies and physicians. The 63 
interviews were conducted with the patients’ proxies (n=37) and their treating physicians 
(n=26), 10 in Romania and 16 in Switzerland.  Five physicians in each country discussed 
more than 1 patient case. 
In Switzerland, interviews were also conducted with 17 minor patients as part of the SNSF 
study’s aims and methodology. These interviews will be used for the purposes of the doctoral 
thesis as part of a theoretical exploration of children’s involvement in research. 
 
Quantitative methods 
Interview participants were also asked to fill in one cross-sectional survey to collect 
demographic information about parents, physicians and patient medical data about diagnosis, 
prognosis, treatment. This data was used for the purposes of describing the characteristics of 
the participant sample in study publications.  
Aditionally, as part of the SNSF project, cross-sectional surveys (n=229) gathering 
demographic data, diagnosis and treatment information, as well as attitudes and preferences 
for decision-making were completed by physicians and parents in Switzerland.  In Romania, 
63 surveys were completed as part of a pilot project on decision-making.  
 
 38 
Research ethics approvals 
 
Ethics approval was obtained from the responsible Ethics Committees (EKs) in each of the 
eight participating states (cantons) in Switzerland and from each Research Ethics Committee 
(REC) in place at the 3 collaborating pediatric centers in Romania. 
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‘Les grandes personnes ne 
comprennent jamais rien toutes seules, 
et c’est fatigant, pour les enfants, de 
toujours et toujours leur donner des 
explications….’ 
 
(Antoine de Saint-Exupéry, Le petit prince)1  
Chapter I 
 
Perspectives on communication challenges in 
pediatric cancer care 
  
  
                                                          
1Antoine de Saint-Exupéry. Le petit prince. Évreux (Eure), France; Folio, Kapp Graphic; 
2015, p. 14. 
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Abstract 
 
Background 
Professional guidelines encourage physicians to provide children with as much information 
regarding their health as deemed developmentally and emotionally appropriate. However, 
empirical research indicates that in clinical practice, an open discussion with children about 
cancer is often lacking. This study explores impeding factors to and possible strategies for 
open communication of cancer diagnosis to children from the perspectives of parents and 
physicians. 
Procedure 
Semi-structured interviews were conducted with 18 parents of children with cancer and 10 
treating oncologists. The patient sample was obtained from three pediatric units in Romania. 
Interviews were transcribed verbatim and interpreted using thematic analysis. Inductive open-
coding procedures identified participants’ accounts regarding their experiences with cancer 
diagnosis and treatment. Final themes were selected by grouping codes that formed a pattern 
in the data. 
Results 
An interplay of mainly three different factors – information overload and emotional turmoil, 
lack of knowledge and skills for disclosing the diagnosis, and assumptions about burdening 
the child when discussing cancer – restricted parent-patient communication and subsequently 
affected physician-patient exchanges. Oncologists recommended open communication at 
diagnosis, but left the final decision to the parents. They adapted their communication style 
with patients to parents’ preference. 
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Conclusions 
Although physicians need to respect the wishes of children’s legal representatives, they also 
have a duty to promote patients’ best interests. We recommend that physicians employ a 
proactive stance in ensuring that children with cancer are appropriately informed about their 
diagnosis. In case of parents’ arduous objections to full disclosure, an ethical consultation 
should be considered. 
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Introduction 
Professional guidelines recommend that communication of diagnosis for children with cancer 
should be conducted in a planned manner, and include both the patient and the parents. 
Physicians are encouraged to provide children with as much information as deemed 
developmentally and emotionally appropriate. At the same time, communication should take 
into account parental wishes1-5. The recommendations on communication of diagnosis to 
minor patients are supported by a growing research body evidencing the positive outcomes of 
communication with children and adolescents. Quantitative and qualitative studies show that 
children who are informed gain a sense of control that not only reduces anxiety and facilitates 
treatment, but also helps them understand their illness6-8. However, these studies were 
conducted in different settings, such as emergency department, surgery, infectious diseases, 
and oncology, and not all included children with life-threatening illnesses. There is a lack of 
studies capturing the benefits of open communication for children with cancer. One study 
found that children wished to be informed to different degrees, with some wanting to know 
the bare minimum6. In another study, although parents recognized the advantages of open 
communication, they expressed difficulties with child’s presence particularly when sensitive 
information, such as prognosis, was discussed9. 
Empirical studies on the practice of communicating diagnosis of cancer with children indicate 
that there often is a considerable gap between recommended and actual practice. Parental 
control on both the content and completeness of information provided to children and the 
desire to protect them from distressing news have been identified as contributing factors to 
this gap8,10-15. However, there is scarcity of research on how to deal with situations in which 
physicians’ open approach to diagnosis communication conflicts with parental behavior 
aimed at avoiding direct communication. 
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This study provides a detailed reconstruction of the communication of cancer diagnosis to 
children in Romania by means of semi-structured interviews with their proxies and treating 
oncologists. The focus of the analysis is on the identification of factors that contribute to 
restricted provision of information about diagnosis to children. Based on the empirical 
findings, we discuss potential strategies and professional duties to reach an open 
communication with children with cancer in cases when parents oppose disclosure. 
 
Methods 
Conducted in Romania, the study is part of a larger project on children’s participation and 
decision-making in pediatric oncology. It is based on semi-structured interviews carried out 
with physicians and parents of minor patients diagnosed with cancer and undergoing 
treatment in three university-affiliated pediatric centers. We used purposive strategy to 
sample participants16 based on the following criteria: they are the parents or treating 
physician of a minor patient aged 8-18 years receiving cancer treatment at one of the study 
centers. When parents were not the main caregivers, the proxies accompanying patients were 
approached. The treating physicians selected patient cases fulfilling the criteria. Proxies 
judged by physicians unsuitable for enrollment due to child’s delicate situation or burdening 
psychosocial difficulties were excluded. In total, 21 proxies were introduced to the researcher 
for a detailed discussion about the study’s goals and procedures and from these, 18 
participated in the study. Researchers also invited the treating physician for each 
corresponding patient case to be interviewed. Proxies’ and physicians’ characteristics are 
described in detail in Table I. Participant recruitment was carried out between May and 
October 2013, and all interviews were conducted in person at a time deemed convenient by 
each participant. Informed consent was obtained from all participants. The study received 
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approval from the Ethics Committee at the researchers’ institution in Switzerland and the 
institutional Ethics Committees at every study center. 
 
Table I. Characteristics of proxies and physicians 
 
Proxies (n=18) 
Male 1 
Female 17 
Agea 
34-39 7 
40-45 4 
> 46 5 
NA 2 
Months since child’s diagnosis 
0-6 8 
6-12 8 
> 12 2 
Physicians (n=10) 
Age 
30-39 3 
40-45 3 
≥46 4 
Experience (years)  
0-4 1 
5-12 5 
>12 4 
a Data missing for two proxies 
 
Interview questions were semi-structured according to protocol in three categories (Fig. 1) 
and allowed participants to freely describe their experiences. Whenever necessary, the 
interviewer asked prompting questions to explore topics generated by participants17,18. 
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Fig. 1. Interview topics 
All interviews were analyzed using thematic analysis19 to identify and select accounts 
reported by participants when talking about their experiences of caring for a child with 
cancer. In a preparatory phase, three researchers (D.O.B., T.W., and K.R.) forming the core 
research team and trained in qualitative research methods used inductive open coding for a 
sample of three interviews. This initial coding was done independently and codes were 
compared and discussed among the team until consensus on a systematic coding scheme was 
reached19. All interviews were then analyzed inductively following this coding scheme. For 
any emerging issues described by participants, new codes were added. Thereafter, codes 
identified to form a pattern were grouped under specific themes that were discussed within 
the research group. Finally, we selected specific themes relating to the communication of 
diagnosis topic. The selected themes and coded extracts of data pertaining to these were 
reviewed together with an independent researcher familiarized with the interview data (J.S.) 
 
Protocol topics 
• Experiences with diagnosis and 
treatment 
• Communication and decision-
making 
• Patient participation 
• General attitudes towards child 
involvement in health care 
 
• Meaning of cancer 
• Patient’s experience with 
illness 
• Hopes and spirituality 
Interview generated 
topics 
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and further refined. We discuss the product of this final analysis in the Results section and 
provide typical quotes from the original interviews as illustration. 
 
Table II. Patient information 
 
ICCC-3 main classification diagnosisa 
 
Patientb 
Age 
groupc 
 
Sex 
I Leukemias Chris 
Cody Ray 
Aaron 
Bruce 
Melissa 
I 
I 
II 
III 
I 
M 
M 
M 
M 
F 
II Lymphomas Anthony 
John 
III 
III 
M 
M 
III CNS and miscellaneous intracranial 
and intraspinal neoplasms 
Tracy 
Celine 
Carrie 
Harry 
Rick 
Sawyer 
I 
II 
II 
I 
II 
II 
F 
F 
F 
M 
M 
M 
IX Soft tissue and other extraosseous 
sarcomas 
James 
Tyler 
I 
III 
M 
M 
X Germ cell tumors Desiree I F 
XI Other malignant epithelial 
neoplasms and malignant 
melanomas 
Steven 
Lisa 
II 
III 
M 
F 
M, male; F, female;  
aInternational Classification of Childhood Cancer, Third Edition (ICCC-3). 
http://seer.cancer.gov/iccc/iccc3.html; 
bAll patients have been assigned a false name following the data anonymization process; 
cAge group I  (8-12 years), age group II  (13-15 years), age group III (>16 years). 
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Results 
In total, 28 interviews were conducted with proxies and physicians of 18 patients aged 
between 8 and 18 years. Patient characteristics are described in detail in Table II. From the 21 
proxies approached, one mother declined participation, two others were not available for 
interviewing due to patient’s condition, and 18 consented to participation. The participants in 
the proxies group included 14 mothers, one father, and three grandmothers. All 10 physicians 
approached and caring for those 18 patients participated, with five physicians being 
interviewed for more than one patient. Twenty-four interviews were recorded and for three, 
the interviewees (all proxies) declined the use of audio devices. One more interview was 
partially recorded as the participant was overwhelmed by emotions. To allow the participant 
to recompose, the researcher stopped the device and out of sensitivity, when the participant 
continued to tell about her experience, did not restart it. Recorded interviews were translated 
and transcribed in English. Detailed notes were taken for the interviews that had not been 
(completely) recorded. On average, interviews with parents were 53 min long (range: 25 min- 
1 hr and 20 min), whereas physician interviews lasted around 50 min (range: 26 min- 2 hr and 
3 min). 
Based on our analysis, the common model of initial communication of diagnosis was a 
discussion between parents and physician only. According to physicians, this discussion was 
usually well planned with the aim to explain the diagnosis and following procedures. 
Physicians perceived this discussion as a starting point for a process of communication about 
disease, prognosis, and treatment options and also as a means to get to know the family. 
 
Desiree’s physician: ‘[…] First we talk with the parents, with the surrogates, 
who are accompanying them. […] Afterwards, with time...ahhh...you cannot 
know, neither the surrogates, nor the child from just one talk. Usually you 
Chapter I: Perspectives on communication challenges in pediatric cancer care 
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know them along the way. You know them, their character, temper, this 
psychological side.’ (Patient age 11) 
 
Factors limiting communication about diagnosis between parents and children 
The narratives of parents about the time subsequent to the first discussion with the physician 
indicate that some parents took a proactive role in informing their children about their 
disease. However, several parents reported that they did not or only partially inform their 
children about the disease. One factor reported by parents as contributing to a restricted or 
lack of communication with their child was information overload and emotional turmoil. 
Communicating the diagnosis to their children was broken down to several continuous, 
unstructured stages. Parents reported explaining the illness at first and gradually starting to 
provide more specific information, such as naming it and filling in the blanks for their 
children (Quotes 1 and 2 in Table III). 
Parents identified lack of knowledge or inexperience with the medical setting to be another 
inhibitor to open discussions with children. These parents described being unsure about how 
to have such a first talk with their child and feeling unprepared for discussing the cancer 
diagnosis (Quote 3 in Table III). 
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A third factor identified as a barrier toward discussing the diagnosis was the assumptions that 
communication about the disease would be a burden to the child. Some parents expressed 
incapacity to fully reveal the diagnosis due to uncertainty regarding how children’s attitudes 
toward the illness might change. Others anticipated an emotional harm whose impact they 
found difficult to assess or control. In part, these expectations were influenced by the fact that 
parents (and patients) had been in close contact with (other) family members suffering from 
cancer. Particularly, parents feared addressing the life-threatening nature of the illness. They 
did not want children to make a connection between their diagnosis and the possibility of 
dying from it (Quotes 4 and 5 in Table III). 
 
Physicians’ perceptions and strategies in cases of lack of open communication 
Interviews with treating physicians revealed that they were often aware of the state of 
communication between parents and children and respective deficits. In such cases, some 
physicians reported that they had recommended an open communication. However, 
physicians mentioned that they did not directly interfere in the communication within the 
family and left to the parents the control over whether they disclosed the diagnosis to patients 
(Quotes 6 and 7 in Table IV). 
However, in cases where parents did not openly communicate the diagnosis to their children 
physicians said they talked to the patients themselves. They described several communication 
strategies when discussing directly with the child. One of these strategies was to stay focused 
on factual medical information in talking to the patient, while maintaining an “air of 
optimism” (Quote 8 in Table IV). 
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Physicians perceived parental approach to limit communication as problematic. As legal 
requirements in Romania give parents authority over healthcare decisions for their minor 
children, physicians perceived a conflict between the responsibility to inform patients 
truthfully and the desire of parents to withhold information. As a consequence, most 
physicians reported to adopt a non-direct and passive disclosure strategy. Several physicians 
said they preferred to only react to patient inquiries and explicit concerns. Their descriptions 
of how they would react if directly confronted by patients to answer the diagnosis question 
showed clearly that they were unwilling to deceive (Quote 9 in Table IV). 
 
Discussion 
Communication of diagnosis in pediatric oncology is a complex process determined by 
triadic influences on the direction and depth of communication14,20. Our study has the 
advantage of confronting both parents’ and physicians’ views on disclosing the diagnosis of 
cancer to children. The qualitative design of the study facilitated obtaining in depth 
information on factors hindering parents from open communication with their child and 
physicians’ reluctance to intervene in such situations. This provides new insights into 
diagnosis disclosure practices and points to strategies for facilitating an open communication 
with patients. In the discussion, we use these empirical findings to explore feasible 
procedures to improve communication of cancer diagnosis and professional duties in cases of 
lack of open discussions between parents and children. 
Our research indicates that an interplay of mainly three different factors – (1) information 
overload and emotional turmoil, (2) lack of knowledge and skills with disclosing the 
diagnosis, and (3) assumptions about burdening the child when discussing cancer - 
contributes to restricted communication between parents and children. Parents of children 
diagnosed with cancer consider the presence of minors in discussions of diagnosis 
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problematic9 and sometimes resist disclosing the illness to their children8,20,21. Our study 
shows that, in spite of cultural differences, these attitudes are more likely to be affect-driven 
(1). It may come as a natural parental response to a life-threatening situation that physicians 
should be aware of. Participants in both groups acknowledged the great impact emotions had 
on communication of diagnosis, as well as on the content of information provided to children. 
The more troubled the parents were, the more difficult it was for them and physicians to give 
the patient complete diagnosis related explanations. An inclination toward limited sharing of 
information may be stronger at the time of diagnosis and shortly afterwards. Similar to a 
study conducted only with parents9, participants reported the struggles proxies faced and their 
avoidance of discussing the life-threatening aspect of the illness. However, in our study, 
informing patients about side-effects was not as problematic, as physicians would take the 
lead and support proxies in explaining and re-assuring patients. 
At the same time, this study suggests that physicians need to be trained on how to explore 
different reasons that prevent parents from communicating openly and to select appropriate 
strategies. In this respect, physicians need to know for example how to deal with parents’ 
information overload and emotional turmoil. Proxies in our study reported an acute need to 
be listened to and to have several detailed illness related discussions with physicians at the 
time of diagnosis. Although this need was identified by oncologists in most cases, they felt 
pressured by lack of time. They considered a solution the advice they provided to parents to 
be open with children about the illness. 
Other studies10,22,23 have shown that in some cases, it may be sufficient to let time pass to 
allow parents to cope with the cancer diagnosis and enable them subsequently to speak 
openly to their children. In other cases, additional information for parents on the adverse 
outcomes of limiting information or consultation with a member of the psychosocial team 
may be required. Furthermore, physicians have to understand that it is normal that parents 
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lack skills to communicate a life-threatening diagnosis (2) and they routinely need help. 
Although in some countries, large medical centers have a communication of diagnosis 
protocol requiring multidisciplinary support (usually a social worker, nurse, psychologist) for 
parents and children for the initial discussion sessions24-26, this is not the standard in many 
countries and even not for all institutions in countries with well-developed healthcare 
services. Communication of diagnosis is not always conducted by a multidisciplinary 
team10,22,27 and it may happen during routine check-ups, in the emergency, or surgery 
department10. This was the case for the oncology units where our study was carried. Child 
psychologists to whom patients can be referred were present, but a coordinated care system 
lacked. A multi-professional team with specialist nurses and psychosocial trained members to 
support parents were not in place in these institutions. However, volunteering social workers 
were present at all participating sites and psychosocial care offered by social workers was 
available on specific week days. These services were offered through a large national 
privately funded charity (P.A.V.E.L. Association)28. At the same time, it should be 
acknowledged that parents vary in their preferences regarding who should be present for the 
communication of diagnosis25. 
Physicians, nurses, or even other parents with similar experiences can provide support by 
suggesting “how” to discuss bad news with a child, particularly when there is no 
multidisciplinary team approach. After all, this is a difficult task also for professionals29-31 
and it seems likely that elements of open communication can be learnt more efficiently by 
parents with healthcare professionals’ aid27,32. Physicians also need to be aware that reported 
anticipation of possible harm to the child (3) requires them to further explore parents’ 
reasons. Physicians should routinely discuss with parents the benefits and harms of an open 
versus restricted parent-child or physician-patient communication. During the communication 
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of diagnosis discussion with parents and subsequent encounters, physicians could offer to 
disclose information to children together with parents. 
Our study also clearly points out a need for further training of physicians with regard to 
ethical and legal issues involved in (non-)disclosure of cancer diagnosis to children. One such 
tool for training is the Oncotalk33, a teaching module to improve communication skills. This 
is freely available online (http://depts.washington.edu/oncotalk/) and can be a great source of 
developing skills for breaking bad news. It is available only in English, which may 
sometimes be a barrier for some healthcare professionals in different countries. In our study, 
data indicate that physicians do not actively engage with or sufficiently support parents who 
repeatedly object direct communication to carry out more open discussions with their child. 
Using the Oncotalk tool, which includes a module on teaching family conferences, may help 
overcome this. Moreover, physicians in our sample seem to be wary of what is the most 
appropriate way to deal with legal provisions that entitle the child’s proxy to set the tone for 
physician-patient discussions. Balancing this requirement with patient’s best interest when it 
may go against parents’ wishes is a delicate issue. Physicians’ reluctance to challenge parents 
may be tied to considerations for the deep bond parent and child share, but also to 
apprehension of litigation34. Accordingly, the question from a professional and legal point of 
view is what should physicians be expected to do in situations when there is no open 
discussion with the child about cancer? Although legal aspects with regard to parental rights 
must be considered2,21,35,36, we argue that physicians underplay their duties to act in the best 
interest of children, as studies show a beneficial effect of information on some children and 
negative effects for lack thereof in others6,7. From an ethical perspective, such circumstances 
demand a proactive stance on the physicians’ side to elicit patients’ own preferences 
regarding information provision, which can be defensible even from a legal point of view35. 
Although it is beyond this article to provide a concrete operating procedure, we suggest that a 
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first step is to schedule regular follow-up meetings with parents to discuss the state of 
information between parents and children. Furthermore, these discussions between physicians 
and parents should include an exploration of possible factors contributing to parents filtering 
information or employing avoidance techniques when discussing disease and treatment with 
their children. Identifying hindering factors leads to a better understanding of parents’ 
attitudes. At the same time, it provides physicians with an opportunity to address them and to 
point out the potential harms, such as isolation and anxiety, that children face due to lack of 
clear communication6,7. It is important that physicians remain understanding toward parental 
attitudes and avoid coercion. Instead, they should employ techniques for encouraging and 
supporting parents in open communication to children21,35,37. In cases when even a repeated 
proactive approach by physicians and the intervention of psychological support fails to 
produce an open communication with the child patient, we suggest to use ethical case 
consultations or comparable interventions. This intervention should be sought primarily when 
resources within the team are not sufficient to deal with the situation at stake. As such, it is 
rather complementary and its focus should include context sensitive analysis of all clinical, 
personal and ethical issues in question. Additionally, it should involve and engage with all 
members of the medical team and family. 
 
Limitations 
There are a few limitations with regard to this research. First, this study was conducted in 
three Romanian centers, and therefore findings should be interpreted against the background 
of cultural and center-specific organizational factors. However, there is no reason to believe 
that the included centers have unique characteristics or adopt special attitudes as compared to 
other centers in Romania. Although our data were collected in one country, as pointed out in 
the discussion, we identified a number of characteristics of communication between parents, 
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children with cancer, and physicians that seem rather typical for the clinical pediatric 
oncology setting and go beyond the selected country and cancer centers. A second limitation 
is that we recorded participants’ experiences within different lengths of time from diagnosis. 
Re-call bias may have influenced participants’ accounts. Interviewees’ answers may have 
also been biased by social desirability. However, in light of the honest accounts of partial 
disclosures of diagnosis information to patients as reported by both participant groups, this 
bias seems to be modest. A bias may be also caused by the selection process as we relied on 
collaborating physicians’ interest in the study’s topic and their drafting of patient cases. 
Finally, although the design of our study allowed matching the narratives of parents and 
physicians, we did not elicit the perceptions and views of the children themselves. Therefore, 
research which includes patients’ perspectives may yield further information that is relevant 
to guide parents and clinicians with regard to communication with minor patients about 
cancer. 
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Abstract 
 
Communication about diagnosis and medical treatment for children suffering from life-
threatening illnesses is complex. It is a primary step in involving underage patients and 
families in care and lays the foundation for obtaining parental permission and patient assent 
for treatment. In practice child participation in care is often difficult to obtain due to patients’ 
different and sometimes fluctuating preferences, but also parents’ protective strategies. 
Physicians may be susceptible to parental wishes to limit information and feel uncomfortable 
discussing issues related to uncertainty of cure with patients. A qualitative study in Romanian 
pediatric oncology units was conducted to explore children’s involvement from the 
perspectives of parents and oncologists. Interviews with participants discussed 18 patient 
cases. Data were transcribed and thematic analysis was used to interpret and mine patients’ 
involvement during treatment. Different facets of patient participation were identified: 
restricting, widening and enhancing involvement. A fourth category, unintentional 
involvement, occurred for all patients due to children’s observations during long-term 
hospitalizations and access to Internet. Uncertainty overarched parental attitudes regarding 
the extent to which children should be included. Physicians usually complied with parental 
wishes to limit involvement, but together with parents involved patients at least in a practical 
way. Adults’ protective attitude may backfire, as adolescents’ online searches often expose 
patients to worse-case scenarios. Further research should acknowledge the hazards of 
restricted diagnosis disclosure and develop clinician tools to support families in 
communicating with patients. This should be paralleled by physician efforts to elicit patients’ 
needs regarding participation. 
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Introduction 
Provision of information is a fundamental step towards shared decision making. It enables 
minor patients and families to frame personal values when making decisions1. 
Communication is a complex process and studies report that children wish to know what is 
happening to them and for clinicians to listen to their preferences2-4. Some patients prefer to 
know only certain aspects, to receive information from their parents or to leave decisions up 
to adults3. The process is further complicated by parents’ reaction to diagnosis and inclination 
to protect children from distressing news5,6. Most physicians consider it disrespectful to 
withhold information, but may comply with parental restrictions7. 
This study is part of a project conducted in Swiss and Romanian pediatric departments. It 
explores the complex process of involving patients with cancer in their care from the 
perspectives of oncologists and parents in Romania. It analyzes how adults act either to limit 
or support patient participation by evaluating the impact of these actions on childreni. 
 
Methods 
Semi-structured interviews were conducted with proxies and treating physicians of patients 
aged 8-17 receiving treatment at collaborating centers in Romania. Interviews with children 
were conducted only in Switzerland and are reported elsewhere8. We employed purposive 
sampling9 to enroll 28 non-representative participants between May and October 2013 
(Figure 1). The study was approved by the ethics committee at the researchers’ home 
institution in Switzerland and institutional ethics committees at Romanian participating 
centers. Informed consent was obtained from all participants. 
 
                                                          
i When used in text, the word child is meant to represent all minor patients, including 
adolescents, unless otherwise specified. 
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Figure 1 Participant recruitment procedure  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Proxies - parents or caregivers with legal power. Three patients were accompanied by 
grandmothers acting as proxies and in charge of care; all other 15 interviews were with 
parents. 
2 3 proxies declined participation due to child’s advanced illness or disinterest in the study’s 
topic. 
Physicians at 3 pediatric oncology centers identify patients 
undergoing cancer treatment 
Introduce parents/grandmothers interested in 
the study to the researcher 
Interview date – the researcher obtains 
informed consent from proxies (N=18)2 and 
treating physicians (N=10) 
 
Physicians approach proxies1 caring for 
a child or adolescent ages 8 -17 
Researcher explains study and schedules 
separate, in person interview with proxies 
(N=21) and treating physicians (N=10) 
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Interviews were recorded, transcribed and thematic analysis was applied for all datasets8 by 
identifying codes that formed a pattern and  organizing them in major themes synthesizing 
participants’ experiences10. 
 
Results 
Eighteen proxies and 10 physicians of 18 patients participated in the study8. Parents’ and 
physicians’ attitudes contributed to the pace of involvement which can be construed by four 
themes: restricting, unintentional, widening and enhancing involvement. The unintentional 
category applied to all patients. Children either passed through all involvement stages, from 
restricting to enhancing, remained in the restricted and unintentional categories or started 
from limited involvement at diagnosis and leapt into the widening or enhancing phase. 
 
Restricting involvement 
Many physicians reported that at diagnosis time they often refrain from disclosing the exact 
nature of the illness to patients due to uncertainty about parents’ preferences on how much 
children should know. Clinicians found it challenging disrespecting parents’ attitudes on 
information provision and accepted to restrict involvement at parents’ request. This impacted 
the timing and depth of some patients’ involvement and limited information provided at 
diagnosis and shortly afterwards. (Quotes 1 and 2 in Table 1) 
Parents requested partial disclosure because of fear that the word “cancer”, usually associated 
with dying, would have a negative impact on their child’s willingness to fight. (Quote 3 in 
Table 1) Retrospectively, parents regretted and recognized that they cannot shield children 
from all distressing information and the steps they took may not entirely control what 
children, particularly teenagers learnt about the illness. (Quote 4 in Table 1) 
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Unintentional involvement 
Despite desires to control the pace of information provision, parents could not buffer the 
outside world or prevent children from seeking information from other sources, such as 
conversations on the ward and the Internet. Both parents and physicians were aware that 
parental boundaries on children’s knowledge about their illness were fragile and could easily 
be transgressed. (Quotes 5-7 in Table 2) 
Involvement was in many ways unavoidable in the context of hospitalization. Physicians 
mentioned that children were exposed to observation during medical rounds, other patients’ 
experiences, and medical procedures. This also implied that patients were confronted with 
the possibility of treatment failure and of dying by witnessing other patients’ evolution. 
(Quotes 8-10 in Table 2) Some physicians mentioned that they did not want to take the first 
steps towards revealing the exact diagnosis. This way those children who wanted to know 
may decide whether to seek more information, how much and when. (Quote 11 in Table 2) 
 
Widening involvement 
As parents and patients became more acculturated with hospitalizations and had the time to 
come to terms with their new situation, many parents slowly abandoned efforts to shield 
children. While some parents involved their children concurrently or immediately after they 
were told the diagnosis, for most parents the gradual awareness that involvement was 
somehow inevitable made them change their attitude and support widening child 
participation. Over time they provided more information in steps. Parental avoidance of full 
diagnosis disclosure persisted only for few patients after treatment started. (Quotes 12-14 in 
Table 3) 
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For many patients widening involvement mainly consisted of information on treatment and 
possible side-effects. Parents and physicians considered these discussions necessary to 
prepare children and ascertain their collaboration for painful procedures. Physicians often 
reported that they could not force children to undergo treatment and some parents 
acknowledged child benefits from participation. Typical of this “practical” involvement is 
that when parents resisted open communication about the diagnosis it did not always lead to 
full disclosure. This resulted in physicians and parents walking a fine line between providing 
and withholding information. (Quotes 15-17 in Table 3) 
 
Enhancing involvement 
Physicians described children’s involvement in care in relation to the information they 
provided and to actions taken to elicit preferences and give children a voice. (Quotes 18 and 
19 in Table 4) Enhancing involvement was grounded in assessing patient perceptions and 
tailoring information to expressed needs11. According to physicians, some children limited 
themselves to asking more daily-life affecting questions. Other patients were curious and 
took on a more active role regarding the course of the illness, recommendations for treatment 
and dietary regimens. (Quotes 20 and 21 in Table 4) 
Parents also mentioned discussing with physicians test results and treatment uncertainties in 
children’s presence. This tactic allowed patients to participate in the sharing of information 
and created opportunities for them to react. Proactive parental approaches helped support and 
encourage some children to ask questions and engage with them regarding what patients 
learned from observation or other sources of information. (Quotes 22 and 23 in Table 4) 
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Discussion 
Communication about cancer is shaped by societal views of illness and breaking bad news 
practices12,13. This study adds knowledge on the challenges and risks of involving children in 
care when they are not immediately or fully informed about their cancer diagnosis. 
Patient participation was described as a step-by-step, intermittent process resulting in various 
types of involvement. Provision of information and explanations regarding care are the main 
tools to foster participation in pediatric oncology14,15. In our study, participation was 
dominated by parental and physician uncertainties regarding how and to what extent they can 
and should involve their children3,7. Uncertainty was linked to fears of children’s emotional 
reaction to the cancer diagnosis. For parents themselves the diagnosis evoked a powerful 
threat, of dying, which accounts for the withholding techniques16. 
Physicians often complied with parents’ requests to withhold the exact diagnosis in view of 
legal parental rights, but most saw it merely as delaying patients from finding out on their 
own3. This results in an ethical conundrum: limiting truth telling poses moral internal 
dilemmas for physicians, leading to conflict with some parents7. Despite uneasiness, 
physicians in this study complied with parental wishes. This does not reflect a denial of 
patients’ right to information, as patients were gradually involved in care, even in the absence 
of full disclosure for some. This finding highlights the grey zone of how to professionally and 
empathically disclose diagnosis to families and children17. The degree of involvement desired 
by patients is difficult to assess especially when parents and oncologists take an adult-centric 
view and exclude child participation from what they consider difficult situations2,18. 
Participation and information sharing related to treatment occurred even as physicians 
accepted parental restrictions. Physicians considered discussing likely side-effects and 
explaining treatment procedures an imperative as these often result in pain and considerable 
physical changes. This communication was a way of soliciting and obtaining assent. As such, 
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children’s involvement was seen as valuable in and of itself, rather than just a foreseeable 
maneuver to achieve patient compliance and collaboration. In other studies, clinicians held 
the same view that causing harm to children is ethically charged7,19. 
For some patients, communication became more open between parties and information flow 
was less and less inhibited by parental or physicians’ attitudes. Oncologists allocated time for 
children to ask questions and reassured them with each medical visit that they could voice 
concerns. These actions aimed to build patient confidence to engage in care and facilitate a 
two-way communication. Similarly, parents supported children by including them in 
discussions with physicians and in some cases encourage them to have direct contact with 
clinicians. These attitudes may be highly supportive of adolescents’ needs during cancer 
care3,4. In early diagnosis stages, children may prefer parents to act as buffers and messengers 
of medical communication3 but they also need to have access to physician time without 
parental involvement4. Physicians’ and parents’ accounts in our study are aligned with such 
adolescent wishes as participants were aware of differences in patient preferences. When 
parents agreed to open communication, they were guided in their supportive actions by 
teenagers’ own behavior and wishes. 
Besides parental and physician sources of information, children were reported to acculturate 
to the hospital setting and therefore knowing more about diagnosis, treatments and illness 
consequences. Participants mentioned that some children manifested a wish to know more 
detailed information about their illness and likely outcomes. These patients also went 
searching online20,21 or when parents opposed absolute disclosure some teenagers researched 
their symptoms on the web to arrive at a concrete diagnosis on their own. This scenario 
exposed children to abundant information (poor prognosis, end-of-life issues and long-term 
effects) that they may not be able to filter or structure in the same way as when informed by 
clinicians. Patients may think their situation is direr than it is in reality22. This shows how 
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ineffective restricting child involvement for protection can be: it can trigger patient curiosity 
and exacerbate fears. 
 
Study limitations 
We relied on treating physicians’ judgement in approaching parents for interviewing. This 
may have led to selecting less difficult patient cases or families that physicians had a good 
relationship with. The study has the strength of capturing both parental and physician 
perspectives on child involvement and juxtaposing their views to identify challenges to 
patient participation and risks when restricting involvement. By having the double 
perspective parent oncologists and in light of reports of limiting involvement, we believe that 
social desirability tendencies were minimized. Recall bias may have also played a role in 
interviewees’ accounts. Interviewing allowed in depth probing of parental and physician 
actions and attitudes towards child involvement. This qualitative method may limit to some 
extent the results’ generalizability to other pediatric oncology contexts. However, the issues 
identified may be relevant for similar crowded oncology treating centers with limited 
psychosocial services. 
 
Conclusion 
Parents’ and physicians’ accounts paint an image of children’s involvement in cancer care 
that has different facets. It can be described along a continuum: restricted but widening for 
some patients and then further being enhanced depending on parental and physician behavior. 
Some parents who adopted restricting techniques, particularly concerning diagnosis 
disclosure, viewed involvement rather as a practical step or as being unavoidable given the 
long treatment and different sources of information to which patients were exposed to. 
Parental explanations further emphasize that child involvement in care is indisputable, despite 
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the many grey areas in allowing or ensuring patient participation in care. High parental 
uncertainty and fears related to cancer diagnosis suggest the need for research on how 
clinicians can support parental communication with patients. Physicians should aid patients in 
their involvement, separate from actions to soften parents’ boundaries. Oncologists and 
parents should be aware of the hazards of leaving patients with unanswered questions about 
diagnosis for a long time. Patients may resort to external sources of knowledge and face 
information overload, no longer being able to pace its rhythm. Professional support is 
essential in untangling information relevant to patients’ situation from worst case scenarios. 
All physician actions aimed at supporting patients’ participation should be paralleled by 
parental involvement in care. 
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‘The world is so unpredictable. 
Things happen suddenly, unexpectedly. 
We want to feel we are in control of our 
own existence. In some ways we are, in 
some ways we're not. We are ruled by 
the forces of chance and coincidence.’ 
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Abstract 
 
Shared decision-making in pediatric care requires the collaboration of physicians, parents and 
minor patients. Children’s ability to understand and reason about information provided to 
them regarding disease and treatment is a key determinant of their decision-making capacity 
(DMC). Physicians are tasked with assessing patients’ DMC, but in practice encounter 
various difficulties related to: (1) inconsistent use of terminology and poor definition of the 
concept, (2) absence of reliable instruments tested in minor patients, and (3) of a framework 
of children’s and adolescents’ developmental abilities applied to DMC. This article explores 
these three issues in relation to ethical considerations of children’s participation in care 
according to their developing mental and emotional capacities. The results of this analysis 
refine the concept of DMC in pediatrics and offer advice on its clinical applicability, taking 
into consideration physician roles and attitudes when assessing minor’s capacity. Flawed 
understanding of DMC in children and adolescents is a serious barrier to achieving adequate 
participation in healthcare for minor patients. Revisiting the concepts’ interpretations and 
definition and clarifying issues surrounding assessment and child development is necessary 
for overcoming challenges in this area and improve pediatric practice. 
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Introduction 
In view of the ethical principle of respect for children1 as persons with developing autonomy 
and research that points to clinical benefits, minor patients’ participation in healthcare is 
commended by different pediatric associations1-3. Shared decision-making, a process in 
which physicians engage with patients to make decisions is recommended also in pediatrics, 
thus requiring the collaboration of parents and children4-6. The parties’ contribution to this 
process varies depending on the available options and their complexity, and for children and 
adolescents it is also shaped by their cognitive and emotional development7. Children’s 
abilities to understand and form judgments based on the information provided to them define 
their decision-making capacity (DMC)4,7 and therefore their aptitude to provide consent for 
treatment8. Valid and informed consent also requires that information is provided in a clear 
manner and adapted to individual patients’ understanding, and that patients express a wish to 
decide. The essential elements for children’s capabilities to consent to treatment - decision-
making capacity, information provision and voluntariness - are subjected to physician and 
parental influences, social customs and regulations, developmental aspects intrinsic to every 
child, ethical and legal prioritization of best interest or burgeoning autonomy9-12. 
Capacity assessment is the responsibility of physicians and can be carried using the criteria 
proposed in adults. This includes patient understanding of essential information, analysis of 
the situation and likely outcomes, ability to reason about and communicate choices13. 
Additionally, in children and adolescents, DMC considerations have to account for patients’ 
evolving abilities in the context of maturation processes and learning experiences14. 
However, in view of children’s changing abilities in general and of variations of capacities 
within a patient when faced with making various decisions that pose different levels of 
complexities, capacity in minors is not easy to identify. Moreover, assumptions about age-
                                                          
1 Patients who have not reached the usual legal age of maturity (18 years old) will be referred 
to as children, adolescent or minors throughout this article. 
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based abilities and caution in interpreting capacities by applying stringent standards of 
reasonableness of choice further complicate DMC assessments13,15,16. In fact, the DMC 
concept in children is poorly understood in practice and inconsistently studied. Most research 
focuses on separate criteria of capacity assessment, usually understanding, while neglecting 
reasoning abilities or comprehension of the situation17.This article explores issues regarding 
(1) conceptual definitions, variations in terminology and their confusing effect; (2) practical 
aspects of DMC use and measurement, and (3) the implementation of developmental 
framework in DMC assessment in pediatrics. 
 
Terminology and jurisdiction 
Capacity to make decisions has also legal implications, as it is a pre-requisite of competence. 
For adult patients, legal competence, understood as the recognition of a person’s authority to 
decide for herself, is presumed. However, it can be overridden on the basis of clinical 
evaluations of DMC showing flaws in patient understanding of incapacity to reason about a 
particular task. Children’s and adolescents’ legal competence is generally not recognized and 
parents are charged with providing permission for treatment17. Nevertheless, minor patients 
can have clinical DMC and some legislatures have legal provisions that recognize the right of 
children who display sufficient abilities to make healthcare decisions18. Differences in the 
legal and clinical language used to describe patient capacities to comprehend and balance 
different information leads to confusion19,20. In practice, this can result in broad application of 
DMC assessments from one medical choice to another without conducting different clinical 
examinations13. For children, differences and dealing with the conflation between the two 
concepts is essential, particularly in jurisdictions such at the United Kingdom that recognize 
minors’ right to consent to treatment, but ban the power of declining it19. Additionally, 
legislations vary also in whether they enforce age limits when recognizing children’s right to 
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assent or consent to treatment or support participation based on capacities rather than 
biological considerations. Both approaches have distinct implications for clinicians and 
patients. Age limits may result in very young children not being viewed as able to have 
DMC, while adolescents may be presumed as possessing capacity that can be refuted in 
practice21. The absence of age standards has also its own disadvantages, leaving physicians 
with little guidance and more inclined to appeal to their clinical experience and intuition 
when choosing to support patients to assume a more prominent role in decision-making. 
 
Operationalization and measurement 
Apart from variation in legal norms, physicians also encounter difficulties because there is no 
reliable tool or framework for examining children’s and adolescents’ capacities to participate 
in decision-making17,22. DMC has to be assessed for individual patients, taking into 
considerations personal characteristics when sharing treatment information, and for a 
particular decision. The standard for DMC should be correlated with the gravity of the 
outcome for each choice available to patients23. At the same time, here are no stringent 
criteria for how high the DMC should be in relation to serious outcomes24. 
Appelbaum’s MacArthur Competence Assessment Tool for treatment (MacCAT-T) 
investigates all domains related to DMC in adults13. However, its applicability in pediatrics is 
difficult to establish as there is no solid evidence of its reliable use in children and 
adolescents13,24. Efforts to develop a meaningful tool that serves as support for minors’ 
participation in care, sensitive to their developing abilities, needs to include objective 
parameters of DMC while also taking into account parental judgments25. Additionally, as all 
assessments have to ultimately be judged by physicians, they have to collaborate with minor 
patients when making decisions in order to build a solid understanding of how the DMC 
operates in practice22. 
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Including developmental factors of DMC in pediatrics 
Although DMC establishes which children can participate or make healthcare decisions and 
which cannot, the participation of all patients in care is unquestionable. As such, those minors 
who do not have sufficient abilities to meet requirements for DMC upon first assessments 
should still be involved, as they bear the potential of reaching the threshold for capacity later 
in the course of illness11,26. The developmental aspect is important because although children 
are not the final decision-makers when they lack DMC, they can have the abilities to 
understand information and identify a choice. Therefore, physicians have to take into 
consideration different levels of child participation and recognize that minor patients without 
DMC can assent to treatment even if decisions are made for them by parents. However, the 
assent concept itself can be confusing, especially when there is disagreement between child’s 
choices and parents’ decisions27. In all steps taken to include children and adolescents in care, 
adults have to be careful not to deceive children and clarify that while it is important for them 
to also express their preferences, they can be over-ruled by parents27. Step by step, repetitive 
evaluations of child abilities and voluntariness are imperative in ensuring their inclusion in 
care according to their changing capacities. It assures the adequate transition from being 
informed, to giving assent and, when meeting DMC criteria, to providing consent28. 
 
Supporting DMC in pediatric practice 
Children’s inclusion in care is highly dependent on the attitudes and actions of those involved 
in their care. DMC assessments are more demanding than in adults and each time require 
careful individual examinations and reflection on child-specific characteristics and abilities to 
understand information. This is highly demanding in practice, particularly in view of the 
issues identified above: (1) conceptual blurriness, (2) lack of instruments, and (3) including 
the developmental continuum in DMC. Institutional based protocols developed based on 
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sound ethical and legal principles and with the contribution of pediatricians may open the 
way for practical implementation of current guidelines on child participation in care1,3. Apart 
from institutional guidance that accounts for different legal provisions, the inclusion of 
children should be researched in various medical settings and taking into account factors such 
as disease experience, parenting styles and power-dynamics. Studies should examine the 
relation between level of participation and adults’ attitudes, as well as its effects on all parties 
involved. Knowledge obtained from both standardized practice and empirical data can then 
be used to develop a comprehensive framework for assessing the developing DMC in 
children and adolescents. 
Clinicians and researchers should be aware of the perils of implementing standardized tools. 
In practice, measurements can be arbitrarily applied and be used and interpreted as tests with 
definite answers25,29. In reality, children’s behavior is easily shaped by context and 
relationships. Reliable DMC measurements tools need physician and parent input before and 
after they are applied with children. Communication with patients and between parents and 
physicians is important and is one of the elements that can support or inhibit children’s 
abilities necessary for DMC assessments. Moreover, information about individual patient’s 
abilities should be gathered from various sources, including formal and informal care 
providers28. These reiterative processes emphasize the triadic relationships and the shared 
decision-making specific for the pediatric setting, where decisions for patients require 
physician, parent and child collaboration1,15. 
 
Conclusion 
Progress regarding children’s participation in care and the advancement of clear standards for 
DMC assessments in pediatrics requires theoretical, empirical and educational work. 
Research is needed to better understand the development of children’s abilities in healthcare 
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and under specific circumstances, and to build a DMC tool that captures changing and 
evolving capabilities13. Physician training in ethical and legal issues pertaining to minor 
patients’ rights, assent, and principles of respect for persons and best interest is also needed30. 
Ultimately, any objective DMC measurements have to be interpreted by clinicians who need 
to reflect on those results as they regard an individual patient within a specific context31. How 
to achieve child participation in care should be at the core of analyzing DMC issues and 
implementation. 
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Abstract  
 
Background 
Decision-making is a highly complex task when providing care for seriously ill children. 
Physicians, parents and children face many challenges when identifying and selecting from 
available treatment options. 
Methods 
This qualitative interview study explored decision-making processes for children with cancer 
at different stages in their treatment in Switzerland and Romania. 
Results 
Thematic analysis of interviews conducted with parents and oncologists identified decision 
making as a heterogeneous process in both countries. Various decisions were made based on 
availability and reasonableness of care options. In most cases, at the time of diagnosis, 
parents were confronted with a “choiceless choice” - that is, there was only one viable option 
(a standard protocol), and physicians took the lead in making decisions significant for health 
outcomes. Parents’ and sometimes children’s role increased during treatment when they had 
to make decisions regarding research participation and aggressive therapy or palliative care. 
Framing these results within the previously described Decisional Priority in Pediatric 
Oncology Model (DPM) highlights family’s more prominent position when making elective 
decisions regarding quality-of-life or medical procedures, which had little effect on health 
outcomes. The interdependency between oncologists, parents and children is always present. 
Communication, sharing of information, and engaging in discussions about preferences, 
values, and ultimately care goals should be decision making’s foundation. 
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Conclusions 
Patient participation in these processes was reported as sometimes limited, but parents and 
oncologists should continue to probe patients’ abilities and desire to be involved in decision 
making. Future research should expand the DPM and explore how decisional priority and 
authority can be shared by oncologists with parents and even patients. 
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Introduction 
Decision making for pediatric patients is no longer a practice solely based on a clinician-
centered model1-4, but features collaboration between three parties5-7. Known as shared 
decision making, this model is the guiding process in all physician-patient-parent interactions 
in healthcare8,9. It requires adequate communication of medical information and options, 
while engaging all parties to contribute their views and identify values and preferences in 
order to reach a decision that is best aligned with the patient’s best interest, parents’ values 
and rights, and the child’s wishes2,4,6,10,11. 
Shared decision making is increasingly complex and challenging when providing care for 
seriously ill children5,12-14. Cancer in particular is a context in which decision making is 
charged with uncertainty and emotions15-18. It is not only a lengthy but also a dynamic 
process across the illness’ trajectory. It often requires striking a fine balance between 
maintaining hope and sharing responsibility for very difficult decisions19-22. Retrospective 
research investigating parental experience and roles for children suffering from cancer reveal 
parents’ willingness to be included in decisions and their struggle with constraints such as 
insufficient information, time pressure and poor communication with physicians19,23. Parents 
usually want to share responsibility with physicians for decisions being made. They are less 
likely to trust physicians and may even experience regret if they perceive their role as 
marginal23. Especially when it comes to making very difficult decisions at the end of life, 
studies report that physician-parent collaborative decisions provide parents with a sense of 
having made the right choice24. 
Studies on children’s engagement in medical communication and decisions concerning 
cancer care show that children appreciate receiving information and being involved, though 
preferences about the degree of participation vary25,26. Qualitative studies describe how 
involvement of children and adolescents in decision making is often limited26,27. Due to the 
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nature of cancer treatment decisions, which often involve to standardized diagnostic, 
therapeutic, and follow-up protocols, patients do not have a real choice and eliciting 
preferences is many times futile27. Studies have shown that patients may not always be 
encouraged to ask questions, parents tend to shield children from information they deem 
difficult, and physicians give children short and technical answers26,28. These tactics in turn 
may lead to exacerbation of children’s uncertainty and to children imagining something 
worse than their actual condition28,29. 
At present there is no standardized blueprint for how the triad should operate and collaborate 
in making decisions4,13,30. This may explain data showing difficulties faced by parents, 
physicians, and children themselves when engaging in treatment discussions. Given the 
preference for shared decision making and the difficulties it poses in clinical practice, this 
study was conducted to explore decision-making processes for children with cancer at 
different treatment stages and from two European countries. As decision making is 
influenced by context, we selected countries with different cultural and institutional norms, 
and diverse legal prescriptions regarding treatment consent for minor patients. While 
Romanian law supports parental permission and for adolescent patients recommends assent, 
Swiss regulations stipulate that patients possessing capacity can provide consent, regardless 
of age31,32. However, in both countries a treatment refusal can be overruled based on the 
child’s best interest standard. The aims of this article are to examine the perspectives of 
parents of children with cancer and the children’s physicians on their experiences with 
participation in decision making. Furthermore, clinician and parental views and attitudes 
regarding minor patients’ participation in discussions regarding treatment choices are also 
investigated. Child and adolescent wishes and views were sought only in Switzerland and are 
reported separately33. Based on our findings we propose new elements to be factored in when 
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mapping decision-making processes for children diagnosed with cancer. Study results are 
therefore framed within the Decisional Priority in Pediatric Oncology Model (DPM)4. 
 
Theoretical framework: The decisional priority in pediatric oncology model 
In discussing treatment options, the DPM considers two characteristics - cure probability and 
superiority of each option - and distinguishes decisions based on availability of choices that 
can potentially lead to higher patient benefit. Decisions are classified in three categories 
based on (1) whether the superiority of a choice is undetermined, (2) whether the two options 
are fairly equal, or (3) whether a choice requires significant trade-offs between chances of 
cure and quality of life4. Depending on how the two characteristics of any treatment option 
combine for a given clinical case, the decisional priority can rest with one of the parties 
involved. That is, the physician or family can take the lead in identifying a preferable choice, 
assuming priority in decision making. For most decisions, the model recognizes the reality of 
physician’s priority and allocates more space for parents and patients in decisions that have 
higher uncertainty regarding cure and when choices are similar in relation to expected 
outcomes. However, authority for approving the implementation of an identified choice 
(decisional authority) is recognized as belonging to parents, while children’s opinions should 
weigh more heavily as they mature4. 
 
Methods 
This study presents data from participating parents and physicians in Switzerland and 
Romania, which were collected as part of a larger project investigating views and attitudes on 
child and adolescent capacity in health care in Switzerland. Interviews with minor patients 
were conducted only in the Swiss pediatric oncology setting and were previously published33. 
Research involving minor patients, labeled vulnerable by most research guidelines34,35, was 
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more challenging in Romania and unsuitable due to the fact that the researchers were in the 
first stages of establishing a collaboration. The study took place in eight pediatric oncology 
centers in Switzerland and three pediatric oncology centers in Romania. Four participating 
centers in Switzerland are university-affiliated pediatric clinics, while the remaining centers 
are within the cantonal pediatric hospitals. These centers are located in three different 
linguistic regions (German, French, and Italian) of the country. The three participating 
centers from Romania are university affiliated and are located in two distinct regions of the 
country. These centers care for children from all Romanian counties diagnosed with either 
solid tumors or oncological/hematological illnesses. The study was approved by the 
responsible ethics committees in Switzerland and the institutional ethics committees of 
participating centers in Romania. 
Participant recruitment 
The study sample was a nonrepresentative, purposive sample of volunteer participants of 
parents/proxies1 and treating physicians caring for children (8-18 years) suffering from 
cancer. Participants were eligible for the study if they spoke English, German, French, or 
Italian (in Switzerland) and Romanian or English (in Romania). Recruitment of proxies was 
based on physician selection of patient cases that met the study inclusion criteria. Physicians 
informed the family about the study and asked whether participants would agree to be 
approached by a member of the research team. Given the sensitivity of the study topic, 
proxies were informed of the study by collaborating physicians at the earliest 3 weeks after 
the diagnosis disclosure. In Switzerland, after obtaining proxy permission, the physician 
would forward their contact details to the research team. In Romania, once the proxies 
agreed, the physician would introduce them to the researcher in the hospital on the same or 
following days. 
                                                          
1 Parent(s) and proxy are used interchangeably in text to mean the adult, legal representative 
in charge of the minor patient’s medical care.  
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The research team gave proxies detailed presentations about the study and invited them to 
participate in an interview. If they accepted, a day and time for the interview was agreed 
upon. For each proxy interviewed for the study, the treating physician’s participation was 
subsequently requested to discuss corresponding patient cases. Interviews with physicians 
usually took place in their offices, while those with proxies were carried out mostly in a 
private hospital area. 
Sample 
Interviews were conducted with 63 participants, 35 (16 physicians and 19 parents) in 
Switzerland and 28 (10 physicians and 18 proxies) in Romania (Table 1). The total number of 
physicians participating in this study is lower because five physicians in Switzerland and five 
in Romania discussed more than one case. Most of our proxy sample included parents, with 
the exception of three grandmothers in Romania. These grandmothers were involved in 
patient care from diagnosis onward and were accompanying the patient during hospital stays, 
and therefore were interviewed as patient proxies. Participants were interviewed only once 
and the discussions took place either at 3 weeks, several months, or at a maximum of 2 years 
after the initial diagnosis of cancer in Switzerland and 5 years in Romania. Two parents in 
Switzerland and one in Romania were interviewed after their child had relapsed or a 
secondary tumor was diagnosed. In the case of one patient in Romania the tumor was 
inoperable, and two more proxies were interviewed after being informed that their child 
developed metastasis. At the time of the interviews patients were still undergoing therapy 
with a curative goal. Participants’ characteristics from Romania were previously described36. 
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Table 1 Participant characteristics (N=63) 
 Proxies (N=37) Physician (N=26) 
Switzerland n=19 n=16 
Age (years) Gender Age* (years) Years of experience in 
pediatric oncology* 
44.6  
(range 33-52) 
Male  n=4 43.6 
(range 36-
54) 
>12 6 
9-12 3 
Female n=15 5-8 3 
0-4 2 
Romania n=18 n=10 
Age* Gender Age Years of experience in 
pediatric oncology 
43.3 (range 
34-60) 
Male n=1 45.3  
(range 30-
62) 
>12 4 
9-12 1 
Female n=17 5-8 4 
0-4 1 
*Not all participants provided this information. 
 
Data collection 
Three members of the research team conducted the interviews (one in Romania; two in 
Switzerland). Physicians in Romania invited 21 proxies to participate, 3 of whom declined 
participation due to their child’s advanced illness or disinterest in the study’s topic. In 
Switzerland, as parents were selected by physicians and only those interested in the research 
contacted the study team, the exact number of initial families is not known. Interviews were 
audio-recorded, except for four in Romania where participants declined and for which 
detailed notes were taken. Proxy interviews lasted from 25 to 80 minutes and physicians’ 
interviews ranged from 20 to 123 minutes. Interviews followed the same semistructured 
interview guide that was developed by the researchers based on empirical research conducted 
on decision making in pediatric oncology by Hinds and colleagues37. The guide was divided 
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into three sections, covering general information about the patient’s situation; treatment 
options; and discussions and decision making and patient’s participation in discussions (see 
appendix). 
Data analysis 
Tape-recorded interviews were transcribed verbatim in the language in which they were 
conducted, except for those in Romanian, which were directly translated into English during 
transcription. Romanian interviews translations were checked by an independent researcher 
fluent in both languages. Transcript quality was double checked by one member of the 
research team. Interviews were analyzed using thematic analysis approach38 and employing 
MAXQDA 11 software (1995-2015 VERBI GmbH product) for qualitative data. Swiss 
interviews were transcribed in the original German, French, Italian, or English language and 
the researchers conducted the analysis on multilingual material. In a first step, three members 
of the research team open-coded three transcripts to build a coding scheme38. For this step, 
researchers were fluent in all languages of the transcripts that were analyzed in a group of 
three: English for the Romanian interviews, and French and English for the Swiss. Thereafter, 
two members fluent in each of the transcript’s language coded most of the interviews together 
using the coding scheme. For the Swiss interviews one pair of researchers fluent in Italian 
and French and another pair fluent in German and English carried out this step. One 
researcher was fluent in all four languages and conducted all Swiss data analysis. Throughout 
the coding process, new codes were added where needed. In a final step, all codes were 
checked and grouped together under specific topics such as Medical Communication, 
Decision Making, Inclusion of Children, Lived Experiences, and Hope and Spirituality. All 
coders came together to discuss the topic of decision making in pediatric oncology to agree 
upon data interpretation. Thereafter, all coded segments of the 63 interviews related to 
decision making were sorted out and further categorized. Discussions among researchers led 
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to the development of three main categories and subcategories. Representative texts for this 
final analysis step were chosen and where necessary translated from German, French, or 
Italian to English by two researchers, and were checked by one fluent in all languages. 
Fictitious child names followed by patient’s actual age accompany the quotes. 
 
Results 
Our thematic analysis resulted in three main categories that describe how decision making 
occurred in pediatric oncology: heterogeneous decision making at diagnosis; elective 
decisions; and decisions outside standard protocol. 
 
Heterogeneous decision making at diagnosis 
In both settings, at the time of diagnosis, proxies and physicians described there being little or 
no room for making a decision. Physicians and their expertise usually played a major role at 
this time. However, in the course of illness greater parental input and collaboration took 
place. Parents’ and sometimes children’s participatory role increased when prognosis was 
poor or patients were diagnosed with rare cancers with no standard treatment. 
Standard protocol as the sole decision 
At the time of diagnosis, most parents felt they had no or little choice concerning essential 
decisions that determine health outcomes. For most cases, the only reasonable treatment 
option was to follow established treatment protocols for that particular oncological illness 
(Quote 1 in Table 2). Parents and oncologists reported that if a decision were to be made, 
then theoretically, it had to be between having and not having treatment. The latter was not 
considered an option since they were dealing with a life-threatening illness. Likewise, opting 
for treatment meant following the standard protocol (Quote 2 in Table 2). At the same time 
and in relation to the option to follow a protocol, for parents the decision to start treatment 
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was essential, as this had real consequences for likelihood of cure. As one mother put it, it 
was the “only chance to get to a good result” (Melissa, 10-year-old, Romania). 
Parental challenges in considering the treatment protocol 
Irrespective of type of cancer, parents and oncologists in both Switzerland and Romania 
mentioned how treatment decisions, even for standard protocols, bear complex levels of 
uncertainty. Families were ill situated to interpret all factors that go into determining the best 
treatment. Parents emphasized difficulties with participating in health care decision making 
and viewed oncologists’ guiding role as paramount. Equally, they appreciated being listened 
to by physicians when decisions were made (Quotes 3 and 4 in Table 2). 
Exercise of therapeutic privilege in decision making 
Oncologists’ views on decisions considered essential included their primary role in 
identifying best options. In few centers, physicians reported that at the time of diagnosis they 
discussed therapeutic choices among colleagues in order to select the protocol to propose to 
parents. This was regarded as an a priori step in decision making, before involving parents, 
and was more likely to take place for patients diagnosed with rare tumors. Oncologists 
described subsequent parental participation as not influential, but necessary in authorizing 
treatment administration (Quotes 5 and 6 in Table 2). 
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Shared decision making: poor prognosis at diagnosis 
For three patients, physicians described how at diagnosis treatment was completely outside 
standardized protocols due to the gravity and rarity of the type of tumors in children. Decision 
making for these cases required specialist collaboration and team efforts to come up with a 
treatment plan. Under these circumstances parental involvement in decision-making processes 
heightened as more discussions took place before arriving at a decision (Quotes 7 and 8 in 
Table 2). 
 
Elective decisions 
Participants reported that once treatment was established, parents and children were provided 
with opportunities to take charge of so-called elective choices that included two categories: 
those that concerned quality of life and those medical in nature. Elective decisions were 
distinguished from the protocol decision based on the fact that the health outcome was 
independent. These optional choices did not have a direct impact on therapy results, unless 
they meant postponing treatment. 
Improving quality of life during treatment 
Elective decisions regarding the modality of administering the treatment (orally or through an 
intravenous line) and adjusting sessions around holidays had the purpose to improve quality 
of life during treatment. They were made available by physicians as long as they did not 
interfere or impact the cancer-directed therapy (Quotes 9 and 10 in Table 3). Oncologists also 
mentioned choices that were in children’s hands, such as what devices to use for 
administering medication. They reported that such involvement of children gave them some 
control over what was happening (Quotes 11 and 12 in Table 3). 
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Medical choices  
Some elective choices involved more intricate considerations. With respect to cancer 
therapy’s immediate or late side effects, parents and children were confronted with several 
medical options. However, these choices, though of a medical nature, posed lower degrees of 
complexity, and were deemed to be safe if made by parents and patients as they did not 
interfere with the cancer-directed therapy. One mother mentioned her son experiencing some 
side effects from the medication prescribed for his heart condition. After consulting with the 
cardiologist he decided between two drugs (Quotes 13 and 14 in Table 3). 
In four Swiss cases, participants discussed the option of undergoing fertility preservation 
therapy. Parents noted that choices to undergo procedures for fertility preservation weighed a 
great deal on their adolescent children and three of them clearly expressed the desire to 
become parents. Despite it being an elective choice, the patients’ role was sometimes 
challenged when parents viewed it as too hasty or likely to delay cancer treatment (Quotes 15 
and 16 in Table 3). 
In contrast to Switzerland, where fertility options were discussed, one oncologist from 
Romania mentioned that measures for storing sperm and eggs are usually not addressed with 
parents and patients. The limited capacity to offer this treatment and the technique’s 
associated costs were considered restrictive (Quote 17 in Table 3). 
 
Decisions outside standard protocol 
Some participants were confronted with decisions involving a choice between the standard 
protocol and a research protocol or clinical trial. For some, such an option was given early 
after diagnosis, while for others research participation choices arose when standard protocols 
failed. These decisions differed from those made at the time of diagnosis not because of the 
point in time when choices were presented, but due to physicians’ medical assessments. In 
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proposing research participation, oncologists either considered the research protocol to be 
equally effective to the standard one or evaluated a clinical trial to be superior to attempted 
standard therapies. 
Choosing between standard or research protocol 
In the Swiss sample, several patients and parents were asked quite early in their treatment to 
choose between standard and research protocols. Mia’s mother (patient age 14, Switzerland) 
explained, “They [the physicians] said there is either the standard arm or a [research] study 
on the side. In the end, she [Mia] is in the standard arm”. However, she also reported that this 
was not viewed as a decision to be made by parents (Quote 18 in Table 4). Another parent 
highlighted the choice made in collaboration with the child to enter a research protocol after 
the completion of the standard treatment as an additional measure to reduce relapse chances 
(Quote 19 in Table 4). 
Decisions to step out of standard protocol were also made in a few cases as a result of 
patient’s poor response to therapies. In such circumstances, physicians described how they 
looked for alternative solutions that could increase patient’s sensitivity to treatment (Quote 
20 in Table 4). In contrast to the Swiss data, parents in Romania did not discuss participation 
in research in a straightforward manner. The research option was not identified overtly, but 
some parents did mention children undergoing treatment that was not the standard protocol. 
Cody Ray’s mother (Patient age 10, Romania) mentioned that her child “did not respond to 
treatment like all the other children” and that the physician had to try something different 
with her child. However, she did not perceive it as a decision, but as an exercise of 
physician’s expertise (Quote 21 in Table 4).Comparable to parents’ reports, physicians in 
Romania did not discuss proposing as treatment option a research protocol besides the 
standard one. They only talked about improvements in cancer therapies for children in 
general. Oncologists in Romania mentioned different standardized protocols based on the 
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country where they were developed and that they differ in small ways. They further 
elaborated that the change in the line of therapy took place when the standard treatment did 
not render the expected results in a patient (Quote 22 in Table 4). 
Stepping into the unknown after several treatment decisions 
As treatment continued, for 14 patients (7 in Switzerland and 7 in Romania), events arose 
where additional essential decisions became necessary. Participants in both groups mentioned 
that these situations often arose in case of treatment failure, relapses, and when standardized 
options were no longer available. These decisions were made collaboratively with parents 
and sometimes children (Quotes 23 and 24 in Table 4). 
Evident from participants’ accounts is also parents’ and physicians’ unwillingness to let go 
even when the illness took a downward turn where patient’s demise could be anticipated. 
Thus, both parents and oncologists felt that all should be done to make sure that patients got 
all chances to fight against their odds (Quote 25 in Table 4). Typically, oncologists believed 
that in these complex situations the decision had to be more up to the parents and patients. 
However, the grim circumstances and the unlikely cure were not openly discussed with 
patients (Quotes 26 and 27 in Table 4). 
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Discussion 
Results from this study highlight decision making’s complex and heterogeneous nature in 
pediatrics5,9,14,15. At the time of diagnosis, physicians’ guiding role was dominant as they 
identified the appropriate treatment and a suitable protocol for the particular cancer and 
advised starting the treatment. However, in the case of rare malignancies, decisions outside 
standard protocols were made that required not only consultation with different specialists, 
but also more discussions with families, highlighting their participatory role in decision 
making. Additionally, for elective decisions, many times parents and patients had a 
prominent role. Therefore, there was a shift in control from physician to family when choices 
affected quality of life without jeopardizing treatment outcome. The heterogeneity of 
decision-making processes is illustrated by the choices offered to some families to opt for 
research protocols when prognosis was poor. 
Our research shows that the central focus of decision making in both countries and in 
reference to essential and elective choices was the child’s best interest. Parents and 
sometimes patients made various choices regarding treatment, medical tests, or care 
procedures. They distinguished decisions based on the number of options offered by 
physicians - only standard protocol or opting between research and standard treatment - and 
based on their content and significance for health outcomes - essential decisions versus 
elective ones. These constitute different decisional levels, at which decisional priority is 
assumed by one party or shared, depending on context and available choices. These levels 
can be incorporated into Whitney’s two-dimensional decision plane4, which also describes 
decision making as heterogeneous. Based on the study’s results, we explore how the model 
fits the reality of clinical practice and challenge decisional priority and authority roles 
attributed to parents and/or physicians. A standardized blueprint for triadic decision making 
has to be more sensitive to switches in decisional priority and authority among parties. In 
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decision making for pediatric oncology patients this must also encompass more strengthening 
of patient involvement in this process.  
At diagnosis, for most patients decisions were perceived as a “choiceless choice”39 situation 
for parents and children. Oncologists proposed a standard protocol because, in their view, it 
was the best treatment available for the specific cancer diagnosis. Interviewees described 
these decisions as essential insofar as they had a direct impact on chances of cure. Coyne and 
colleagues27 describe them as “no real decision”. This raises questions because parental 
authorization of treatment is still necessary even when decisional priority lies with 
oncologists4. In considering physicians’ leading role in treatment selection at diagnosis, it 
should be emphasized that families still participate in voluntary decision making. What 
appears a “choiceless choice” for families is not the result of physician constraint or 
preexclusion of other similarly good options, but the consequence of a constraining context40. 
In pediatric oncology, decision making is an ongoing process and participants identified 
several instances along their children’s illness when they were faced with one or more 
essential decisions. As such, reflections on a model of decisional priority and authority 
should not obscure parties’ interdependency, particularly that of parents and oncologists. Our 
results reflect this potential conflict: Parents discussed their challenges with authorizing 
decisions and simultaneously described physicians’ role as inextricable to parental permission 
for treatment. Parents expressed how they trusted physicians and how medical expertise was 
crucial in making treatment decisions. This is consistent with previous research reflecting the 
influences of social factors on decision making27,39, which is subjected not only to 
determinations of risk and benefits, but to a broader social interaction context in which 
relationships and trust factor in39. This expands the notion of physicians’ decisional priority 
in relation to chances of cure at the time of diagnosis as framed by the DPM. Whitney’s 
model acknowledges the pivotal role of oncologists in prioritizing the treatment option based 
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on medical assessments4 when, in fact, parents invest and support oncologists with decisional 
priority through their trust and appreciation of their professional recommendations. 
Some parents and patients were confronted with making essential decisions when they had to 
opt between standard and research protocols. This finding complements research on how, in 
pediatric oncology, parents and children could realistically make only small decisions27. 
Additionally, for other patients for whom therapy failed, decisions had to be made in 
consideration of how invasive or aggressive the treatment should be. Choices included 
experimental treatment and palliation with low doses of chemotherapy. These decisions were 
subsequently characterized by increased family involvement, especially in view of the lack of 
choice at diagnosis. Parents and sometimes children had greater input in late phases of the 
illness. This greater sharing of decisions in the context of relapse or terminal illness is 
observed in studies investigating end-of-life decision making and transition to palliative 
care24,37,41. The DPM4 includes such essential decisions, termed “no best option”. These 
decisions depend on context and must be shared between families and physician or may be 
fully assumed by either parents or patient. These elements proportionately define the benefit 
margin to be expected to result from choosing one option over the other, as the medical 
superiority of the available treatment options is not clear4. 
Families had opportunities to make elective decisions, similar to nursing or care procedures 
identified in other research27. They were confronted with several decisions involving at least 
two options around how and when care will be delivered. These decisions mainly consisted 
of elective choices, usually whether to take drugs orally or intravenously, that paralleled the 
more complex cancer-related treatment. Participants described how patients were encouraged 
to make such decisions or their preferences were accommodated as much as possible. The 
leeway parents and particularly children had to opt for something was greater because the 
final decision would not interfere with cancer therapy. In Swiss interviews, fertility 
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preservation was one of the available elective decisions. These decisions were significant and 
of higher complexity than daily care options. However, patients’ role was overshadowed in 
some cases when final decisions were more a result of parental persuasion. Adolescent 
preferences can be swayed by parents’ and oncologists’ prioritizing the start of treatment over 
desires to undergo fertility preservation. Young females may receive disparate support for 
fertility preservation decision making compared to males. This can partially be explained by 
the relatively uncomplicated technique to collect and preserve sperm as opposed to egg and 
ovarian tissue42,43. These elective options, especially complex ones, and the decisional 
priority clash that may emerge are not explored by Whitney’s model4, which overlooks that 
in the course of illness parents and patients are likely to face multiple decisions outside 
cancer-directed therapy. These options may be important in giving patients back some of the 
sense of control that usually is lost in the context of a cancer diagnosis25,27. The DPM also 
does not address the more difficult decisions around opting for medical procedures that are 
highly personal (fertility preservation) and can impact health outcomes, or who should give 
authorization for them. 
Regarding opportunities for treatment decisions, we observed some differences between 
countries. Fertility preservation was an elective choice discussed only in our Swiss data, 
which may be explained by the existence of a Swiss therapeutic network since 201044. In 
Romania, fertility preservation is available, but offered only in private hospitals and 
practices45, and, as mentioned in Swiss interviews, physicians and parents may discourage 
such treatments when they cause delays to cancer therapy. Additionally, the procedures for 
preserving fertility are expensive, which would restrict access for Romanian patients, but also 
poses a barrier in Switzerland, where oncofertility is not covered by health insurances44. In 
Swiss interviews both oncologists and parents mentioned choices regarding research 
participation, whereas in Romania participants did not openly address such options. The latter 
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appear to have fewer opportunities to make or participate in essential decisions. This finding 
has a twofold consequence for the DPM. First, the threshold for requiring patient assent may 
be higher in research than clinical care - and patient dissent is ethically binding8. Therefore, 
for these decisions authority may be equally shared between parents and children, who can 
even make the final decision, provided they are mature enough46. One of DPM’ pillars refers 
to the decisional priority and authority necessary to reach a decision and which is assigned to 
oncologists, parents, and sometimes patients4. While the priority in selecting an option is 
presumably shifting between parties, the DPM fails to explore whether the authority to decide 
truly lies with parents only or should be shared with oncologists and even with children30. 
Regarding research participation, differences between Swiss and Romanian legislation about 
recognizing patient assent significantly influence the sharing of decisional authority with 
patients. Under Romanian legislation, children’s interests are promoted by parents31 and, 
similar to the United States, it is only when parents are neglectful that the patient’s wish can 
weigh more heavily in medical decision making47. Swiss law supports the self-determination 
of competent patients, independent of age32, and therefore promotes minors’ participation and 
decisional authority when it comes to research also based on the requirement of 
voluntariness. 
Second, research suggests that decision making may be influenced by factors such as 
institutional organization and differences in clinical communication46,48,49. In our study, it 
appears that families in Switzerland were explicitly offered opportunities to participate in 
essential decisions concerning research. This difference may partially be the result of varied 
practices of informing patients about and offering them clinical trials48, of seeking permission 
or assent and supporting patients and families in making decisions46,50. It may also be the 
result of a conflation of protocols for standard and experimental therapy, as many standard 
protocols have some research component51,52. The research topic was more predominant in 
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Swiss interviews, as only some physicians in Romania mentioned research trials in general, 
while parents rarely talked about different or new protocols. This country difference may 
reflect research capacities and infrastructure imbalances within Europe and disparities in 
access to the newest clinical trials53. It could also stem from lack of protocols for 
communicating with families about research, limited capacities in terms of multidisciplinary 
support (such as a research nurse, ancillary personnel), and physician lack of time due to high 
number of patients53-55. These issues can be observed even in countries that have well-
developed health care systems, but are more likely to affect smaller, regional clinics or 
crowded hospitals in both countries. However, decreased research infrastructure and 
increased patient burden per physician are typical of Romanian hospitals. Such contextual 
issues are not fully explored within the DPM, thus limiting its usefulness for diverse clinical 
situations or settings. 
Furthermore, the model fails to recognize external influences, such as consultation with other 
family members to identify choices, which shape decision making and go beyond evaluations 
of medical facts39. It overlooks potential for disagreements or open conflicts not only between 
physicians and parents, but parents and patients30. As our data suggest, lack of consensus may 
occur even when deciding on elective choices and it is more likely that patient’s voice will 
dim when it does not match parents’ and physicians’ views47. As such, it seems intuitive that 
in a theoretical decision-making model, patient role should be considered independently of 
parents’ and not merely collapsed under that of the family30. 
 
Study limitations 
This study’s results need to be interpreted in view of its strengths and limitations. Data 
analysis was conducted on multilingual materials (English, French, German, and Italian), 
which may be challenging for interpretation. However, all coders were fluent in English and 
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the Swiss data coders were always grouped in language pairs according to fluency, with one 
researcher proficient in four languages conducting all stages of analysis. Additionally, all 
other researchers in the team have very good knowledge in all languages. They participated 
in discussions on data and conducted the final analysis for the decision-making topic. 
Interview participants are from two distinct European countries with different health care 
systems, disparities in infrastructure, and care services provided within pediatric cancer 
units53. Despite these differences, participants in both countries described decision-making 
processes in similar ways, and patterns across the data overlapped to a great extent. 
Additionally, the study captures both parental and oncologist perspectives and therefore 
offers a comprehensive representation of the communication and experiences of making 
decisions regarding cancer for minor patients. Perhaps in view of some parents’ refusal to 
participate due to their child’s being at the end of life, the results are more representative of 
decision making for patients for whom treatment has a curative goal, including cases of poor 
prognosis. We did not include patients’ voices, which might have given a clearer and perhaps 
more comprehensive portrayal of decision making. However, interviews conducted with child 
and adolescent patients in Switzerland, published elsewhere33, support the decision-making 
processes described in this study. Parents and physicians did mention instances of patient 
participation in expressing preferences, choosing options, or making elective decisions. The 
results may be biased by the fact that we interviewed participants about decisions and 
experiences that in some cases took place as long as 12 months or more in the past. 
Additionally, participant inclusion may be biased by personal views and interest in interview 
topics. Social desirability may have also played a role in the way participants described 
certain situations. Innate to the design of qualitative methodology, results are not 
generalizable to all pediatric oncology settings. Nevertheless, the diversity of pediatric 
oncology units included in this study, from university-affiliated hospitals to smaller clinics 
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belonging to two European countries with different health care systems, is likely to be 
representative of oncology care in pediatrics in both high- and medium-income countries. 
Results also represent a deep exploration of experiences around decision making in these two 
settings. 
 
Conclusion 
Overall, results from our study show that decision making in pediatric oncology evolves 
along a continuum, with families and physicians having to sometimes make decisions at 
diagnosis based on a sole choice, only to be presented later in the illness’ course with other 
decisions involving more options and of different complexity. These processes match 
Whitney’s DPM4 and point to its adequacy in guiding clinical practice. However, in moving 
forward to empirically support a decision-making framework in pediatric oncology, 
researchers need to consider its flexibility to accommodate contextual differences and 
potential cultural nuances. Clinicians, ethicists, and researchers should broaden the concept of 
collaboration to bring the focus not on who makes the decision, but how a decision is being 
made. Elements such as the distinct role of patients, parents, and oncologists, diverging 
opinions and conflicts, and the existence of different types of decisions have to be 
incorporated. Taking into account the different constraining factors - no choice or difficulties 
in distinguishing between several choices, uncertainty, and time pressure - communication 
and sharing of information among the three parties seem to be the optimal manner of 
increasing both parental and patient participation in these processes. The DPM is a good 
starting point and reflects the constraining context of a cancer diagnosis, but fails to 
recognize the many ways oncologists can share decisional priority and/or authority with 
parents and even patients. Future endeavors to improve decision-making frameworks should 
place more emphasis on physician-parent-patient collaboration and the support families need 
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to enhance their role in these processes. Additionally, the importance of communication in 
reaching decisions with which all parties can comply and adhere to needs more 
acknowledgement. 
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Appendix. Examples of questions from the semistructured interview guide for parents 
and physicians 
 
Parent Interview Guide 
General information about the patient’s situation 
Let me start by asking you about your family. Could you tell me about them? 
Please briefly describe the circumstances regarding your child’s diagnosis? 
Was your child present during the diagnosis discussion? Why or why not? 
How did you feel about your child’s presence in regards to the diagnosis communication? 
Since the diagnosis was made, have you informed your child about the diagnosis? How did 
you do so? Could you tell me the words you used? For example: what was the first sentence 
you used to start the discussion?  
Treatment options, discussions, and decision making 
What were the treatment options? 
Who was present when treatment options were discussed? 
How were these treatment options described to you and/or your child by your physician? 
If your child was not present during treatment discussions, have you discussed treatment or 
non-treatment options with your child? 
Patient participation in discussions 
In your previous response, you stated that your child was present (absent) during treatment 
discussions. Could you explain the reasons for this? 
Why do you think it was necessary/appropriate to include (exclude) your child from these 
treatment decisions? 
Under what conditions would you absolutely include (exclude) your child in such 
discussions? Please explain these conditions. 
Physician Interview Guide 
General information about the patient’s situation 
How long have you known the patient and his or her family? 
Who did you disclose the diagnosis and prognosis to? If your patient was not present, please 
indicate why. 
What was the parent’s reaction when the diagnosis and prognosis were made? If you 
discussed the diagnosis/ prognosis with the child, what was the child’s reaction? 
Who initiated this discussion related to diagnosis and prognosis with the parents and/or the 
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child? How did you feel during the discussion? 
Treatment options, discussions, and decision making 
What were the treatment options? 
Who did you discuss the treatment options with? 
How did you describe the treatment options to the child and/or the parents? 
How comfortable did you feel discussing treatment options? Please explain. 
Patient participation in discussions 
In your previous response, you stated that the child, i.e., patient, was present (absent) during 
treatment discussions. Could you explain the reasons for this? 
Why do you think it was necessary/appropriate to include (exclude) the patient from these 
treatment decisions? 
Under what conditions would you absolutely include (exclude) patients in such discussions?  
Please explain these conditions. 
Generally, when parents include (exclude) their child from making or taking part in such 
decisions, what kind of reasons, for example values and attitudes, do they give you? 
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Abstract 
 
Insufficient recommendations and practical steps make the implementation of the ethical 
desirability of child participation in care challenging. A qualitative research study conducted 
with 17 minor patients, 19 parents and 16 oncologists explored the practical experiences of 
these participants with child involvement. Results show that for children and adolescents with 
cancer participation is defined by three themes: modes of participation, regulating 
participation and influencing factors. In pediatric oncology the involvement of patients in 
care is complex and the subject of many challenges for physicians. Ultimately, clinicians are 
best positioned to positively shape parental influences on involvement and ensure space for 
children’s expression of choices. 
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Introduction 
Adequate participation of children and adolescents in care is ethically motivated by 
promoting respect for their developing autonomy1,2. In practice, involvement can also 
facilitate understanding about the illness and mediate psychological wellbeing3,4. However, 
participation of minor patients in care is difficult to achieve because it is individual based and 
has to be calibrated to personal abilities that are evolving in the course of treatment5,6. This 
requires close physician-parent communication and sharing rather than exchange of 
information between all parties3,7. Physician training may be inadequate to meet all these 
standards8. In view of these issues, the present study aims to examine how participation is 
materialized in pediatric oncology centers in Switzerland. 
 
Methods 
Semi-structured interviews were carried separately with parents, patients and treating 
oncologists recruited from 8 centers of the Swiss Pediatric Oncology Group. Eligibility 
criteria included: patient age between 9 and 17 years and receiving treatment at any of the 
centers. Ethics approval was obtained from Ethics Committees from each of the states 
(cantons) where the centers were located. All participants offered informed consent before 
the start of the interviews. Data was recorded and transcribed verbatim. Analysis was carried 
by using MAXQDA software and employing thematic exploration of interview themes. 
 
Results 
Fifty-two interviews were conducted with 19 parents, 17 patients and 16 physicians, with five 
oncologists discussing two patients each. Participant accounts portray described child and 
adolescent participation in relation to three themes: (1) mode, (2) regulating participation and 
(3) influences.  
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The first theme describes the different ways in which children were involved in their care. 
Some patients were present from the first parent-physician discussions and received 
unfiltered information. Others were informed by parents after physician-parent 
communication took place. Most children would switch between these two modes of 
communication throughout treatment. Besides participating in discussions, children were 
reported to actively engage through asking questions, gather knowledge by observing and 
sometimes express preferences for care procedures that accompany treatment. This step 
resulted in the inclusion of children in some of the decision-making processes related to care.  
Children’s involvement in care was subjected to actions to regulate their participation. These 
were exerted by patients, parents and physicians. Parental strategies concerned limiting 
participation by controlling the information shared with patients. Together with physicians, 
parents also used pacing of information as a means to avoid overwhelming children. Children 
also used the pacing mechanisms to allow themselves to get used to difficult information.  
In general, participation was shaped by parenting styles, adherence to treatment and 
following strict protocols that inhibit significant participation in treatment decision-making 
and by a desire to foster compliance in children. 
 
Discussion 
Data from this study highlights practical ways in which children and adolescents are 
participating in care during cancer treatment. The inclusion of patients is usually achieved by 
sharing information and inviting their opinions in decision-making processes. However, there 
are limits to their participation that are controlled by parents and physicians. These are 
evident in what concerns treatment decisions or increased risks due to poor prognosis7. 
Similarly, children and adolescents use mechanisms of pacing information and observation to 
establish the level of communication and participation that best fits their needs. Involvement 
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preferences differ among patients and can change in the course of illness for individual 
children. Physicians duty to engage with children is therefore very complex and made more 
difficult by parents’ wishes and views on how best to involve their children in care5,8. 
Adequate physician training on communication with families and children and on how to 
reduce the impact that cancer experiences have on them is necessary9. 
 
Conclusion 
Professional guidance is insufficient when dealing with patient participation in pediatric 
oncology practice. There are several non-static ways in which patients are involved in 
healthcare. Moreover, patients, parents and physicians have their own mechanisms with 
regulating participation and dealing with factors limiting information sharing. Physician 
specific training on how to adequately identify patient wishes and support them in view of 
parents’ influences can improve children’s modes of participation. 
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Abstract 
 
Children diagnosed with cancer and their families experience significant distress during 
treatment. Ensuring their satisfaction with healthcare professionals’ support is important for 
improving health outcomes and delivering patient cantered care. This study examines 
parents’ and patients’ satisfaction with care in Swiss paediatric oncology units and identifies 
areas of improvement. Qualitative interviews were conducted with parents and their children 
undergoing treatment for cancer. Data was subjected to thematic analysis to explore the topic 
of satisfaction with care. Thirty-two participants were interviewed about their experiences 
with care and clinicians. Satisfaction was rated high by parents and children who identified 
good communication, clinicians being available and approachable, making extra efforts to 
support families based on individual needs as improving their experiences. Suggestions on 
how to improve the quality of hospitalizations referred to reducing fragmented care, 
improving communication among healthcare workers and between departments, providing 
solutions to language barriers, and reviewing approaches when offering reproductive health 
choices. Working towards addressing the issues highlighted by participants can have 
reverberating positive effects on improving patients’ and families’ experiences, but also 
medical care and communication within the organization. 
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Introduction 
Clinician behavior and communication when caring for patients diagnosed with cancer and 
their families contribute to improving their experience with the illness1. Physicians’ ability to 
relate to children and their parents influences the building of trusting relationships and higher 
satisfaction2. Apart from clinicians’ characteristics and social capacities, families appreciate 
access to services and competent care, as well as adequate information provision3,4. Research 
on satisfaction in pediatric oncology has mainly focused on end-of-life care and studies do 
not include the patient perspective5,6. We conducted a study in Swiss pediatric oncology units 
to examine parent and child views and satisfaction on provision of care, as well as the issues 
they encountered. 
 
Methods 
Interviews based on a semi-structured guide were used to collect data from 8 pediatric 
oncology centers in Switzerland. Participants were parents of children receiving treatment for 
cancer at those centers, as well as patients between 9 and 17 years old. Data was analyzed 
through repetitive readings and initial open-coding of all data sets. Text excerpts that relate to 
the topic of satisfaction with care were then selected and subjected to thematic analysis. 
 
Results 
Interviews were conducted with 19 parents, 15 mothers and 4 fathers, and 17 children and 
adolescents. Most families were in treatment for less than one year. Participants expressed 
several positive aspects during the care they received, most related to clinicians’ interpersonal 
skills. Parents and patients identified as valuable the caring of the staff, good communication 
and taking extra steps. Information provision and sharing among physicians, parents and 
patients was particularly tied to higher satisfaction. The manner in which physicians 
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approached parents and patients by communicating clearly and not in a condescending way, 
gave families a feeling of being supported.  
Participants reported some difficulties related to transfers to other units, receiving treatment 
in a different center and break-down in communication between different physicians. These 
gave parents additional reason to worry and feel overwhelmed. Additionally, communication 
that was not tailored to their needs lead to dissatisfaction and in the case of one patient, it was 
made even more serious given language barriers. Discussions on preserving fertility in 
teenagers also left parents feeling unease and confused when left to talk about it with their 
child. Children’s reports on care provision gravitated around practical aspects to make them 
more comfortable while being in the hospital: difficulty to handle multiple tests and 
procedures in one day, the sterile environment and limited selection of entertainment games. 
 
Discussion 
Results from this study offer a varied perspective on aspects of care and provision of services 
that influence patient and parent satisfaction, and contribute to wellbeing. These views may 
be easily overlooked during crowded round or routine visits. Considering the many stressors 
that affect families undergoing cancer treatment, clinicians should address the concerns raised 
by participants in this study. 
Communication, when carried in a sensitive way, offering clear information and responding 
to individual needs, was the central factor to influence parental and child satisfaction. 
Similarly, difficulties in communication led to dissatisfaction and restricted parents’ 
participation in their child’s care or their understanding regarding treatment and procedures7. 
Balancing individual parents’ information needs is not an easy task and physicians should 
receive additional training support on how to deal with it8. Parents perceived discussing 
fertility issues and informing children as a very delicate issue. Therefore, good 
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communication may require physicians to pay additional efforts when proposing preservation 
therapies and offer better parental support9. Additionally, communication improvements are 
warranted also within the medical team and attention should be paid to difficulties arising 
from discontinuation of care. 
Language problems were identified by one parent, but given the diversity of Swiss population 
and the existence of 4 national languages, this is unlikely to be an isolated hurdle. This issue 
in particular raises the risk not only to increase parent anxiety and result in dissatisfaction, but 
to limit parental comprehension on treatment and important aspects of care. Developing 
protocols and structures to offer translation services for such patients and their families 
should be a priority. 
 
Conclusion 
Parents’ experiences with pediatric oncology care highlight a general satisfaction with 
clinician competencies, both medical and personal. However, most significant difficulties 
detailed in this study remain in the area of communication. 
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‘Abby is dying. She is eligible for the drug study, but it holds 
only the most remote prospect of helping her. At the same 
time, the drug may be risky and could accelerate her death. (…)  
Abby looks at me and asks whether I think she should be in the 
study. (…) Do I owe it to all the children who will get cancer in 
the next several decades to say yes (to her participation) or 
should I protect Abby from further suffering and say no?’ 
 
(Eric Kodish, MD; 20051) 
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Abstract 
 
Vulnerability is a highly debated topic in research with human subjects. In “Shared 
Vulnerabilities in Research” the author analyses the adequacy of the U.S. Code of Federal 
Regulations 45 (CFR 45) to protect vulnerable human research subjects. He concludes that 
research conferring no direct benefit conducted with a subject from a vulnerable group cannot 
be morally justified on the grounds that the beneficiaries of that research share the subjects’ 
vulnerability. While we agree that the paper’s central argument is not only compelling but 
also valid, we suspect that the argument is unsound, as it rests on the faulty premise that one 
(A) suffers for the benefit of another (B). The argument thus focuses on the individual, rather 
than addressing the collective (group level), as stated by the regulation’s broad wording. 
Hence, the author wrongly extracts A from his group (of vulnerable subjects). Consequently, 
any opportunities or benefits that may come to the group will exclude A. We determine that it 
does make a moral difference whether the beneficiaries share the research subjects’ 
vulnerability. 
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Vulnerability is a highly debated topic in research with human subjects. Although the 
construct of vulnerability is widely used, there is no consensus on its definition or on the 
practical application of vulnerability to protection of research participants, e.g.1,2. In “Shared 
Vulnerabilities in Research” Chwang3 examines whether the U.S. Code of Federal 
Regulations, title 45, part 46 (CFR)4, offers adequate protection to vulnerable human research 
subjects. He concludes that research conferring no direct benefit conducted with a vulnerable 
subject cannot be morally justified on the grounds that the beneficiaries of that research share 
the subjects’ vulnerability3. 
While we agree that the article’s central argument is not only compelling but also valid, we 
suspect that the argument is unsound, as it rests on the faulty premise that one (A) suffers for 
the benefit of another or others (B). The article’s central argument thus focuses on individual 
benefits to B, rather than addressing the group of beneficiaries as a whole, as implied by the 
regulation’s broad wording4. Only by doing so can the author formulate the assumptions to 
support his thesis “that harmful research with to-kind benefits is no less wrong than harmful 
research with not-to-kind benefits”3. 
The subtle difference between individual and group benefits is also considered in the Belmont 
Report5 when fairness is evoked as a guiding principle in research subject selection. In 
discussing the nature and scope of risks and benefits, the Report points out that these “affect 
… society at large (or special groups of subjects in society)”5. Therefore, it is concluded that 
while the protection of subjects should always prevail, group interests such as expected 
benefits in the form of generalizable knowledge may sometimes be sufficient to justify the 
risks of research5. The group argument is compatible with the view that ethically conducted 
and scientifically relevant research that is likely to yield generalizable knowledge constitutes 
a social benefit6. In research, the social benefit is understood as “something of positive value 
related to [the] health or welfare”5 of a particular group5,7,8. Likewise, group theories state that 
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the group as a whole would derive some gains if the group’s objective (i.e. generalizable 
knowledge) is achieved9. In this respect, the thesis should not be framed solely around the 
moral difference of “shared vulnerabilities” between individuals A and B, but also on 
another key difference: whether individual A is a member of the particular group that 
benefits. 
Indeed, we assume that any research subject A, who is vulnerable and shares that 
vulnerability with others, is part of a group together with these others and not with any others. 
As exemplified by the CFR4, this particular group could be one of several classes: pregnant 
women, fetuses, and neonates; prisoners; or children. By accepting the label of vulnerability 
typified by the CFR, the author himself tacitly admits that the vulnerable research subject A 
is part of a group of vulnerable subjects3. This does not equate to saying that A will receive 
direct, indirect, or ancillary individual benefit from research participation, while being part of 
the group. Rather, it seems more plausible that any opportunities or benefits that flow to the 
group as a result of A’s role as a research participant would naturally flow to A, too, as they 
will to the group as a whole. In fact, all individuals in the group will not only seek their 
individual benefit, but also a group benefit that equates to the social benefit of generalizable 
knowledge. As in group theory, individuals’ action in research with no direct benefit is driven 
by necessity (the knowledge cannot be gained in any other way) and is dependent on 
individual behaviors (some vulnerable individuals might consent, while others might not)9. 
Realistically, of course, there will be cases in which research does not yield benefit to the 
targeted vulnerable group as a whole, but these facts cannot be established before the 
research is conducted. In such cases, the priority of the research question and of the expected 
social benefit, as well as the scientific relevance and rigor of the research, are essential to its 
ethical justification. 
Although, “there is no settled framework for how potential social benefit should be balanced 
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against individual risk”10, the group benefit should not be excluded from any such 
assessments and should be explicitly disclosed to individual research subjects11. Ultimately, it 
does make a moral difference whether the beneficiaries share the research subjects’ 
vulnerability, because the shared vulnerability is the core reason around which the group that 
benefits from research with vulnerable subjects is formed. 
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Abstract 
 
Children’s participation in research that does not provide a direct benefit is necessary for the 
advancement of treatment and improving health outcomes in pediatric populations. However, 
the ethical discourse is split between pro-research arguments and cautionary discussions on 
risks and potential exploitation of some children for the benefit of future minor patients. This 
article addresses this controversy in relation to Wendler’s thesis of fostering altruism and by 
taking into account risk-benefit assessments. It further adds a phenomenological approach to 
conceptualize children’s bodies and their vulnerability in research not as mere objects of 
research, but as means to contribute as persons to a project that may not offer any clinical 
advantage to them. Therefore, we propose moving away from viewing children in non-
beneficial research as body-objects and acknowledge their contribution as body-subjects, 
independent of their ability to consent. 
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Introduction 
Research that does not offer the potential of clinical benefit for participants is subjected to 
strict ethical criteria and justifiable in adults by the doctrine of informed consent1-3. Justifying 
the conduct of non-beneficial research with children is more complex. Legally they are 
incompetent, therefore incapable of giving valid informed consent and ethically they are 
labeled vulnerable, deserving additional protections2,3. Different solutions to allow research 
with no direct benefit to child subjects have been formulated but did not result in finding an 
ethical consensus: requirement for substituted consent from a legal representative, enrollment 
only for research that has high social value, that imposes minimal risk for children and cannot 
otherwise be conducted, and the assent of minor participants4. While some scholars argue that 
a degree of exploitation is unavoidable, but acceptable as long as children’s fundamental 
rights are safeguarded5,6, Ramsey declares that research with no prospect of direct benefit to 
the child participant is always unethical7. Studies that do not seek to improve or cure the 
illness of the individual child enrolled are morally wrong because parental consent cannot 
repair the harm inflicted by bodily invasions7,8. This view is too restrictive and risks exposing 
children to harmful experimental treatment without the chance of gathering solid knowledge 
to advance pediatric therapies9. This article contributes to the debate by discussing a 
phenomenological view on the permissibility of enrolling children in non-beneficial studies. 
We leave aside arguments around risks and benefits and analyze the morality of enrolling 
children by looking at the relationship between children as persons and their bodies to avoid 
objectification. This analysis expands Wendler’s thesis of “contribution to a valuable project” 
to incorporate the body-subject view of children’s offerings to knowledge independent of 
their presumed incapacity to consent. 
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Protection and access 
Research restrictions and ethical dilemmas concerning  non-therapeutic research with 
children are the result of past abuses and mistreatment10. Using some minor patients for the 
purposes of developing treatments to benefit others may be acceptable on consequentialist 
grounds, but it remains morally wrong as it instrumentalises some children11. McCormick 
pointed out that even under these circumstances, children can derive a moral benefit by acting 
as agents belonging to a community they can contribute to12. Guidelines incorporated this 
view of children as social beings who have an indirect benefit and allowed their participation 
in research without direct clinical benefits on a “last resort” basis – after tests were done in 
animals and then adults8,13. This approach was too narrow to help advance treatments for 
specific pediatric health issues and in the 1990s a new criteria, the imperative of pediatric 
research, was included to push for improved health outcomes in the pediatric population and 
to limit the off-label use of drugs in children8. Current guidelines specify that non-beneficial 
research can be conducted with children if risks are minimal or slightly above the minimum 
threshold, but have the potential to generate important results and do not expose children to 
procedures that they would not encounter in their daily care14. 
Changes in regulations from limited research to increased child participation have advantages 
and disadvantages. Progress in health outcomes and treatment of children was achieved, but 
guidelines may be too weak to offer protection in what concerns loose clinician interpretation 
of minimal risk and the development of an utilitarian approach in the study and diagnosis of 
some child disorders13,15. However, these drawbacks did not result in questioning the 
necessity of such non-beneficial research or calls for proposal of a better ethical justification 
in research with children16. 
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Developing a non-consequentialist argumentation for research with no clinical benefit 
Treating children only as means is morally wrong and efforts to show how children enrolled 
in non-beneficial research can be ends in themselves take into consideration either children’s 
choices or their interests17,18. The first thesis is based on a will-approach that requires 
researchers to engage children’s wishes. It presumes that present participation in research will 
match the decisions children would make later in life out of altruism. This view is 
intrinsically flawed as it is based on children’s presumed or later capacity to consent and, 
despite empirical research to the contrary, suggests that persons will always act 
altruistically16,19. The second thesis is centered on children’s wellbeing in relation to research 
risks19. Such analysis helps identify what should be an acceptable threshold risk in order for 
the research to be ethical, but does not address the children’s contribution as social 
beings19,20. Several scholars who focus on altruism in children as a justification and means to 
benefit them are equally unconvincing. Evidence lacks on how such children may experience 
their participation and it cannot be assumed that young children with low cognitive capacities 
can even grasp the meaning of their contribution for others18. Therefore, the fostering 
wellbeing approach leaves unanswered the question why non-beneficial research should be 
allowed in the first place16,19. 
 
A contribution to a valuable project 
Wendler proposes an ethical analysis based only on risks and benefits, emphasizing the 
acceptability of exposing some children to harm for the benefit of others within certain limits, 
as imposed by legal provisions16. This approach allows for the inclusion of the societal aspect 
of research and the identification and role of non-clinical benefits to research participants19. 
He contends that it is in the interest of persons to have a better overall life and that 
participation in research, viewed as ways to engage in community activities and build 
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meaningful relations, can help achieve this19. Furthermore, Wendler16 affirms that children, 
even in the absence of capacity are contributing their bodies and that this benefit is only 
maximized for children with increased cognitive capacities16. 
The contribution to “a valuable project” fails in consideration of several aspects: not all 
children will cherish their participation in research as a beneficial contribution, and the 
research study may not reach the anticipated aim of producing important generalizable 
knowledge21. Furthermore, Wendler’s focus on risk/benefit ratio16 cannot identify why it is 
morally wrong when children from a particularly disadvantaged group are overrepresented in 
non-beneficial studies22. This issue is particularly important when analyzed in relation to 
Ramsey’s absolute claim that all non-beneficial research with children is wrong7. In the end, 
children can achieve a meaningful life by making different contributions which do not 
necessarily involve exposing them to physical risks18. 
 
The body as subject 
Both the will and the best interest approach described above take as a given the fact that 
children are vulnerable due to their incapacity to consent and their propensity to be harmed 
by research. However, all persons experience vulnerability in their bodies as it is an inherent 
condition of being human23. The likelihood of being harmed through the body is not specific 
to children or linked only to specific activities, such as pediatric research. As such, persons 
are not only vulnerable in their bodies, but are vulnerable to their bodies, as the person and 
her corporality form the whole human being24. 
Vulnerability in bioethics is usually interpreted as a weakness that needs to be corrected 
either through protective practices or by elimination23,25. It poses the danger to stigmatize 
some groups26 and may not be able to recognize or be sensitive to different vulnerabilities 
that may concurrently act upon a person27. Correction as a remedy to vulnerability is usually 
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connected to emphasis on the power of informed consent and the role of autonomous 
decision-making, therefore acknowledging that persons can dispose as they see fit of their 
bodies28. However, people do not own their bodies, from which they cannot be separated and 
which are part of the person they are29. Furthermore, the vulnerability intrinsic to having a 
body cannot be eliminated. At the same time, persons interact with others through their 
bodies which facilitate building relations. As such, the body becomes an expression of the 
person and the means with which she engages with the world28. Particularly for children, this 
embodiment of the person is visible when, as their cognitive and emotional capabilities are 
developing, they use their bodies to communicate.  
Understanding children’s participation in non-beneficial research through the lenses of the 
body as expressive of the person shifts the focus from a passive contribution to an active one. 
As such, the body is not a mere object that, used to instrumentalize children, but a subject that 
actively contributes. This view resolves the problem of children’s inability to provide consent 
and does not necessarily require a conscious knowledge of the symbiosis between self and 
body30. The relation body-self becomes evident in case of illness, when one experiences the 
harms of the corporeal being through pain and other physical symptoms31. What becomes 
evident in this situation is also the impossibility of eliminating the vulnerability given by the 
body, as the suffering cannot be transferred to another person. 
 
Conclusions 
A body-subject interpretation to children’s participation in non-beneficial research 
contributes to finding a solution to the ethical dilemmas that this type of research poses in 
relation to minor patients and their vulnerability. Wendler’s suggestion to acknowledge 
children as participants and not mere subjects of research hints to the validity of the 
contribution made through embodiment19. The embodiment-approach also incorporates the 
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additional non-clinical benefits that children may experience and supports the need for child’s 
developmental assent and the importance of respecting dissent. However, it is not a standard 
to be applied practically, but rather offers a general defense of conducting non-beneficial 
research ethically. 
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Abstract 
 
Being involved in healthcare can result in benefits for children and adolescents, but some 
patients may choose to have a reduced involvement in decision-making and information 
sharing. In order to explore children’s perspectives on being involved in cancer care we 
conducted a qualitative study in Switzerland. Interviews with 17 pediatric patients were 
coded using thematic analysis. Participants’ accounts described participation ranging from 
direct to indirect involvement, with more child input in general discussions regarding 
treatment and care. Patients were in the background of decision-making processes regarding 
treatment, but had their voice heard in matters regarding care delivery. Variation in patient 
involvement in care may account for children’s and adolescents’ preferences and fluctuating 
wishes while undergoing treatment for cancer. 
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Introduction 
Children’s participation in care can be achieved in different ways, most of which are part of 
communication processes: information exchange, expressing opinions, collaborating in 
making decisions1,2. The different degrees of involvement in care are influenced in pediatric 
oncology by prioritization of compliance with strict treatment protocols3,4. As such, 
children’s preferred level of involvement may be difficult to achieve and result in increased 
loss of control, anxiety and uncertainty2,5. We conducted a qualitative interview study in 
Swiss pediatric oncology centers to investigate child and adolescent views on how they 
participate in care, their position and needs in communication. 
 
Methods 
Interviews with the three parties – parents, patients and physicians - involved in care for 
children diagnosed with cancer were conducted in Switzerland. For the purposes of this study 
we report data only on child and adolescent interviews. Collaborating physicians recruited 
families from 8 pediatric oncology centers from three linguistically diverse Swiss regions, 
Swiss-French, -Italian, –German. Purposive sampling was used for sampling procedures. 
After parental agreement, minor patients were invited to participate. A guide with semi-
structured questions on experiences from diagnosis onwards was used to elicit children’s 
opinions. Data was analyzed using qualitative thematic analysis. 
 
Results 
Interviews were conducted with 6 female and 11 male patients with ages between 9 and 17 
years at the time of diagnosis. Discussions with participants and data analysis resulted in the 
identification of three themes of participation. The first theme on communication and 
decision-making roles revealed various positions that minor patients occupied at diagnosis 
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and then later in the course of treatment. These oscillated between being present in 
communications regarding treatment and hospitalization procedures and contributing to 
discussions or in making decisions. Direct involvement for most patients started with 
diagnosis disclosure. However, few patients did not witness the diagnosis discussions 
between parents and physicians. These children were later informed by their parents.  
Children and adolescents described how in the course of treatment they started to participate 
in discussions by asking questions and through physician and parent invitation to contribute 
to making decisions. Accounts of involvement in decision-making highlight the fact that the 
patient’s role was stronger in choices regarding care. In what concerned treatment decisions, 
children and adolescents were sometimes given the opportunities to express choices 
regarding research participation or fertility preservation. However, their position was not that 
of a final decision maker. Research participation decisions were made collaboratively with 
parents and physicians and fertility preservation choices were taken into consideration only 
when they did not delay treatment.  
The second theme of participation highlights the effect that it had on children. In general, 
participants were satisfied with their participatory roles and with how communication was 
carried. However, some children identified difficulties in the way information was shared. 
These ranged from inability to understand, physician use of medical language, excess of 
information in relation to technical procedures (e.g., insurance schemes and payments) and 
insufficient explanations regarding medical tests and side-effects. This sometimes left 
patients feeling frustrated and anxious, particularly in the context of decision-making. 
Participants’ thoughts and opinions about participation is the third identified theme. Children 
and adolescents perceive involvement as the normal thing to do, as they are the ones having 
and suffering from the illness. Moreover, patients expressed a wish to receive information 
from the most competent persons, the physicians. Oncologists were perceived as qualified to 
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explain the illness and treatment and also patient-physicians direct communication can 
undercut parental strategies to limit information. Preferences for how communication should 
be carried varied among patients and even changed for some children at different times in the 
course of illness. 
 
Discussion 
Child and adolescent accounts of participation in cancer care emphasize the need to advance 
patient involvement in care. Similar to previous studies, participants in Switzerland described 
their involvement in communication and decision-making as convoluted3,6,7. They discussed 
difficulties with both involvement and non-involvement as shaped by parents’ and 
physician’s behavior. At the same time, children reported their own struggles to find a 
context dependent degree of involvement that is satisfactory to them. Their preferences to 
sometimes participate and other times to be less active in communication and decision-
making emphasize the need to repeatedly assess their needs5. 
Hart’s model of participation describes various involvement levels that are similar to those 
discussed by participants in the study8. The ladder has its range from a bottom child-initiated 
level to a model of collaborative decision-making placed at the top. The visual pyramid of 
this model suggests that at the higher levels the achieved participation of children is more 
important compared to the bottom levels8. However, involvement has a qualitative value and 
when in harmony with child abilities and wishes it is appropriate and meaningful. Different 
types of involvement can be better conceptualized by introducing a concept of degree of 
participation. This can account for various influences and burdens experienced by patients 
and should be individual based. As such, children may favor different degrees of participation 
and be satisfied with moving from one to the other depending on context and their specific 
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preferences at that time. The degrees of participation from less to more involvement are 
likely to meet children’s fluctuating and developing needs3,9.  
Future studies should examine how clinicians can better identify and assess the needs and 
preferences of individual patients. Steps to facilitate communication among physicians, 
parents and children should be explored with the aim to improve patient comprehension. 
 
Conclusions 
Children’s and adolescents’ views are not commonly explored in clinical research. This study 
contributes minor patients’ reflections on their care and emphasizes that participation is 
desired and meaningful for children with cancer, despite difficulties. 
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“Dry your tears up, all your crying 
Cannot fix me up my darling  
(…) Twisty, turning winding path 
I could listen to your laugh 
As we tiptoe on these humble truths” 
 
(Fix me up, Sammy Brown & Zach Sobiech1) 
 
Chapter IV 
 
End-of-life care: controversies and ethics  
in search of a good death 
 
 
 
 
                                                          
1A Firm Handshake, Fix me up. Lyrics written by Sammy Brown and Zach Sobiech. 
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Abstract 
 
Children’s and adolescents’ abilities may support their involvement in decision-making at the 
end-of-life. The developmentally appropriate involvement can be ethically justified, but the 
outcomes of minor patients’ contribution to make difficult choices when treatment fails are 
unclear. The purpose of this article is to offer a systematic review of pediatric studies carried 
at the end-of-life and investigate what are the effects of children’s inclusion. Searches in five 
biomedical databases were carried to identify research with minor patients at the end-of-life. 
We screened overall studies for patient characteristics, choices that were made available and 
the outcome of final decisions. From 57 included articles, the majority examined family and 
clinician experiences and only 14 looked at child and adolescent views. Both positive and 
negative outcomes of participation were identified. These results emphasize a lack of 
research to identify factors that have a positive influence on child and adolescent 
participation at the end-of-life. Also, barriers and possible frictions between physicians, 
parents and patients are overlooked. This stalls progress on developing mechanisms to 
resolve eventual communication problems in decision-making processes and to support child 
participation at the end-of-life. 
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Introduction 
Childhood cancer treatment improvements have reduced mortality rates1. However, for some 
patients therapy will fail, leaving families, children and physicians to make difficult decisions 
regarding enrollment in phase I clinical trials, opting for withholding or withdrawing of life 
support, trying aggressive chemotherapy or choose palliative care. Professional organizations 
in pediatrics propose a developmental approach to patient participation, which in practice 
should result in different levels of involvement, from being informed to being the main 
decision maker2,3. Minor patients’ involvement is limited by legal provisions and should take 
into account parental and patient wishes for involvement. 
Research on benefits of child inclusion in care at the end-of-life (EOL) suggests that open 
communication helps relieve anxiety and may results in improved outcomes for parental 
wellbeing. However, positive outcomes have not been weighed against negative effects of 
inclusion and there is significantly less knowledge on harms4-6. At the same time, patient 
preferences and needs of inclusion and communication vary in the course of illness and some 
children may resort to avoidance to protect themselves against distressing information7-9. 
The purpose of this review is to assess the involvement of children in end-of-life decision-
making (EOL DM), the effects of their participation on all parties and on the process itself. It 
systematically analyzes EOL studies to identify ways in which children are involved and 
subsequent outcomes. 
 
Methods 
A three-phase systematic literature review based on the PRISMA10 protocol was conducted to 
scan for original studies on child and adolescent involvement in EOL care in five databases: 
PubMed, Medline, PsycInfo, CINAHL, and Sociological Abstract. Research in neonatal care 
and on physician assistance in dying and euthanasia were not included. 
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Results 
A majority of the 57 research articles selected at the end of the systematic review process 
were concerned with parents’ or healthcare professionals’ views and only 14 also captured 
the experiences of children and adolescent patients. Decisions offered to families and patients 
included: withdrawing/withholding of treatment, advance care directives, phase I clinical trial 
participation, continuous deep sedation, choosing place of death. 
From the studies that had adult participants, some mentioned children’s preferences, 
emotions or choices as being taken into account in decision-making11-20. A small number of 
articles described in more detailed how child participation was achieved and even fewer 
reported outcomes15,20-23. Parents stated that children sometimes were told about the adults’ 
decisions to stop treatment20 and had a gradual involvement in decision-making processes23. 
Participation was influenced by how much children understood what they were told, their 
individual awareness about what was happening around them15,23 and cultural attitudes 
towards cancer21. The approaching of death was discussed rarely with children22 and only in 
five studies some children were the ones to make decisions17,24-27. 
Studies that enrolled child and adolescents participants examined their views on being 
involved and their preferences for collaborating with adults or being the sole decision 
makers28,29. Six articles also tested the development of advance care tools or directives for 
minor patients and reported better agreement between child and parent preferences after 
implementation30-35. In one qualitative study patients were supported to explore their 
preferences and values regarding the illness and decisions around the time of death29. A 
report study on end-of-life decisions highlighted the burdensome effect and the distress these 
can cause in a patient as her condition deteriorated36. 
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Discussion 
Child and adolescent patients’ views at the EOL are scarcely researched and the outcomes of 
their involvement in care are inconsistently reported and cannot be compared across studies. 
Parents’ and clinicians’ attitudes and experiences with child involvement are examined more 
often. Adults’ accounts show that children’s preferences influence decision-making 
processes, but it is unclear how and to what extent. Different aspects of participation were 
identified in the reviewed studies: offering information37,38, engaging children and 
adolescents in planning future care30,31,33,34, supporting patient expression of personal beliefs 
and wishes for when they die23,36, seeking child agreement with what adults decided20, 
communicating with patients about decision-making and collaborating with them4,36,37. 
However, some possibilities reported under child participation, such as patient consultation 
after the decision is made, may be viewed as barriers to involvement or parents’ strategies to 
avoid discussing difficult treatment decisions with children. Despite these findings, there is 
research showing that teenagers wish to have a say and make decisions in collaboration with 
parents28. Several advance care planning tools prove to have clinical utility and facilitate 
EOLDM30,31. 
 
Conclusions 
Minor patients’ involvement in EOLDM is difficult, but gradual efforts to identify children’s 
preferences can result in positive experiences by showing respect for patients and help them 
leave behind memories. Helping children and adolescents voice how they want to be 
remembered can improve medical and spiritual care and thus benefit patients and families. 
Future research should explore how to adequately and better achieve participation in 
EOLDM. 
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Abstract 
 
Debates on morally acceptable and lawful end-of-life practices in pediatrics were reignited by 
the recent amendment in Belgian law to allow euthanasia for minors of any age who meet the 
criteria for capacity. Euthanasia and its legalization in pediatrics are often opposed based on 
the availability of aggressive palliative sedation. For terminally ill patients this type of 
sedation is often identified as continuous and deep sedation until death (CDS). We 
demonstrate that this reasoning is based upon flawed assumptions: (1) CDS is a morally 
preferable alternative to euthanasia; (2) CDS can meet the same patient needs as euthanasia; 
(3) children lack the capacity and experience to make end-of-life decisions; (4) unlike 
euthanasia, CDS does not raise capacity issues. Our aim is not to reject CDS as a valid option 
at the end-of-life, nor to offer a clear-cut defense of euthanasia for minors, but to emphasize 
the ethical issues with both practices. 
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Introduction 
Dying patients with refractory symptoms face physical and psychological suffering as 
symptoms are no longer controllable by standard therapies. To relieve their suffering, patients 
receive palliative sedation, that is, the monitored and intentional administration of sedative 
drugs to induce reduced or absent awareness (unconsciousness)1,2. Sedation can be mild, 
intermittent, superficial or continuous3. Professional guidelines consider palliative sedation 
an accepted and established form of care at the end-of-life (EOL) if patients are (1) terminally 
ill; (2) in the last stages of life and (3) suffering from one or more refractory symptoms2-8 (see 
Table 1). 
Continuous deep sedation (CDS) is the means to render the patient fully unconscious until the 
moment of deathi. In addition to the above criteria, this sedation is accepted only for 
imminently dying patients for whom intermittent or respite sedation fails to provide relief8,9. 
Therefore, CDS has to be proportional, a last resort after other palliative means have failed. 
The proportionality principle guides medical procedures by balancing harms to the patient 
(suffering from refractory symptoms) with side-effects (reduced or loss of consciousness) and 
risks (potentially life-shortening). The greater the suffering, the higher the risks physicians 
can take10. It is important to emphasize that CDS is a last resort measure which requires the 
consent of the patient (or surrogate)9. When these two additional conditions are met, most 
institutions do not require a review process by another physician or to report the procedure to 
institutional or health authorities2-4,6,7. Some organizations suggest an interdisciplinary 
consultation prior to starting CDS4,6,7. However, there is no agreement on the type of experts 
that should be involved and whether the consultation should result in consensus (see Table 1). 
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CDS administration is recommended after careful consideration of the adverse outcome of 
taking away consciousness, and the risk of potentially shortening life2. These negative effects 
are condoned because CDS is considered to be the only means to alleviate patient’s suffering. 
Clinicians seem thus to be operating under the doctrine of double effect (DDE), which plays a 
central role in justifying and permitting certain practices at the end-of-life when the physician 
(non-)intervention brings about both good and bad effects11. The DDE’s classical 
interpretation originates from the Roman Catholic moral tradition. It has often been used to 
solve moral dilemmas regarding end-of-life practices11 and formulates that an agent’s 
(physician’s) actions are licit when 4 conditions are met cumulatively, at the same time: (a) 
the action, in itself, should be positive (good) or at least neutral; (b) the action intends to 
achieve the good and not the bad effect; (c) the good effect cannot be achieved through the 
bad effect and (d) effects must be weighed so that only a “proportionally grave reason”12 
allows for the bad effect to happen13. In CDS clinicians’ aim is not to hasten death, but to 
provide relief in the face of the anticipated, parallel, though unsought, consequence of 
possibly shortening life14-16. Therefore, the good, intended effect is to alleviate pain and the 
bad effect is the loss of consciousness, also sought, but licit only when the proportionality 
principle is respected and there is a valid informed consent, as explained above. 
Hastening death in CDS and survival time in patients receiving palliative sedation is a highly 
debated issue9,17-20. Studies correlating time of death and palliative sedation21-23 report that 
there is no evidence that sedation significantly hastens death: “sedation has no apparent 
effects on patient survival, at least on a mass level”23. Only for a limited number of patients, 
palliative sedation is associated with catastrophic events, causing death23. In light of such 
conclusions it seems that DDE’s use to justify CDS is superfluous. 
A systematic literature review24 concludes that evidence provided by studies should be 
interpreted with caution given the high bias risk due to lack of randomization. Most studies 
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fail to provide adequate description of the timing, duration and level of sedation24. In these 
clinical trials a comparison is made between non-sedated and sedated groups, but the degree 
of sedation is generally not further specified (mild, intermediate or deep and continuous or 
intermittent). Thus, the impact (or lack thereof) of CDS, on the time of death remains difficult 
to ascertain. This difficulty also stresses the need to use terminology accurately. Palliative 
sedation includes a spectrum of different interventions that might evolve from relatively light 
sedation to CDS toward the end of a patient’s life. While it is important to recognize the 
proportionality principle (correspondence between symptoms and level and length of 
sedation) and not to equalize CDS with palliative sedation as such, it is equally important not 
to “hide” or “obscure” CDS under the umbrella term of palliative sedation. Even if CDS 
“rarely if ever hastens patient death”10, it takes away an important human good, 
consciousness9; a dying patient might claim that his “real” life is ending when he loses 
consciousness following CDS. It is this particular context that needs to be considered when 
discussing the DDE. 
In ethical discussions around CDS the DDE plays an important role, but it is also criticized. 
Not only it is impossible to know what is in a physician’s heart and mind regarding hastening 
death as intentions are often ambiguous and contradictory25, but the fact that loss of 
consciousness is the means to the good effect (pain relief) and thus not just an unintended 
negative side-effect, significantly undercuts the force of the entire DDE argument as it is 
clearly in opposition to the third condition (c)9,12. 
Despite difficulties in applying DDE to CDS, guidelines rely on it to draw a clear distinction 
between the palliative scope of CDS and the more direct life-shortening intention of other 
EOL practices, such as physician-assisted suicide (PAS) and euthanasia2. PAS refers to the 
practice of prescribing drugs in lethal dosages by a physician with the purpose of providing 
patients with a means to end their life26. Voluntary active euthanasia (VAE)ii is the practice 
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of a physician intentionally ending a patient’s life upon the voluntary and persistent request 
of that person. In those (few) countries where PAS and VAE are lawful, a review and report 
to health authorities are mandatory27. 
Recently, the debate on morally acceptable and lawful practices at the end-of-life has been 
reignited by a change in the Belgian law to allow euthanasia for minors of any age, as long as 
they meet the criterion for capacity28. Critics of this bill argue that euthanasia is morally 
wrong as the physician’s aim should always be to relieve suffering, not to end life. In their 
view, euthanasia is not only incompatible with physician’s role as healer, but also the 
availability of aggressive palliative sedation or CDS eliminates the need for the legalization 
of euthanasia as it can alleviate even extreme suffering29. The main purpose of this article is 
not to reject CDS as a valid option, nor to offer a clear-cut defense of euthanasia, but to 
overcome the deadlock in this debate by raising awareness about the ethical issues with both 
practices. Decisions at the end-of-life are loaded with uncertainty and require demanding 
clinician responsibilities in guiding honest communication for patients approaching death30,31. 
Death and dying, and EOL options often incite many passionate reactions in the public sphere 
that overshadow the personal experiences of dying patients. Despite advances and significant 
financial and structural efforts, palliative care services are still underdeveloped and care does 
not always reflect patients’ wishes on how to die32. Resisting euthanasia by proclaiming 
aggressive sedation to be a “panacea” ignores the shortcomings it may have in eliminating 
various forms of physical and existential suffering33. That leaves little room for discussing 
what patients envision as a death without suffering, commonly referred to as a death with 
dignity. Also for minor patients dying under sedation may infringe upon their dignity when 
this process does not correspond to their wishes for a “good death”. It may circumvent patient 
needs and be disrespectful toward children who have the capacity and experience to express 
such wishes. The dilemma for these patients and their families is not if they will die, but how 
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they will die. We believe euthanasia and its legalization in pediatrics should not be opposed 
based on the availability of CDS because this type of reasoning is grounded upon 4 flawed 
assumptions: (1) CDS is a morally preferable alternative to euthanasia; (2) CDS can meet the 
same patient needs as euthanasia; (3) children lack the capacity and experience to make end-
of-life decisions; (4) CDS does not raise capacity issues. 
 
1. Is CDS a morally preferable option? 
The practice of palliative sedation (“to the point of causing unconsciousness and hastening 
death”) has been used in courts in North America as an argument against the need for 
legalizing PAS. In court decisions the two practices are placed side by side, separated by a 
lawfulness criterion and the seemingly arbitrary proclamation that the former is morally 
preferable to the latter, as long as it operates under the DDE34. This means that even if the 
life-shortening effect of CDS might be rare, its potential to hasten death is not fully excluded 
as the strict rules under which sedation to unconsciousness is condoned derive exactly from 
accepting this possibility. This also means that the intention of the moral agent, i.e. physician, 
cannot be overlooked in the ethical evaluation of CDS. 
The “preferable alternative” (PA) argument has been criticized18,20,35 by focusing among 
others on physician intent, informed consent and the so-called natural death hypothesis20,36. 
The same PA argument has been used in opposing euthanasia legalization in children in 
Belgium29. Therefore, we briefly recast this ethical discussion by focusing on CDS and 
euthanasia within a pediatric context. 
Studies investigating CDS, mostly come from European countries (Belgium, the 
Netherlands, United Kingdom)37-39, but also Asia23. This research shows that an intention to 
hasten death might be either concomitant or explicit to physicians’ reasons for starting 
CDS37-39. The one study conducted in pediatrics suggests that this might also hold true for 
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CDS in children. For a quarter of minor patients in a study in Flanders (Belgium) hastening 
death was concurrent to or the aim of administration40, eroding thus the apparent distinction 
between CDS and euthanasia. Contrary to the stipulated guidelines, almost none of the 
children had requested or given consent for CDS and in over 20% of the cases parents’ 
consent for deep sedation was missing40. Research also seems to indicate that the use of CDS 
has increased in end-of-life care21,37,38,41,42. This seems to be in contradiction with the “last-
resort” framework within which CDS should operate. This reported increased use may only 
concern a small series of studies that are in no way generalizable to the use of routine 
palliative sedation or of CDS in all contexts. Also, the ethical evaluation of a practice such as 
CDS cannot be based solely on its possible “abuse”. However, these studies highlight that 
both patients’ and physicians’ true intentions are difficult to assess. Goals and motives are not 
only multiple25, they are also often the expression of unconscious volition. Hence the DDE 
does not constitute a reliable moral basis to distinguish CDS from other EOL practices17. In 
practice, the cumulative conditions for DDE are difficult to apply and adherence to moral 
norms may be inconsistent when considering the two bad effects, loss of consciousness until 
death and the potential to shorten life. 
The increased frequency use might also indicate that CDS is becoming more and more 
acceptable among patients, family members and physicians. According to Raus and 
colleagues36 increased acceptability has something to do with the growing association 
between CDS and the concept of a “natural death”, where nature determines the timing of 
death as opposed to a so-called medicalized death. To patients and their families, CDS may 
offer comfort as it resembles a deep sleep in which patients gradually fade away due to their 
illness and without apparent direct human interference. In the case of children these elements 
are even more likely to be sought, as it is particularly difficult for parents and care providers 
to face such losses30,31,43,44. However, CDS is only a mimicry of a natural death as the patient 
Chapter IV: End-of-life care: controversies and ethics in search of a good death 
 184 
is not sleeping, but in a medically induced coma. Death is not automatically the result of the 
underlying disease, but can be caused by the unpredictable effects of sedation, such as 
respiratory depression and aspiration2,45. Besides that there is not a clear correspondence 
between CDS and natural death, this association is also deeply problematic as it minimizes 
the ethical problems of CDS and sidesteps the debate about its ethical safeguards. Natural, in 
fact, is often equated with being morally good and therefore upheld as a normative ideal. 
Depicting CDS as “natural”, signifies portraying CDS as a normal and acceptable practice as 
opposed to deaths caused by other end-of-life practices, such as euthanasia36. However, as 
might clear from the above, in practice this ethical difference is not as clear-cut as often 
presumed because it is not always easy to determine whether a physician aims exclusively at 
the relief of suffering or also at the hastening of death. Moreover, if CDS is practiced without 
patient consent, it has an element of non-voluntariness and possibly becomes more 
problematic than euthanasia. Hence, it is highly problematic to oppose euthanasia by arguing 
that CDS is an ethically preferable alternative because in practice the standard ethical norms 
for CDS are difficult to apply and often violated. 
 
2. Does CDS meet the needs of all dying children? 
Patients with terminal illnesses experience many physical and psychological debilitating 
symptoms and may express different wishes at the end-of-life. For some patients, living with 
a poor prognosis and declining health prompts them to make a request to die with dignity27,46. 
Research shows that those who are granted euthanasia are often younger (below age 65) and 
highly educated patients. They experience both physical and existential (fear of loss of 
autonomy and quality-of-life) suffering, in the whole of their person47. CDS is more 
frequently used in elderly patients (over age 65)27,48 who are near to death and have 
unbearable physical pain combined with other refractory symptoms, such as dyspnea and 
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anxiety37-39,42,49,50. CDS use is generally not accepted for the only purpose of relieving 
existential suffering10. 
Legal regulations portray a similar image: in countries or states where euthanasia is legal, it is 
an option for patients who seek a dignified death on their own terms in order to avoid 
unbearable physical or psychological suffering51-53. In the Netherlands and Belgium, 
euthanasia is allowed independent of a narrowly defined expected survival time. CDS on the 
other hand, is indicated for imminently dying patients with intolerable physical symptoms 
that have proven refractory to standard treatment2-4,9. Hence, CDS and euthanasia seem to 
meet distinct needs of different kind of patients. Therefore, it would be wrong to preclude 
considering euthanasia a priori by referring to the CDS option. 
In pediatrics, the criterion for CDS administration is more rigidly applied considering the 
limited evidence base of palliative sedation in this population. Due to the relative lack of 
data, administered doses could be too high and increase the risk of hastening death to a 
greater degree than necessary40,54,55. As a consequence, CDS in children is usually used very 
restrictively and started only in the week or even a few days before death. Although 
withholding or withdrawing medically provided fluids and nutrition is consistent with 
symptom relief at the end-of-life, for pediatric patients they are generally continued40. This 
shows the difficulties pediatricians face in limiting therapeutic treatment when confronted 
with children at the end-of-life. It may also explain the general concern and disquiet about the 
Belgian Parliament’s decision to allow euthanasia for chronically ill children. 
In Belgium euthanasia has been legal since 2002 for persons 18 years or older, but since 
March 2014 the age limit has been removed. Euthanasia is considered an option in pediatrics 
if patients are terminal and experiencing constant and unbearable suffering. Other criteria 
include: an explicit and voluntary request made by the minors themselves, consent from both 
parents and a multidisciplinary team should examine the children’s decision making capacity 
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for discernment. Therefore, children with an intellectual disability or mental illness are 
excluded from opting for euthanasia28,56. Moreover, unlike for adults, the Belgian law 
excludes existential suffering as a self-standing criterion to request euthanasia in children.  
Despite these criteria, the recent amendment has been fiercely opposed not only because of 
its possible misuse in a vulnerable population such as children (the so-called “slippery slope” 
argument), but also because it is presumed that the request for euthanasia by children cannot 
be motivated by the same “sophisticated” needs that adults express in their requests29. 
Children can be vulnerable to unbearable pain, but they do not have enough life experience to 
understand death or to be susceptible to fear of humiliation or loss of control that end-of-life 
conditions may bring about. Their physical suffering can be relieved by aggressive palliative 
sedation. 
For patients sedated to unconsciousness until death, it is impossible to know if their pain and 
suffering was alleviated, as no means of self-report are possible. However, observational 
studies on the effects of palliative sedation at the end-of-life produce limited evidence of 
palliative sedation’s efficacy in adequately controlling symptoms as patients showed signs of 
fear and anxiety23,24,42,57. This should be considered worrisome, especially in pediatrics where 
pain management is a sophisticated issue. 
Research shows that, compared to their healthy peers, children with terminal illnesses often 
have a mature concept of death and develop an understanding of how they want to die and 
how they want to be remembered58-60. Some minors even express the belief that “life on a 
machine is not living”61. Some children may want control over what is happening and to 
enjoy life as long as possible 58,61. These considerations about death and dying mainly come 
from their illness experience, the familiarity with the medical context and their interactions 
with health care professionals and parents62-64. Hence, we should ask ourselves whether CDS 
can really meet the needs of all dying children or whether such an assertion is the expression 
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of an adult-centric view that circumvents knowledge gained on children’s understanding of 
illness and death as described by several scholars59,60,65-67. 
 
3. Children’s capacity for end-of-life decisions 
Closely connected to the needs-discourse is the one concerning capacity. Opponents of 
euthanasia in pediatrics, not only argue that children lack so-called “sophisticated” needs, 
they also deny that children have the capacity to make legitimate requests for euthanasia29. 
This view seems to be grounded in the widespread belief that children are impaired and 
inexperienced and adults know best. The problem is that such generalizations keep us from 
acknowledging what children can really achieve. Moreover, it sidelines the ever growing and 
significant body of international pediatric guidelines that seek to recognize children as moral 
agents capable of making decisions regarding their own health, at a level commensurate with 
their cognitive and emotional abilities4,68,69. Observance of this recommendation requires a 
careful assessment of the individual child’s capacity in order to achieve involvement that is 
adequate and desired by the patient70. However, it would be wrong to claim that children’s 
inclusion amounts to them dominating the decision process. The pediatric setting is unique as 
it is characterized by triadic discussions, involving health care personnel, children and 
parents. As such, physicians and parents should not only pursue children’s best interest, but 
also facilitate decision-making by equipping children with the abilities to form and express 
their choices and wishes. Decision-making is influenced by personal values71, which weigh 
heavier when making end-of-life decisions. One of the arguments put forth to object 
awarding decision-making capacity even to those underage patients who meet the criteria for 
understanding and reasoning is related to their developing values. In order to provide assent 
or consent to treatment, patients have to be able to appreciate and apply the information in 
relation to their own context and values72,73. Children often do not hold a stable set of values 
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until they reach adulthood or preferences and wishes fluctuate with age and depending on the 
decision to be made74. However, in the case of children facing terminal illness the change or 
maturation of values is cut short and the present held beliefs should be properly 
acknowledged75. This is especially the case in end-of-life situations when curative goals are 
no longer an option76. 
The transformation in goals of care and re-orientation towards quality of life and a painless 
death should incite clinicians and parents to initiate discussions on end-of-life issues and ask 
questions regarding minor patients’ views, wishes and preferences. The use of advance 
directives can successfully foster communication between the three parties66,77 and reveal 
children’s wishes for funeral arrangements, the image they leave for others to remember, 
dying surrounded by family and last opportunities to say goodbye62,78,79. The Belgian 
euthanasia law is very much in line with these pediatric guidelines and triadic context as it 
requires not only the explicit and repeated request of the child, but also the consent of both 
parents and physician assessment of capacity discernment. Still, since there are no 
standardized methods to assess children’s capacity80,81, health care professionals mostly have 
to rely on their intuitive judgments on whether and how to apply these guidelines. The 
uncertainty about children’s capacity may explain the protective attitude many people 
continue to have towards children and why the Belgian law may be disturbing to them. 
However, this difficulty does not clarify why CDS would be a morally “safer” option in 
pediatrics than euthanasia. This brings us to the fourth and last assumption of the preferable 
alternative argument. 
 
4. Doesn’t CDS raise capacity issues too? 
The pediatric guidelines regarding child participation also regard palliative sedation. This 
means that also in the case of CDS, physicians and parents should involve children and seek 
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their consent. However, if we assume (for the sake of argument) that children are incapable to 
consent to euthanasia, then how could they possibly consent to CDS? What do opponents of 
euthanasia intend when they assert that children’s request for euthanasia is not legitimate and 
CDS is ethically “safer”29? They seem to suggest that CDS does not raise the same issues 
regarding capacity as euthanasia because sedation does not involve any “sophisticated” 
choice82. Children merely consent to the ending of unbearable suffering and not to the 
hastening of death. Still, it is only thanks to its growing association with the concept of a 
natural death that CDS seems to involve less complicated choices. We should not forget, 
however, that CDS is a medically induced coma which leads to a complete loss of 
consciousness and amounts thus to a kind of social death35. This is why we should not merely 
condone the fact that in many cases the decision to start CDS is taken either by the parents 
and the physician together or only by the physician without asking the child’s consent. Since 
the intent is not to kill, but to relieve pain, CDS might seem compatible with parents’ and 
physicians’ roles as respectively protectors and healers, but, although CDS does not kill the 
patient (or at least not in principle), it takes away consciousness. It suppresses sentience up to 
the point of passing away and thus entails a complex choice at the EOL. Some children may 
wish to express the desire not to spend their final days fully sedated. As such, CDS raises the 
same issues regarding decision-making and capacity as euthanasia. 
 
Conclusion 
In the literature euthanasia and its legalization in pediatrics are often opposed based on the 
availability of aggressive palliative sedation. We have shown that this argumentation is 
unsound as it is based upon 4 flawed assumptions. First, the ethical difference between 
sedation and euthanasia is not as clear-cut as often presumed given the uncertainty about 
physician’s intent and the frequent absence of pediatric consent9. Secondly, as a measure of 
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pure pain relief CDS cannot meet the needs of all patients. Euthanasia choices alleviate not 
only physical, but also existential suffering. Relief from existential suffering may be 
especially valued by children who suffer from loss of control as a result of the experience 
with the illness and long hospitalization. Third, although children’s capacity remains difficult 
to assess, pediatric patients, especially those who are severely or long-term ill often possess 
the abilities to form and express their choices and wishes. These capacities develop due to 
their ongoing interactions with physicians and parents regarding their illness and care, 
including at the end-of-life. Fourth, like euthanasia, CDS raises capacity issues since it is not 
just a way to alleviate suffering, but a medically induced coma to which children should give 
their consent. Still, as argued in the introduction, our aim was not to reject CDS as a valid 
option at the end-of-life, but to express our concern about the way CDS is used to cut off the 
debate on euthanasia in pediatrics as it not only precludes an open discussion on what might 
be a legitimate end-of-life choice for a certain type of patients, but it also keeps us from 
acknowledging the persisting ethical issues regarding the practice of CDS itself. 
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i This paper looks into the ethical issues associated only with the practice of CDS that renders 
the patient unconscious and keeps her in that state till the moment of death. The act of 
continuous deep sedation is also referred to as terminal sedation, sedation to unconsciousness, 
end-of-life or total sedation. These terms may be used interchangeably in the text, but only to 
refer to the practice of CDS as described above. 
ii Throughout the text we use the term euthanasia only to refer to the practice of voluntary 
active euthanasia, as opposed to withdrawal or withholding of treatment (passive euthanasia) 
or actions that end a person’s life without the request and consent of that person (non-
voluntary euthanasia). 
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Discussion 
 
Families’ and patients’ experiences of a cancer diagnosis are unique and there is little to 
prepare them for what comes after the initial disclosure1-4. Parents’ needs and wishes for 
information and on how to have it delivered vary and indeed can fluctuate within one person 
during cancer treatment1,3,5-8. Some require more support in dealing with their emotions and, 
on the contrary, others feel disinclined to discuss or express feelings and fears, and prefer to 
focus on medical facts8-10. Physicians experience the toll of being the messenger of bad news 
and face challenges to identify what is the adequate information to share with individual 
families and patients11-18. Children’s own needs and preferences and, above all, the suitable, 
effective clinician’s and parent’s actions to uncover their wishes make communication even 
more complex13,19-22. This work delves into the experiences of 35 parents and their children’s 
oncologists, their descriptions and takes on communication and decisions about treatment and 
care. By analyzing participants’ accounts against professional guidelines23-26 and ethical 
principles23,27, the doctoral work identifies different contexts - disclosure of diagnosis, 
treatment and care decisions, poor prognosis and relapse - and the ethical issues surrounding 
communication in these particular situations. Furthermore, the thesis then uses the knowledge 
gained from the empirical project to theoretically explore questions about communication in 
two other instances - end-of-life care and participation in research with little prospect of 
clinical benefit. The analysis is carried out by reflecting on ethical concepts of disclosure, 
parental rights and obligations, shared decision-making, physician responsibilities12,15-17,28-30 
and, more broader, their application in pediatric oncology taking into account diverse 
individual preferences. Recommendations on how to curtail communication breakdowns and 
how to improve the provision and sharing of information between parents and physicians in 
order to positively affect discussions with children are drawn. As the difficulties identified in 
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communication for children suffering from cancer may be common to pediatric chronic and 
life-threatening illnesses, the final guidance is relevant to various pediatric specialties.  
 
Communication in pediatric oncology 
 
Parents of children diagnosed with cancer are susceptible to vulnerability when they enter the 
medical setting, which for most is an unfamiliar environment. Patients and even parents, who 
may interiorize their children’s symptoms31, are rendered vulnerable by the condition of 
being ill and receiving arduous treatment. They, though perhaps to different degrees, 
experience a loss of control and dependency on the medical team31-41. For patients, 
vulnerability stems from young age and diminished maturity and dependence on others27,31,42-
44. One of the main sources of vulnerability for parents comes from the reliance on others to 
provide them with information in order to care for their children2,30,32,37,45. Physicians and 
other medical staff are charged with providing adequate information in a helpful 
manner24,25,39,40,43. Many times clinicians are in the position of being messengers of bad news 
and as such the information they provide startles parents regarding their future15. Medical 
communication is essential for delivering optimal care, tailoring discussions to individual 
needs and for meeting ethical standards of informed consent24,26. Physicians’ duties of 
informing parents and patients are complex. Therefore, communication in pediatric oncology 
cannot be subjected to a simple analysis and it requires a comprehensive understanding of the 
factors influencing all physician-parent exchanges, starting with the day one talk2,11,40. 
 
Diagnosis disclosure - the ethics of “truth telling” 
Disclosure of diagnosis is at the cornerstone of setting the stage for building relationships 
between patients, physicians and parents and ensuing communications5. It is likely it takes 
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place when the family meets the treating oncologist for the first time and on the background 
of parents’ previous experiences with healthcare personnel5,46. 
A cancer diagnosis disclosure model 
According to professional guidelines communicating the diagnosis of cancer to families and 
patients must be based on complete information provision23,25. In practice, initial disclosure 
of diagnosis also identified in Swiss and Romanian pediatric oncology units is usually a 
private discussion between parents and physicians40-42. It is often structured around medical 
facts regarding the disease, additional needed tests, treatment and chances of restoring health, 
as well as common side-effects5,40-42. Additionally, parents’ questions regarding how and 
when to tell children are being addressed13,20,21,40. However, there is no specific framework 
on how to deal with the myriad of parental predilections for delayed, partial or for non-
disclosure to children. Guidelines mention flexibility to meet families’ and patients’ 
preferences and to accommodate different perspectives on disclosure23,25. This apparent 
contradiction between an open model of disclosure and suggestions to honor wishes to 
restrict information provision creates ethical and possibly legal dilemmas for 
physicians14,40,44. Many parents decide to be open with their children from day one, others 
may be encouraged by the first discussion with the physician that disclosure of diagnosis is 
necessary and appropriate40,41. Nevertheless, some parents are reluctant to reveal the exact 
diagnosis to children and some categorically refuse to20,40,47. These scenarios, although not 
the norm, are the ones most likely to uncover the ethical issues in cancer care communication 
and the difficulty to identify what physicians’ responsibilities are and toward whom. 
Professional duties to disclose 
Physicians have a double duty when providing information about cancer, medical and ethical. 
This duty has to be fulfilled in relation to several actors: parents, the patient and other family 
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members, sometimes including children’s friends and teachers5,14,48-50. From a medical point 
of view, deontology requires oncologists to give families and patients information regarding 
the diagnosis, the nature of the illness and its treatment24,25,27. Physicians have to use 
appropriate language that would ensure adequate understanding of medical facts and 
sufficient knowledge for decision-making24,25. 
From an ethical perspective, information sharing has to be individual based in order to 
support requirements for informed consent while be respectful of personal wishes and 
circumstances. Clinicians’ ethical responsibilities extend also to reducing risk of emotional 
harm that can impinge on comprehensiveness essential for informed consent24,25,51. 
Responsibilities toward parents and patients 
When they receive the news that their child has cancer, parents experience a carousel of 
emotions dominated by fears, need of protection and perhaps even denial5,20,32,40,52. Parents 
cannot claim a right not to know the diagnosis, its risks and treatment information as they are, 
under most jurisdictions, the ones designated to make decisions for their children24,25,44. As 
such, any distress that results from communicating essential medical facts is unavoidable and 
will inescapably affect negatively patients’ and parents’ notions of their lives in the present 
and future53. However, physicians have a duty to tend to individual parents’ needs and show 
empathy and compassion in delivering such news8,11,54. Moreover, they have to assess what 
parents want to know and whether it is advisable to discuss cancer related issues in detail 
during the day one talk2,25. Information sharing may be titrated, broken-down to steps to 
allow respite from difficult news in consideration of parents’ psycho-social state and if 
deemed in their interest. Such steps of controlling information provision are justifiable when 
they do not become barriers to delivering life-saving treatment or put at significant risk the 
health and wellbeing of the patient and parents. Similarly, physicians need to approach 
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parents regarding how and when to inform children14,25,40, explore patient wishes and respect 
a child’s expressed right not to know25,55. 
The benefits and harms of communicating openly, from disclosing the cancer and its risk, to 
prognosis and including the possibility of dying from the disease, are not clear cut19,20,32,36. 
Nevertheless, any anxiety resulting from knowing must be weighted with harmful effects of 
not being told anything or not much13,20,32. Moreover, patients hold different views regarding 
what is sufficient information and who should communicate it and how21,22,41,42. Given the 
multitude of factors and the uncertainty regarding benefits of full diagnosis disclosure to 
particular patients and their wishes, physicians should not escape reflecting on and giving 
parents’ requests for limiting information significant weight40,56. 
 
Communication and decision-making 
Parents appreciate when clinicians take time to discuss their situation and show caring 
behaviors, even if only by spending a bit more time at the bedside. Showing availability and 
doing more than just prescribe treatment, order tests and talk about medical results is 
comforting for parents21,39,41,43,56. Similarly, patients, particularly adolescents wish and need 
to establish personal relationships with medical professionals, as their own social network 
becomes limited during the treatment18,42,43.  
Parents in many centers share responsibility in caring for children and play a crucial role in 
ensuring compliance32,39,41,56. They appreciate being recognized as experts5 and eliciting their 
views regarding care and treatment regularly it can render clinical benefits - improved 
understanding of medical facts and adherence43. Parents and patients alike get acculturated to 
the medical setting and if supported can take charge of many aspects of cancer care, such as 
prompt side-effect detection, keeping track of symptoms and what changes improve or 
aggravate them39,41,56. 
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Understanding of information is one of the main elements necessary for providing parental 
permission for treatment24,26. Leaving parents with factual medical information that is 
difficult to sort out or asking them to make decisions for which they judge themselves as not 
qualified to make poses barriers to the decision-making process39,43. Adequate information 
provision is a mandatory step in obtaining informed consent for treatment and ensures that 
parents are equipped with the abilities necessary for making decisions. Just asking parents to 
make a decision, without assessing how they received the provided information is not 
fulfilling ethical standards or requirements for informed consent. Parents sometimes report 
that they cannot make a choice despite being told and explained what the treatment options 
are or when they would prefer more physician input. They need more time to process all 
relevant medical and personal facts before they can judge what is best for their child and their 
family39,56. Cancer treatment often is a context in which parents assess the situation as a 
“choiceless choice”, having a predetermined decision39,43,57. At the same time, decisions 
during cancer care do not bear the same level of difficulty. Parties need to be able to negotiate 
their roles and, as the Swiss-Romanian studies show, sometimes even wish physicians to 
partake in the authorization of treatment40. This fact is surprising and goes against 
mainstream interpretation of autonomy and its role in decision-making. Unless encouraged by 
parental wishes, oncologists can sometimes allow too much autonomy for parental decision-
making which may not be desired or can even be seen as a burden by parents40,41,58. 
 
Communication for research participation 
Treatment in pediatric oncology is uniquely interwoven with innovative approaches and this 
adds another layer of complexity to parent-physician communication59-61. Permission for 
research participation requires additional detailed discussion of research protocols and 
therefore supplementary informed consent conferences and documents24,39,62. For parents the 
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conflation of standard and innovative treatment leads to difficulties in understanding multiple 
therapeutic options and randomized controlled trial (RCT) procedures62. 
Physician communication and limitations on understanding 
Parental comprehension and uptake of information are related to several physician actions 
and attitudes39,41,59. Clinicians’ ability to build rapport and partnerships, lack of skills and 
behaviors that fail to engage parents’ active participation, as well as the content of the 
discussions physicians carry about children’s enrollment in RCTs are associated with 
misunderstanding of fundamental research aspects59,62,63. Concepts such as randomization and 
voluntariness are complex and difficult to understand without some medical knowledge39,41. 
Physician use of metaphors, not regularly offering visual aids or failure to provide written 
research information, as well as clinician’s omission to invite questions during informed 
consent conferences are contributing to low comprehension59,62,63. Research shows that 
employing figures of speech to describe treatment being allocated randomly does not improve 
understanding. Even more worrisome, many of these parents are more likely to enroll their 
children in studies compared to parents who have a good undertanding62. Understanding is 
poor also for voluntariness and parents often report feeling compelled to agree to 
participation62. 
Parents’ ability to understand is also potentially weakened by the additional issues to consider 
in the care of their children39,41,43. The informed consent conference regarding research can be 
an additional stressful factor that impinges on ability to retain and comprehend information in 
a short period of time62,63. Understanding is also associated with socio-economic factors and 
is lower for parents belonging to minority or ethnic groups62. 
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Ethical issues in research with chances of benefit 
Difficulties in communication about research can results also from the fact that clinicians’ 
role can become blurred when combining physician and researcher duties60. Countries have 
varied policies regarding research protocols aimed at testing improvements in treating 
pediatric malignancies39. While some national oncology groups regularly adopt new or 
innovative protocols to be used for all patients without proposing alternatives or the standard 
treatment, other offer treatment on various research protocols64. These approaches beg the 
question of what is research and how to adequately inform parents and obtain informed 
consent. When research is conducted with the prospect of benefiting patients and physicians 
are under clinical equipoise, it can be appropriate to propose parents an innovative treatment 
as a sole choice. For some parents this step can be legitimate, as it leaves them with less 
complicated decisions to make and follow physician expertise39,41,43. However, as Kodish 
cautions, meaningful informed consent needs to emphasize the risks, benefits and treatment 
options64. Parental capacity to comprehend is based on information provision and is essential 
for safeguarding the interests of the child and obtaining a valid informed consent62,65. 
 
Communication about non-beneficial research and other end-of-life options 
Parents of children suffering from cancer are sometimes proposed to allow enrollment in 
phase I protocols66-68. These offer little or no direct benefit to individual patients and raise 
additional ethical challenges. Patients invited to participate have exhausted curative treatment 
options and decisions at this stage can also include limiting treatment or end-of-life care69,70. 
This begs the question of the suitability of inviting such patients to participate in research 
with little or no benefit71. 
Parental understanding of phase I clinical trials and physician communication about 
procedures and study aims are limited61. Phase I studies are designed to study safety in 
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children and not new treatment efficacy. Physician duties toward parents and patients should 
focus on protection and highlight the necessity of developing an ethical justification for such 
research71. Informed consent is a first requirement for morally allowing non-beneficial 
research with children72. Therefore, physicians’ efforts should focus on improving 
communication with parents61,73,74. This can be achieved through education about research, 
mentioning of phase I clinical trials at different points during treatment and specifically in 
case of relapse or end-stage cancer and supporting negotiation processes during informed 
consent conferences results in enhanced comprehension67,73. 
The ethical permissibility of phase I clinical trials in pediatric oncology can be based also on 
parents’ and patients’ accounts that when properly informed, they cherish contributing to help 
others facing a cancer diagnosis64,75. Moreover, the involvement not only of parents, but of 
children is central to treating them as ends in themselves27 and in turn requires proper 
communication to uncover and respect personal values in decision-making71. Discussions 
about research participation at the end-of-life have to extend to incorporate sharing of 
information that is important to patients also as a requirement for obtaining valid assent76. 
When patients’ abilities are not sufficient to allow participation in decision-making, still it is 
important to acknowledge the contribution that children are making through their bodies, as 
part of their whole person71. This recognition can provide an ethical justification for non-
beneficial research with children lacking capacity and has to be supplemented by good 
physician-parent communication at the end-of-life70. Parental understanding of the purpose of 
phase I clinical trials and of the altruistic aspect of their consent can contribute to recognizing 
children as body-subjects and help patients express choices at the end-of-life70,71,77. 
Communication about phase I and end-of-life care 
Besides phase I clinical trial participation, families and patients are faced with other difficult 
options - treatment withdrawal or withholding, transition to terminal care70,78. It is essential to 
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present and discuss all these care options when talking about non-beneficial research, so that 
parents and patients understand their choices and also they are able to separate altruistic 
participation from that with therapeutic chances71,79. 
Guidelines that promote the provision of better palliative care emphasize the importance of 
eliciting patients’ wishes80,81. However, patients’ voices are rarely given a place in decision-
making at the end-of-life82. A recent study in pediatric oncology highlights the aggressive 
care most teenagers receive in the last months of life78,83. The authors hypothesize that in 
cases of poor prognosis and when cure is no longer an option patients are rarely involved in 
treatment planning and discussions about limiting treatment78,83. This robs families and 
patients of chances to say goodbye and does not support the provision of high quality care 
that respects personal and cultural beliefs at the end-of-life84-86. The incremental involvement 
of children for which treatment failed is aligned with their best interest. At this stage, their 
views should guide all decisions to be made, as there is no risk of unwise decisions to their 
health84. Honoring their wishes for a good death84, to discuss death and dying and leave 
memories for families and friends is a determinant of best care. It helps empower children in 
their most vulnerable state by giving them more latitude to decide. This would mean to 
respect them as people and tend to their voices and fears when cure is not possible39,41,82. 
Research shows that communication at the end-of-life is particularly difficult in view of 
families’ attitudes. Parents often exhibit reticence in discussing passing away with patients 
and physician support for families is insufficient70,77,87. Communication and physician 
sharing of information to prepare parents for the challenges of care in the last stages of the 
illness is inadequate and leaves parents doubting what is best for their child. Parents’ needs 
are centered on doing the right thing and “being a good parent”70,88, making communication 
the most important indicator of providing good care. Physician actions in this phase are not 
equally oriented toward relational components of care88, but it is their duty to help parents 
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transition from big to small hopes. Such actions do not imply a destruction of hope, but focus 
on helping parents clarify their expectations - from hoping to see their children cured to 
aiming for more good quality time with their children and meaningful goodbye30,58,77. 
 
Culture and communication 
 
Differences regarding communication for children diagnosed with cancer have been 
attributed to cultural paradigms5,13. The influence of social norms and the adoption of a 
particular belief system is most obvious in regard to disclosure of diagnosis practices47,89,90. 
On one hand, professional behavior in the medical setting in one country is be commanded by 
a primordial respect for autonomy, while in another country is driven by beneficence and 
relational autonomy40,91,92. The latter two principles award physicians more discretion in 
judging what is harmful for relatives and patients11,47,93. On the other hand, disclosure may be 
determined by broader cultural norms and values within society and those held by families. 
Views on cancer and fatalism, truth telling and bearing responsibility for protecting loved 
ones and perceptions regarding hierarchical relationships with physicians influence behavior 
in communicating about cancer46,91,94,95. Given these variations, physician responsibilities 
toward informing the child patient appear to be subjected to geographical or cultural 
interpretations47,96. Solutions for harmonizing patient right to information with perceived 
cultural attitudes that go against full and open communication are ethically complex25,40,46,56.  
Attributing a divergence of opinions on disclosure to children to cultural backgrounds runs 
the risk of assessing the situation as an unsurmountable clash between professionals’ and 
parents’ positions. It easily results in labelling parents who oppose (full) disclosure as 
difficult families and patient cases, feeding into cultural biases97,98. These may be potential 
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sources of conflict or break-down in communication, when parties do not share the same 
values40,46,47.  
As the studies conducted in pediatric oncology centers in Romania and Switzerland show, 
physicians in the two countries have different approaches toward disclosure. Swiss 
oncologists are sternly in favor of delivering the cancer diagnosis to patients and inform 
parents about this approach matter-of-fact41. In Romania, physicians are more cautious 
regarding parental hesitation and wishes40,56. Oncologists share a belief that children should 
be informed, but manifest prudence in relation to the probability that patients, especially 
adolescents, may become depressed32,56,99, and leave significant leeway for parents’ 
preferences40,56. 
Despite the country differences observed in regard to frequency of requests to withhold the 
diagnosis from patients and physicians honoring them, variable behaviors were spotted in 
both settings. Disclosure of diagnosis takes different forms and families born or acculturated 
to the same environment hold different views on if and how, as well as when to inform 
children about the diagnosis40,41,56. In Switzerland, where there is a usual parental agreement 
to share information with children, few parents, at least initially, did not conform to the status 
quo on disclosure41. Likewise, in the Romanian sample parental approaches to 
communicating the diagnosis were diverse, although most parents’ default reaction to 
informing children was protecting them from the truth, as much as possible40. In spite of this 
prevailing stance, some parents who at first believed that it would be best not to share 
information with children changed their mind during the day one talk or soon afterwards40,56. 
These accounts show that communication regarding difficult news is not strictly subjected to 
perceived cultural norms and reveal that parents’ inclination toward non-disclosure can be 
successfully challenged40,46,56. In fact, preferences for not communicating the diagnosis can 
be attributed to what families are used to in terms of directly informing children and 
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customary family structures and values40,41,56. Expectations in the delivery of care also play a 
role in forming preferences to limiting information, but can be shifted by physicians, 
including during the first talk20,40,46,56. 
At the same time, physicians associated with or practicing in a particular culture may not 
always hold a firm attitude toward open disclosure. In an open system where the standard of 
care is to tell patients and families all facts, they are more at ease when disclosing a life-
threatening disease. Such approach can easily fall under a medicocentric view, focused 
primarily on physiological aspects of illness100 when physicians while breaking bad news also 
initiate a “project of cure”25. This seemed to be the case for disclosure of diagnosis in Swiss 
centers41,42. However, even when practicing an open-model of disclosure physicians find it 
difficult to discuss poor prognosis, terminal illness and lack of standard treatment11,29,101. For 
particular patient circumstances and contexts some physicians choose to limit information 
provision at diagnosis in what concerns significant uncertainty in achieving a cure39,41. 
Participant physicians in Switzerland sometimes displayed such tendencies to avoid 
burdening patients with negative and excessive information about the illness41. 
Professional guidelines, despite advocating for an open and full communication about cancer 
also mention that disclosure is not a one-time event24,25. They leave sufficient room for 
interpretation and it is important to distinguish what form of disclosure is best suited for a 
particular child and her parents, especially on the background of ethnically diverse patient 
populations43,46,91 . Classifying parents into binary categories - pro-disclosure and non-
disclosure - ignores the continuum on which sharing of information regarding diagnosis takes 
place and is grounded more on assumptions that behavior and wishes are attributed to a 
certain culture40,41,43. 
Physicians who engage in the endeavor of assessing what is preferable and adequate for 
individual cases should rely on strategies of exploration of parents’ and subsequently 
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patients’ attitudes. How one thinks about a topic is based on individual experiences, the 
perceived situation of others or their reports regarding that subject, personal beliefs and moral 
views. Parents collect their information from different sources, such as the Internet, 
newspapers, including lay persons in their community, circle of friends39,40,102. Attitudes 
incorporate cultural elements, popular and sometimes religious ideas on the topic103, but go 
beyond assumptions that individuals from a predominant biomedical culture have to approach 
cancer strictly from a cognitive and factual perspective104,105 . At the same time, the attitudes 
a person has in relation to cancer drive behaviors that are independent of rational thoughts 
and educated opinions106. 
 
An explanatory model of illness for communication in pediatric oncology 
(EMICPO) 
In order to grasp the attitudes that parents and children have regarding cancer and medical 
care physicians can employ a model of explanatory illness107,108. The basis for the model is 
physician’s acknowledgment of the fact that parents and children may have specific or 
developing attitudes in relation to the patient’s health condition, even before the cancer 
diagnosis is established108. Clinicians recognize and accept “different versions of the clinical 
reality” that are deserving of equal consideration and respect108. Oncologists have to also 
consider that these attitudes trigger individual emotional responses to disclosure of a cancer 
diagnosis and influence preferences for initial communication with the child patient20,32,40,56. 
Attitudes are fundamental elements for parents’ and patients’ first gut feeling reaction to 
diagnosis and can extend into communication about the illness and their behavior during 
treatment56,107. For example, in the Romanian sample many parents purposefully avoided the 
word cancer as a way of obscuring the potentially life-threatening nature of the illness. Both 
parents and physicians believed that the connotation between cancer and dying is always 
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present and did not want patients to think about this likelihood40,56. In Switzerland parents 
and physicians would name the disease but also mention that cancer in children is different 
than in adults and that treatments are better41,43. This is suggestive of efforts to instill and 
emphasize confidence in the efficacy of treatments in curing cancer and provide hope25,109. 
However, even in Swiss centers communication at diagnosis regarding risk factors and 
difficulties in treating rare cancers in children becomes more ambiguous in cases of poor 
prognosis. This perhaps is due to a belief that addressing the dangerousness of some 
malignancies would likely lead parents and patients to question the chances of surviving the 
illness41,42. 
At the same time, physicians need to reflect on their own attitudes toward cancer, which are 
shaped by their medical training and belonging to a subculture centered on understanding 
physiological manifestations of disease rather than patients’ experiences of illness108,110,111. 
Embracing either the patient’s view of illness or the physician’s isolated image of cancer as 
disease is insufficient to gain a comprehensive understanding that educates care practices108. 
Apart from acknowledgment that (different) attitudes, of parents, physicians and patients 
exist, an explanatory model of illness requires physicians to engage with these attitudes. First, 
oncologists have to elicit parents’ views, beliefs and insecurities about the child’s illness. 
Kleinman’s model offers a guiding set of questions which physicians should make use of 
during the first encounter with parents108. This covers several domains of parental thinking 
regarding: cause of child feeling sick and time of occurrence, manifestation of the problem, 
its severity and expectations of what treatment is adequate108. Annex 1 presents a developed 
model of questions, EMICPO, based on Kleinman’s framework108 and drawing from the 
SPIKE tool for communicating bad news54 (Please see Annex 1). Processes in EMICPO 
focus on what parents worry about regarding the diagnosis, how they believe children should 
be told, when and by whom, in relation to prior experiences with cancer. The EMICPO can 
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be adapted to elicit what children know so far, what they believe is the problem, what would 
they like to know more and from whom, and who should be present during discussions 
(Annex 1). Questions can be addressed in one or several appointments, based on parents’ and 
children’s wishes and their emotional state25,40.  
Second, physicians need to address these attitudes, by offering tailored information to what 
they previously heard and by correcting misunderstandings. This process, of “talk-tell-
talk”15,54, helps in the clinical practice to educate parents by comprehensively taking into 
account their experiences with the illness while identifying individual levels of adaptation of 
medical information to lay terminology. EMICPO is a perpetual comparison between 
physicians’ and parents’ attitudes based on information sharing. The model thus recognizes 
and blends parental with physician views and negotiates a common model of understanding 
of illness and experiences with cancer108. It is a mixed model of physiological and psycho-
social explanations of cancer acceptable to both parties110 (Annex 1). The EMICPO 
incorporates medical facts, including the reality of an ever present uncertainty, along with 
personal stories of relatives who did not survive cancer and illness associated fears. At all 
times, physicians must reassure parents that they may ask questions at any time and that 
expressing their thoughts, beliefs and needs is welcomed by and helpful for physicians, as 
well as for care40,41,43,46,56,108. 
The use of EMICPO 
In pediatric oncology moral conflicts and ethical dilemmas are often the result of postponed 
discussions about sensitive issues of care, divergent views regarding treatment course and 
care goals, and parent-physician tensions74,101,112. Lack of adequate communication between 
families and clinicians may develop into latent conflicts that threaten fiduciary 
responsibilities of both parents and physicians when providing care for patients. This 
situation may escalate to the point that external consultation with an ethics committee is 
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required74,112. The use of the EMICPO is a helpful tool to use throughout parent-physician 
encounters, a reiterative operation in providing care and possibly diminishes risks of conflict. 
In both the Romanian and the Swiss clinics the use of EMICPO would have showed that full 
disclosure in one meeting is not always well received by families40,42,43. It could have 
highlighted parents’ needs for clarifying information provided for decision-making about 
treatment, research participation and fertility preservation, and stirred physician efforts in the 
right direction39,41,43. 
Clinicians can adapt questions from the EMICPO to specific context and use it in 
communication with parents and, when adequate, patients during rounds and routine check-
ups. It serves also a control for past information communication after parents had time to 
absorb it and facilitates clarification of things that were left unclear and ask further 
questions43. Especially when new information is presented regarding treatment outcomes, 
medical tests and risk factors, clinicians should assess parents’ and patients’ attitudes. 
Continuing to elicit their views and attitudes regarding their experience facilitates identifying 
their preferred and changing roles in medical communication and decision-making39,41,56. 
Therefore a model of exploration is necessary to allow for identification of what choices can 
be made collaboratively between parent-patient-physicians, which between parent-physician 
and which should be offered to patients39,57. This can positively affect satisfaction with the 
provided care. 
If in communicating with families physicians start with an explanatory model of illness and 
always support and try to help parents and patients to verbalize and explore their fears, 
families will be better prepared. EMICPO can particularly facilitate communication in case of 
difficult decision-making about participation in RCTS, relapse or when facing the end-of-life. 
It therefore makes difficult talks and decisions around treatment failure, prognosis and dying 
easier. Parents who are continuously supported in dealing with and thinking about what is 
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important can better frame their values. The EMICPO can be used in relation to hope 
management and getting parents to talk about and focus on  small hopes (e.g. maintaining an 
acceptable quality of life, returning the child to school, attend graduation, spending more time 
with family, reduce the number of hospital admissions). Furthermore, this exploratory model 
of communication in pediatric oncology is likely to better answer to diverse family beliefs 
and improve care for ethnic groups40,56.  
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Implications for practice and future research 
 
Results of this doctoral research and the above analysis have direct implications for clinical 
practice and emphasize several aspects that need to be investigated further: 
• Disclosure of diagnosis is a complex process influenced by different individual or 
cultural factors that need to be acknowledged by clinicians. 
• Communication in pediatric oncology is deficient in several areas neglected during 
routine medical encounters which result in mundane harms. 
• There is a need to develop, assess and implement disclosure and communication 
protocols with parents and children that take into account explanations of illness. 
• Physicians have a duty to care also for parents and this requires identifying if parents’ 
reactions to diagnosis have a pathological component and take appropriate measures. 
• Conduct regular assessment of information understanding and needs for both parents 
and children, and address them in order to improve decision-making. 
• Research has to investigate patients’ perspective in case of non-disclosure and 
identify risks. 
• Test and further refine a modified explanatory model of illness, the EMICPO; assess 
its effects on communication about diagnosis, prognosis, treatment, research and end-
of-life decision-making. 
• Explore what parents and when adequate patients want to know about short- and long 
side-effects and risks and discuss how they would deal with them. Additionally, 
physicians need to address the issue of different sources of information. 
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• Current standards of decision-making and efforts of distancing from paternalistic 
practices in decision-making pose difficulties for some parents and undercut the 
importance of relational autonomy. 
• Place greater emphasis on elements of micro-ethics, such as building relationships, 
which can be more valuable for parents. 
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Conclusions 
 
Cancer’s burdens cannot be disentangled from families’ experiences with pediatric oncology 
care, even in case of prolonged remission. There are different subtle ways in which parents 
and children are harmed and the relationships between them and physicians tested. 
Communication in pediatric cancer care poses challenges that go beyond medical information 
and is a central aspect of providing high-quality care. Clinicians and families in different 
settings can face various difficulties in communicating about the illness, treatment and 
options. Culture could account for some of these differences and provide different ethical 
solutions. However, as the studies in Switzerland and Romania reveal there is a need to 
explore parental views and attitudes by looking at more than culture. The meaning of illness, 
emotional turmoil, and previous experiences with cancer and encounters with clinicians serve 
better to define differences in communicating about and disclosing cancer diagnosis. The 
EMICPO creates opportunities to take an active approach to elicit and share information with 
parents and patients. It can be applied to different areas and by its reiterative feature 
facilitates communication at the time of diagnosis, during treatment and decision-making 
processes, including regarding therapeutic and non-beneficial research and end-of-life. Its use 
and the results it has on communication need to be tested in practice. 
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Appendices 
 
 
 
Study Title 
Original Study Title in English: Competency and autonomy of children and adolescents in 
pediatric oncology decision making 
Study Title in Romanian: Competenţa şi autonomia minorilor şi adolescenţilor în 
procesul decizional în oncologia pediatrică 
 
Interview Guide for Parents - Romanian study 
English version 
 
Dear participant: Thank you for agreeing to take part in this study and for sharing your 
information with us. You are being asked to take part in the research study of “Competency 
and Autonomy of Children and Adolescents in Pediatric Oncology Decision Making“ 
because your child was diagnosed with cancer and/or is currently undergoing cancer 
treatment in a Romanian Oncology Centre. We understand that this is a very sensitive issue 
and we would seek to be as considerate as possible. If you feel uncomfortable responding to 
any question, please communicate this to me. 
 
During this interview session, we would like to learn about the condition of your child and 
the quality, content, and process of decision making regarding his/her illness. The 
information that we gain from you will help us understand decision making processes and 
contribute towards debates concerning a minors’ decision making autonomy concerning 
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health care. After the interview, we will request you to complete a very short 1 page survey. 
Please be assured that your responses and all the information/data you provide are completely 
confidential and anonymous. We thank you for agreeing to be part of the study and answering 
the following questions. 
 
*Note to the interviewer: For questions marked with *, customize the question based on 
the context. 
For example, for question 1.e, if prognosis is poor - ask questions e.1., e.2.; if prognosis 
is not poor, continue with question 1.f. 
 
1. Understanding the situation: 
a. Let me start by asking you about your family. Could you tell me about them? 
b. Please briefly describe to me the circumstances regarding your child’s cancer 
diagnosis? 
c. How did you first come to believe that your child might have cancer? 
d. When was the diagnosis made? How old is your child now? 
e. What was the prognosis the physician gave you?* 
*(Note to the Interviewer: Ask the following two questions only if the parent 
described the chances as poor) 
1. When did you understand that the chances of cure for your child are rather low? 
2. Could you please tell me more about how you see the chances of cure for your 
child? 
f. Was your child present during the diagnosis discussion? Why or why not?* 
*(Note: If child present, ask question g, else skip to h.) 
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g. How did you feel about your child’s presence in regards to the diagnosis 
communication? 
h. Since the diagnosis was made, have you informed your child about the diagnosis? 
i. How did you do so? Could you tell me the words you used? For example: what was 
the first sentence you used to start the discussion? Why did you choose the words you 
chose? 
j. Did you discuss the prognosis with your child? Did you explain him/her the chances 
of cure? 
k. Who initiated this discussion? How did you feel during the discussion? 
 
2. Treatment options, discussions, and decision making 
a. What were the treatment options? 
b. Who was present when treatment options were discussed? 
c. How were these treatment options described to you and/or your child by your 
physician? 
d. Were these options clearly and carefully explained to you and/or your child by your 
physician? 
e. If your child was not present during treatment discussions, have you discussed 
treatment or non-treatment options with your child?* 
*(Note: if answer is no, skip to question g.) 
f. What did/do you think about this discussion with your child? 
g. What treatment options were selected? And why? 
h. How were decisions made about your child’s illness and treatment choices? 
i. Who was involved in this decision making process? 
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j. To what extend was the child involved? Please provide reasons for extent of 
involvement or non-involvement. 
k. How comfortable were you with the manner and content of these discussions? 
l. Were you satisfied with these discussions? 
m. Please explain what factors contributed to greater or lower satisfaction. 
n. Would you change anything retrospectively? e.g. Is there anything in your opinion 
that would have made these discussions more beneficial? 
 
3. Inclusion or Exclusion of child in discussion: The following questions relate to the 
capacity of children to make decisions concerning their health and medical treatment, in 
particular, if they are severely ill. In society there is a debate about whether and how 
much children or minors should be involved and given the right to make decisions. We, 
therefore, would like to gather your opinion on this topic. 
 
a. In your previous response, you stated that your child was present (absent) during 
treatment discussions. Could you explain the reasons for this? 
b. Why do you think it was necessary/appropriate to include (exclude) your child from 
these treatment decisions? 
c. Under what conditions would you absolutely include (exclude) your child in such 
discussions? Please explain these conditions. 
d. Generally, when parents include (exclude) children from making such decisions, what 
kind of reasons do you think, for example values and attitudes, are associated with it? 
e. In your opinion, should children in general, be allowed to make health care related 
decisions? Please explain your perspective. 
• Would your response be the same or differ based on the following: 
Appendices 
 234 
o Age of the child: younger than 8 years or older than 8 years (or 
another age limit?) 
o Type and seriousness of the disease (depending on curative 
chances/prognosis) 
o Behavior of the child 
o Your religion or personal beliefs 
 
 
 
 
 
 
 
 
 
 
 
 
 
***********************************Thank You ************************** 
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Dear Participant: We thank you for taking the time to complete the following. 
 
A. Demographic Information: 
a. Age:      ________  Year of Birth:      ____________ 
b. Sex:    Male   Female 
c. Nationality:  Romanian        Other –  ______________________ 
Country of origin:      ____________ 
d. Languages:   Romanian      Hungarian   German      
      English   French    
 Other (specify):      __________________ 
e. Marital Status:   Married       Divorced     Widowed   
      Never Married    Other – Specify       ______________ 
f. Religion:   Orthodox  Catholic  Protestant     
      Other (specify):      ______________ 
g. Education:   No qualification  Vocational   High School 
     College Degree    University/Graduate Education   
h. Number of children:      ______________  
 
 
 
 
 
***********************************Thank You ************************** 
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Titlul Proiectului: 
Titlul original în engleză: Competency and autonomy of Children and Adolescents in 
pediatric oncology decision making 
Titlul în română: Competenţa şi autonomia minorilor şi adolescenţilor în procesul 
decizional în oncologia pediatrică 
 
Ghid interviu pentru părinţi - Romanian study 
Romanian version 
 
Stimat/ă participant/ă: Vă mulţumim pentru că aţi acceptat să participaţi la acest studiu şi să 
ne împărtăşiţi informaţii în legătură cu dumneavoastră. Vi s-a cerut să participaţi la studiul de 
cercetare “Competenţa şi autonomia minorilor şi adolescenţilor în procesul decizional în 
oncologia pediatrică” deoarece copilul dumneavoastră suferă de cancer sau/şi în prezent 
primeşte tratament pentru cancer în cadrul unui spital din România. Suntem conştienţi de 
caracterul sensibil al studiului de cercetare şi de aceea vă asigurăm că vom trata cu cel mai 
mare respect acest subiect. Dacă o întrebare vă jenează, vă rog să îmi spuneţi. 
 
În cursul acestui interviu, încercăm să cunoaştem starea actuală de sănătate a copilului 
dumneavoastră, precum şi continutul, modul de derulare al procesului de luare a deciziilor 
medicale cu privire la boala sa. Informaţiile pe care ni le veţi furniza ne vor ajuta să 
înţelegem mai bine procesul de luare a deciziilor, ce va sta la baza dezbaterilor pe tema 
autonomiei, respectiv a recunoaşterii dreptului minorilor de a lua decizii cu privire la starea 
lor de sănătate şi a respectării acestui drept. După ce interviul se va incheia, vă vom ruga să 
completaţi un scurt chestionar de o pagină. Vă asigurăm că atât răspunsurile dumneavoastră, 
cât şi informaţiile/datele pe care ni le veţi oferi vor fi anonimizate (nu vom folosi numele 
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dumneavoastră sau al copilului dumneavoastră sau alte date care v-ar putea identifica). Toate 
informaţiile/datele vor fi tratate de manieră strict confidenţială. Vă mulţumim pentru că aţi 
acceptat să luaţi parte la acest studiu şi să ne răspundeţi la întrebări. 
 
*Notă personală destinată persoanei ce va conduce interviul: în ceea ce priveşte 
întrebarile marcate cu *, avem rugămintea de a le adapta în funcţie de răspunsurile 
oferite anterior. Spre exemplu, în ceea ce priveşte întrebarea 1.d., dacă răspunsul este 
pesimist/negativ/prost, treceţi la întrebarea 1.e.; dacă răspunsul este foarte bun/bun 
etc., vă rugăm să adresaţi întrebările 1.d. 1 şi 1.d.2.. 
 
1. Înţelegerea situaţiei: 
a. Aş dori să încep prin a vă pune o întrebare cu privire la familia dumneavoastră. Îmi 
puteţi spune mai multe despre familie şi membrii ei? 
b. Îmi puteţi descrie pe scurt în ce circumstanţe copilul dumneavoastră a fost 
diagnosticat cu această boală ? 
c. Când a fost diagnosticat copilul dumneavoastră? Ce vârstă are în acest moment? 
d. Care a fost prognosticul oferit de medici? 
 
*(Notă personală adresată persoanei care va conduce interviul: NU adresaţi 
următoarele două întrebări decât dacă părintele a răspuns pozitiv confirmând că 
prognosticul este unul pesimist/negativ.) 
1. Când aţi înţeles că posibilitatea unei vindecări pentru copilul dumneavoastră 
e puţin probabilă? 
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2. Îmi puteţi spune mai multe despre cum vedeţi şansele de 
vindecare/ameliorare a copilului dumneavoastră? Cum v-aţi simţit când vi s-a 
comunicat diagnosticul ? Şi cum vă simţiţi acum? 
 
e. Copilul dumneavoastră a fost prezent în timpul discuţiilor cu privire la dignostic? De 
ce DA? Sau de ce NU?* 
*(Notă: Dacă acesta a fost prezent, a se continua cu întrebarea g. Dacă NU, a se trece 
direct la intrebarea h.) 
f. Ce părere aveţi şi ce aţi simţit în legătură cu prezenţa copilului dumneavoastră în 
cursul comunicării diagnosticului? 
g. După stabilirea diagnosticului, ce i-aţi spus copilului dumneavoastră cu privire la 
diagnostic?* 
*(Notă în cazul în care părintele nu a discutat diagnosticul cu copilul se adaugă 
intrebarea: De ce Nu?) 
 
h. Cum i-aţi comunicat diagnosticul? Aţi putea să descrieţi pe scurt ce cuvinte/limbaj aţi 
folosit? Spre exemplu, cu ce propoziţie aţi deschis discuţia? De ce aţi ales aceste 
cuvinte? 
i. Aţi discutat despre prognostic cu copilul dumneavoastră? I-aţi vorbit despre şansele 
de vindecare? 
j. Cine a iniţiat această discuţie? 
k. Cum v-aţi simţit dumneavoastră în timpul acestei discuţii? 
l. Dacă vă gândiţi la acel moment, credeţi că a fost bine, mai bine să discutaţi deschis 
despre aceste probleme cu copilul dumneavoastră? Vă rog să explicaţi.  
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2. Opţiuni terapeutice, discuţii şi luarea deciziilor 
a. Care au fost opţiunile terapeutice pe care vi le-au dat doctorii? 
b. Cine a fost prezent în cadrul discuţiilor referitoare la opţiunile de tratament? 
c. Cum au fost pentru dumneavoastră şi/sau pentru copilul dumneavoastră descrise de 
către medic aceste opţiuni de tratament? 
d. Credeţi că aceste opţiuni de tratament v-au fost explicate clar şi pe îndelete 
dumneavoastră şi/sau copilului dumneavoastră de către medic? 
e. Dacă copilul dumneavoastră nu a fost prezent în timpul acestor discuţii, i-aţi vorbit 
depre opţiunile de tratament sau despre posibilitatea de a nu accepta tratamentul 
medical?* 
*(Notă: dacă răspunsul este NU, treceţi la g.) 
f. Ce aţi crezut/ Ce credeţi despre discuţia cu copilul dumneavoastră? 
g. Ce opţiuni de tratament medical au fost alese în final? De ce aţi ales aceste opţiuni? 
h. Cum au fost luate deciziile legate de boala diagnosticată şi cu privire la opţiunile de 
tratament pentru copilul dumneavoastră? 
i. Cine a a luat parte în procesul de luare al acestor decizii? 
j. În ce măsură a fost implicat copilul dumneavoastră în acest proces? 
k. Doriţi, vă rog, să explicaţi care sunt motivele pentru care implicarea copilului 
dumneavoastră a avut loc în mai mică sau mai mare măsură sau deloc? 
l. Cât de mulţumit/ă sau liniştit/ă vă simţiţi în ceea ce priveşte modul în care s-au purtat 
aceste dicutii şi conţinutul lor? 
m. Sunteţi mulţumit/ă de rezultatul acestor discuţii? 
n. Vă rog să explicaţi care sunt elementele cele mai importante şi cele mai puţin 
importante care au contribuit la gradul de mulţumire/nemulţumire cu privire la aceste 
discuţii. 
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o. În retrospectivă, aţi dori să schimbaţi ceva referitor la aceste discuţii? Spre exemplu, 
există elemente care au lipsit în cadrul discuţiilor, dar care potrivit dumneavoastră ar 
fi fost binevenite? 
 
3. Includerea sau excluderea copiilor/adolescenţilor din cadrul discuţiei cu privire la 
tratament: Întrebările următoare se referă la capacitatea şi dorinţa exprimată a 
copiilor/adolescenţilor de a lua decizii cu privire la starea lor de sănătate şi tratament, în mod 
special în cazul bolilor grave. În prezent există o dezbatere în mediul medical şi public cu 
privire la implicarea copiilor şi/sau adolescenţilor în astfel de discuţii şi în ce măsură aceştia 
au capacitatea şi posibilitatea de a participa la luarea deciziilor referitoare la starea lor de 
sănătate. Din aceste motive, ne interesează punctul dumneavoastră de vedere pe această temă.   
 
a. În răspunsurile anterioare mi-aţi spus că în cadrul discuţiilor legate de tratament 
copilul dumneavoastră a fost prezent (absent). Îmi puteţi explica motivele pentru 
aceasta? 
b. De ce credeţi că a fost necesar sau potrivit să îl implicaţi (excludeţi) pe copilul 
dumneavoastră din cadrul acestor discuţii? 
c. În ce condiţii v-aţi implica (exclude) copilul din asftel de discuţii? Doriţi vă rog să 
precizaţi aceste condiţii mai detaliat? 
d. În general, când părinţii îşi implică (exclud) copiii din astfel de discuţii, care credeţi 
că sunt motivele pentru astfel de atitudini (aceste decizii)? De exemplu, ce criterii, valori 
sunt luate în considerare? 
e. După părerea dumneavoastră copiii, în general, ar trebui să aibă dreptul de a participa 
la luarea unor decizii ce privesc starea lor de sănătate? Vă rog să explicaţi mai detaliat 
răspunsul dumneavoastră: 
Appendices 
 241 
• Răspunsul dumneavoastră ar fi acelaşi sau diferit în funcţie de:  
o Vârsta copilului: dacă are mai puţin sau mai mult de 8 ani (sau o 
altă limită a vârstei)? 
o Tipul şi gravitatea condiţiei medicale: (în  funcţie de şansele de 
vindecare) 
o Comportamentul copilului 
o Religia dumneavoastră sau convingerile personale  
 
 
 
 
 
 
 
 
 
 
 
 
 
***********************************Mulţumesc ****************************** 
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Stimat/ă participant/ă: Vă mulţumim în avans pentru dorinţa de a completa 
cheastionarul următor: 
 
B. Informaţii demografice pentru părinţi:    
a. Vârsta:      ____________  Anul naşterii:      __________ 
b. Sex:         Masculin   Feminin 
c. Naţionalitate:  Română        Alta –  _____________________ 
Ţara de origine:       ____________   
d. Limbi vorbite:  Româna   Maghiara    Germana  
 Franceza   Engleza    
 Alta (precizaţi):      ____________________________ 
e. Starea civilă:   Căsătorit/ă     Divorţat/ă    Văduv/ă  
    Necăsătorit/ă  Alta- Precizaţi      ___________ 
f. Religia:   Ortodoxă   Catolică      Protentantă 
   Alta-Precizaţi      ______________________________ 
g. Educaţie/ Studii:    nicio calificare   şcoală primară   
 Gimnaziu  Studii liceale   
 şcoală profesională   Bacalaureat   
 Diplomă de absolvire a unei facultăţi/ studii superioare  
h. Numărul de copii:      _________________________________________ 
 
 
***********************************Mulţumesc ****************************** 
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Study Title 
Original Study Title in English: Competency and autonomy of children and adolescents in 
pediatric oncology decision making 
Study Title in Romanian: Competenţa şi autonomia minorilor şi adolescenţilor în 
procesul decizional în oncologia pediatrică 
 
Interview Guide for Physicians - Romanian study 
English version 
 
Dear participant: Thank you for taking the time and agreeing to participate in this study.  
You are being asked to take part in the research study of “Competency and Autonomy of 
Children and Adolescents in Pediatric Oncology Decision Making“ because you are a 
treating physician in a Romanian Oncology Centre for children diagnosed with cancer or who 
are currently undergoing cancer treatment. The information that we gain from you will help 
us understand decision making processes and contribute towards debates concerning a 
minors’ decision making autonomy concerning health care. 
 
During this interview session, we would like to learn about the condition of your patient, the 
quality, content, and process of decision making, and the patient’s competency. After the 
interview, we will request you to complete a very short 1 page survey. Please be assured that 
your responses and all the information/data you provide are completely confidential and 
anonymous. We thank you for agreeing to be part of the study and answering the following 
questions. 
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*Note to the interviewer: For questions marked with *, customize the question based on 
the context. 
For example, for question 2.c., if information is provided together - ask that question; if 
information is discussed separately, rephrase the question for parents and child 
separately. 
 
1. General information about the patient’s case 
a. How long have you known the patient and his or her family? 
b. When did you first see the patient and make the diagnosis? 
c. How old is the patient now? 
d. What were the diagnosis and prognosis? 
e. Who did you disclose the diagnosis and prognosis to? If your patient was not present, 
please indicate why. 
f. What was the parent’s reaction when the diagnosis and prognosis were made? 
g. If you discussed the diagnosis with the child, what was the child’s reaction? 
h. If you discussed the prognosis with the child, did you explain him/her the chances of 
getting better? 
i. If you did not discuss the prognosis with the child, why not? 
j. Who initiated this discussion related to diagnosis and prognosis with the parents and/or 
the child? How did you feel during the discussion? 
k. Can you explain a little more the circumstances and content of these discussions? 
 
2. Treatment options, discussions, and decision making 
a. What were the treatment options? 
b. Who did you discuss the treatment options with? 
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c. How did you describe the treatment options to the child and/or the parents?* 
d. How comfortable did you feel discussing treatment options? Please explain. 
e. Are alternative treatments available for this case? Please explain.  
f. What were the clinically reasonable choices? 
g. Did you discuss the pros and cons of the choices? Why and why not? 
h. In your opinion, how well did the child and/or the parent understand the treatment 
options you provided them with?* 
i. Were these discussions carried out with the child and/or the parent? Please specify 
with whom (if child excluded, explain why). 
j. What treatment options were selected? 
k. Who was involved in the decision making process? 
l. How were decisions made about the child’s illness and treatments? (e.g., what were 
the important issues discussed, how were the opinions of those involved heard, and 
how was consensus formed.) 
m. To what extend was the child involved? Please provide reasons for extending 
involvement or non-involvement. 
n. How engaged were you in these decisions? 
o. Were your opinions and expertise invited? How comfortable did you feel with that? 
p. Were you satisfied with these discussions? 
q. Please explain what factors contributed to greater or lower satisfaction. 
r. Would you change anything retrospectively? e.g. Is there anything in your opinion 
that would have made these discussions more beneficial? 
 
3. Inclusion or Exclusion of child in discussion: The following questions relate to the 
capacity of children to make decisions on behalf of their health and medical treatment, in 
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particular if they are severely ill. In society there is a debate about whether and how much 
children or minors should be involved and given the right to make decisions. We, therefore, 
would like to gather your opinion on this topic. 
 
a. In your previous response, you stated that the child, i.e., patient, was present (absent) 
during treatment discussions. Could you explain the reasons for this? 
b. Why do you think it was necessary/appropriate to include (exclude) the patient from 
these treatment decisions? 
c. Under what conditions would you absolutely include (exclude) patients in such 
discussions? Please explain these conditions. 
d. Generally, when parents include (exclude) their child from making or taking part in 
such decisions, what kind of reasons, for example values and attitudes, do they give you? 
e. In your opinion, should this child be included in decision making. Explain why or 
why not. 
f. In your opinion, what role should the parents play in making decision? 
g. In your opinion, should children in general, be allowed to make health care related 
decisions? Please explain your perspective. 
• Would your response be the same or different based on the following: 
o Age of the child: younger than 8 years or older than 8 years (or 
another age limit?) 
o Type and seriousness of the disease: terminal or non-terminal 
o Behavior of the child 
o Your religion or personal or professional beliefs 
 
****************************THANK YOU***************************** 
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Dear Physician: We thank you for taking the time to complete the following. 
 
Physician demographic Information:         
f. Age:      ___________   Year of Birth:      _____________  
g. Sex:    Male   Female 
h. Nationality:  Romanian    Other –  ______________________ 
Country of origin:      _____________ 
i. Languages spoken:   Romanian      Hungarian   
      German       English   
      French    
      Other (specify):      _______________________ 
j. Marital Status:   Married       Divorced    Widowed   
     Never Married    
     Other – Specify       ___________________________ 
k. Medical Specialty:      ____________________________________________ 
l. Years of experience in pediatric oncology:   
    0 – 4 years     5 – 8 years  
    9 – 12 years  More than 12 years 
m. Religion:   Orthodox  Catholic   Protestant     
    Other (specify):      ____________________________________ 
 
 
****************************THANK YOU***************************** 
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Titlul Proiectului: 
Titlul original în engleză: Competency and autonomy of children and adolescents in 
pediatric oncology decision making 
Titlul în română: Competenţa şi autonomia minorilor şi adolescenţilor în procesul 
decizional în oncologia pediatrică 
 
Ghid interviu pentru medicii participanti la proiect - Romanian study 
Romanian version 
 
Stimat/ă participant/ă: Vă mulţumim pentru că aţi acceptat să alocaţi din timpul 
dumneavoastră şi să participaţi la acest studiu. Aţi fost invitat/ă să participaţi la proiectul de 
cercetare denumit: “Procesul decizional la finalul vieţii: Competenţa şi autonomia 
minorilor şi adolescenţilor în oncologia pediatrică” deoarece sunteţi doctor specialist în 
cadrul unui spital universitar, clincă oncologică sau insitut oncologic din Romậnia, şi aveţi în 
îngrijire pacienţi minori care au fost diagnosticaţi cu o formă de cancer sau/şi care primesc în 
acest moment un tratament împotriva cancerului. Informaţiile pe care ni le veţi furniza au ca 
scop să ne ajute să înţelegem mai bine procesul de luare a deciziilor şi de a stimula 
dezbaterile pe tema autonomiei copiilor şi adolescenţilor cu privire la deciziile referitoare la 
starea lor de sănătate. 
 
În cursul acestui interviu, vom încerca să cunoaştem starea de sănătate a pacientului 
dumneavoastră, calitatea şi conţinutul procesului de luare a deciziilor, de a avea acces la 
informaţii referitoare la capacitatea de decizie a pacientului minor. După interviu avem 
rugămintea să acceptaţi să completaţi un scurt chestionar, ce nu va depăşi o pagină. Vă 
asigurăm că răspunsurile dumneavoastră şi mai mult decât atât, toate informaţiile şi datele 
Appendices 
 249 
furnizate vor fi tratate anonimizat şi în regim strict confidenţial. Vă mulţumim pentru că aţi 
acceptat să luaţi parte la acest studiu şi să ne răspundeţi la întrebări. 
 
*Notă personală destinată persoanei ce va conduce interviul: în ceea ce priveşte 
întrebările marcate cu *, avem rugămintea de a le adapta în funcţie de răspunsurile 
oferite anterior. Spre exemplu, în ceea ce priveşte întrebările 2b şi c, dacă informaţiile 
au fost comunicate în acelaşi timp ambelor părţi, formulaţi întrebarea 2c în consecinţă; 
în cazul în care informaţiile au fost comunicate separat celor două părţi, vă rugăm să 
reformulaţi întrebarea. 
 
1. Informaţii generale cu privire la pacient/caz: 
a. De cậnd cunoaşteţi pacientul şi familia sa? 
b. Cậnd aţi văzut pacientul pentru prima dată şi cậnd aţi pus diagnosticul? 
c. Ce vậrstă are pacientul în prezent? 
d. Care este diagnosticul şi prognosticul? 
e. Cui aţi comunicat diagnosticul şi prognosticul? Dacă pacientul dumneavaostră nu era 
prezent, vă rugăm să ne spuneţi motivele pentru aceasta. 
f. Cum au reacţionat părinţii în momentul comunicării diagnosticului şi prognosticului? 
g. Dacă aţi discutat despre diagnostic cu pacientul minor, ne puteţi spune care a fost 
reacţia sa? 
h. Dacă aţi discutat despre prognosticul bolii cu pacientul minor, ne puteţi spune dacă  
i-aţi explicat şansele de vindecare? 
i. Dacă nu aţi discutat despre prognosticul bolii cu pacientul minor, ne puteţi spune 
care sunt motivele pentru aceasta? 
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j. Cine a iniţiat discuţia cu privire la diagnostic şi prognostic cu părinţii sau/şi pacientul 
minor? Cum v-aţi simţit în timpul acestei discuţii? 
k. Puteţi să îmi descrieţi circumstanţele şi conţinutul acestei discuţii? 
 
2. Opţiuni terapeutice, discuţii şi luarea unei decizii  
a. Care au fost opţiunile terapeutice? 
b. Cu cine aţi discutat aceste opţiuni terapeutice?* 
c. Cum aţi descris opţiunile terapeutice pacientului minor/părinţilor?* 
d. V-aţi simţit în largul dumneavoastră în timpul discuţiilor cu privire la opţiunile 
terapeutice? Am rugămintea să detaliaţi. 
e. Există alternative de tratament în acest caz? Am rugămintea să precizaţi care sunt 
acestea. 
f. Care au fost opţiunile rezonabile pentru un tratament clinic? 
g. Aţi discutat despre avantajele şi inconvenientele acestei opţiuni de tratament? De ce 
da sau de ce nu? 
h. După părerea dumneavoastră, în ce măsură a înţeles pacientul minor şi/sau părinţii 
acestuia opţiunile de tratament pe care le-aţi prezentat?* 
i. Aceste discuţii au fost purtate cu pacientul minor şi/sau cu părinţii acestuia? Vă rog să 
precizaţi cine a fost prezent. Dacă pacientul minor a fost exclus de la aceste discuţii, vă 
rog să explicaţi din ce motive. 
j. Ce opţiune de tratament a fost aleasă? 
k. Cine a fost implicat în procesul de luare a acestei decizii? 
l. Cum au fost luate deciziile cu privire la boala şi tratamentul pacientului minor? (Spre 
exemplu, care au fost punctele centrale ale discuţiilor, în ce manieră s-a ţinut cont de 
părerea persoanelor prezente şi cum s-a ajuns la un consens?) 
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m. În ce măsură a fost implicat pacientul minor în aceste discuţii? Am rugămintea de a 
preciza motivele pentru care copilul/adolescentul a fost/nu a fost implicat în luarea 
deciziilor. 
n. În ce măsură aţi contribuit dumneavoastră la luarea deciziilor? 
o. Experienţa şi părerea dumneavoastră au fost solicitate? Cât de comfortabil v-aţi simţit 
în legtură cu acesta? 
p. Dumneavoastră aţi fost mulţumit/ă de rezultatul acestor discuţii? 
q. Am rugămintea să precizaţi care sunt elementele ce au contribuit la un nivel de 
satisfacţie mai mare sau mai mic în legatură cu rezultatul discuţiilor. 
r. În retrospectivă, aţi dori să schimbaţi ceva cu privire la aceste discuţii? Spre exemplu, 
există elemente care, după dumneavoastră, ar fi putut să fie benefice pentru discuţie/ ar fi 
putut-o ameliora? 
 
3. Implicarea copilului/adolescentului (sau excluderea din) în cadrul discuţiei: 
Întrebările ce urmează se referă la capacitatea pacienţilor minori de a lua decizii cu privire la 
starea lor de sănătate şi la tratamentul medical, în special cậnd suferă de o boală gravă. În 
prezent există o dezbatere în mediul medical şi public cu privire la implicarea copiilor şi/sau 
adolescenţilor în astfel de discuţii şi în ce masură aceştia au capacitatea şi posibilitatea de a 
participa la luarea deciziilor referitoare la starea lor de sănătate. Din aceste motive, ne 
interesează punctul dumneavoastră de vedere pe această temă. 
 
a. În discuţia anterioară mi-aţi spus că la discuţiile legate de tratament pacientul minor a 
fost prezent (absent). Îmi puteţi explica motivele pentru aceasta? 
b. De ce credeţi că a fost necesar sau potrivit îl implicaţi în (excludeţi din) cadrul acestor 
discuţii? 
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c. În ce condiţii aţi implica (exclude) pacientul minor din asftel de discuţii? Doriţi să 
precizaţi aceste condiţii mai detaliat, vă rog? 
d. În general, cậnd părinţii îşi implică (exclud) copiii din astfel de discuţii, care credeţi 
că sunt motivele pentru astfel de atitudini (aceste decizii)? De exemplu: ce criterii, valori 
menţioneaza ca stând la baza acestor decizii? 
e. După părerea dumneavoastră pacientul minor ar trebui să aibă dreptul de a participa la 
luarea unor decizii ce privesc starea sa de sănătate? Vă rog să precizaţi motivele 
dumneavoastră (de ce sunteţi de acord sau de ce nu?) 
f. După părerea dumneavoastră, care ar trebui să fie rolul părinţilor în cadrul procesului 
de luare a deciziilor? 
g. După părerea dumneavoastră, pacienţii minori ar trebui să aibă dreptul, la modul 
general, de a lua decizii în ceea ce priveşte starea lor de sănătate? Vă rog să explicaţi mai 
detaliat răspunsul dumneavoastră: 
• Răspunsul dumneavoastră ar fi la fel sau diferit în funcţie de: 
o Vậrsta copilului: dacă are mai puţin sau mai mult de 8 ani (sau o 
altă limită a vậrstei)? 
o Tipul şi gravitatea condiţiei medicale: (în  funcţie de şansele de 
vindecare) 
o Comportamentul copilului 
o Religia sau convingerile dumneavoastră personale 
 
****************************MULŢUMESC**************************** 
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Dragă participant/ă: Vă mulţumim în avans pentru dorinţa de a completa cheastionarul 
următor:  
 
C. Informaţiile demografice ale doctorilor: 
i. Vậrsta:       __________________ Anul naşterii:      ________________ 
j. Sex:         Masculin  Feminin 
k. Naţionalitate:  Romậnă     Alta – Ţara de origine:      __________________ 
l. Limbi vorbite:   Româna     Maghiara  Germana    Franceza 
 Engleza  Alta-precizaţi:      _________________________ 
m. Starea civilă:   Căsătorit/ă      Divorţat/ă   Văduv/ă  
    Necăsătorit/ă   Alta- Precizaţi      _____________ 
f. Specialitatea medicală:      _________________________________________________ 
g. Experienţa în oncologia pediatrică (în ani):   
   0 – 4 ani     5 – 8 ani  9 – 12 ani  peste 12 ani  
h. Religia:   Ortodoxă  Catolică   Protestantă  
 Alta- Precizaţi      ___________________________________________ 
 
 
 
 
 
 
****************************MULŢUMESC**************************** 
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Study Title: Attitudes and motives concerning end-of-life decisions: Competency and 
autonomy of children and adolescents in paediatric oncology 
 
Interview Guide for Parents – Swiss study 
English version 
 
Dear participant: Thank you for agreeing to take part in this study and for sharing your 
information with us. You are being asked to take part in the research study of “Attitudes and 
motives concerning end-of-life decisions: Competency and autonomy of children and 
adolescents in pediatric oncology“ because your child was diagnosed with cancer and/or is 
currently undergoing cancer treatment in a Swiss Pediatric Oncology Centre. We understand 
that this is a very sensitive issue and we would seek to be as considerate as possible. If you 
feel uncomfortable responding to any question, please communicate this to me. 
 
During this interview session, we would like to learn about the condition of your child and 
the quality, content, and process of decision making regarding his/her illness.  The 
information that we gain from you will help us understand decision making processes and 
contribute towards debates concerning a minors’ decision making autonomy concerning 
health care.  After the interview, we will request you to complete a very short 1 page survey. 
Please be assured that your responses and all the information/data you provide are completely 
confidential and anonymous. 
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1. Understanding the situation: 
 
a. Let me start by asking you about your family.  Could you tell me about them? 
b. Please briefly describe to me the circumstances regarding your child’s cancer 
diagnosis? 
c. How did you first come to believe that your child might have cancer? 
d. When was the diagnosis made? How old is your child now? 
e. What was the prognosis the physician gave you? 
*(Note to the Interviewer: Ask the following two questions only if the parent described 
the chances as poor.) 
1. When did you understand that the chances of cure for your child are rather low? 
2. Could you please tell me more about how you see the chances of cure for your 
child?  
 
f. Was your child present during the diagnosis discussion? Why or why not? 
(*Note: If child present, ask question g, else skip to h.) 
g. How did you feel about your child’s presence? 
h. Since the diagnosis was made, have you informed your child about the diagnosis? 
i. How did you do so? Could you tell me the words you used? For example: what 
was the first sentence you used to start the discussion? Why did you choose the 
words you chose? 
j. Did you discuss the prognosis with your child? Did you explain him/her the 
chances of cure? 
k. Who initiated this discussion? How did you feel during the discussion? 
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2. Treatment options, discussions, and decision making 
a) What were the treatment options? 
b) Who were present when treatment options were discussed? 
c) How were these treatment options described to you and/or your child by your 
physician? 
d) Were these options clearly and carefully explained to you and/or your child by 
your physician? 
e) If your child was not present during treatment discussions, have you discussed 
treatment or non-treatment options with your child? 
(*Note: if answer is no, skip to question g.) 
f. What did/do you think about this discussion with your child? 
g. What treatment options were selected? And why? 
h. How were decisions made about your child’s illness and treatment choices? 
i. Who was involved in this decision making process? 
j. To what extend was the child involved? Please provide reasons for extent of 
involvement or non-involvement. 
k. How comfortable were you with the manner and content of these discussions? 
l. Were you satisfied with these discussions? 
m. Please explain what factors contributed to greater or lower satisfaction. 
a. Would you change anything retrospectively? e.g. Is there anything in your opinion 
that would have made these discussions more beneficial? 
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3. Inclusion or Exclusion of child in discussion: The following questions relate to the 
capacity of children to make decisions concerning their health and medical treatment, in 
particular, if they are severely ill. In society there is a debate about whether and how much 
children or minors should be involved and given the right to make decisions. We, therefore, 
would like to gather your opinion on this topic.   
 
a) In your previous response, you stated that your child was present (absent) during 
treatment discussions. Could you explain the reasons for this? 
b) Why do you think it was necessary/appropriate to include (exclude) your child from 
these treatment decisions? 
c) Under what conditions would you absolutely include (exclude) your child in such 
discussions? Please explain these conditions. 
d) Generally, when parents include (exclude) children from making such decisions, what 
kind of reasons, for example values and attitudes, are associated with it? 
e) In your opinion, should children in general, be allowed to make health care related 
decisions? Please explain your perspective. 
• Would your response be the same or differ based on the following: 
o Age of the child: younger than 8 years or older than 8 years (or another 
age limit?) 
o Type and seriousness of the disease: terminal or non-terminal 
o Behaviour of the child 
o Your religion or personal beliefs 
*********************************Thank You ******************************* 
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Dear Participant:  We thank you for taking the time to complete the following. 
 
A. Demographic Information:         
n. Age:        Year of Birth:      _____________ 
o. Sex:   male   female 
p. Nationality:  Swiss        Other – Country of origin:      _______________ 
q. Languages:   German       French  Italian       
 English   Other (specify):      __________________ 
r. Marital Status:  Married       Divorced    Widowed  
    Never Married    Other – Specify      _______________ 
s. Religion:   Catholic   Protestant     
 Other (specify):      ____________________________________ 
t. Number of children:        
u. Education:   No qualification  Vocational    High School
    College Degree    University/Graduate Education   
v. Living situation:  Alone with children  with spouse and children 
    Other – specify:_________________________________________ 
 
 
 
 
 
*********************************Thank You ******************************* 
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DOMNITA OANA BADARAU 
 
Home Address: BASEL, CH-4056, Switzerland 
Work Address: Bernoullistrasse 28, BASEL, CH-4058, Switzerland 
E-mail: domnita.badarau@case.edu; do.badarau@gmail.com 
 
 
PROFILE                                                         
Professional specialized in research ethics and European and US regulatory frameworks for 
research with human participants, with expertise in compliance for (cross-cultural) clinical 
studies, with over 7 years of interdisciplinary research at the intersection of health, law and 
research, project and grant management, trained in Good Clinical Practice and research 
processes, with working experience in ethics approval, clinical study documentation, 
coordinating communication with diverse teams and clinicians, and over 2 years’ practice in 
financial and legal compliance, risk assessment and loan applications, control and 
administration. 
 
PROFESSIONAL EXPERIENCE                 
 
A. RESEARCH 
Clinical Study Coordinator / Postdoctoral Research Associate (2017 – present), Aston 
University, School of Life and Health Sciences and Aston Brain Centre; Birmingham, United 
Kingdom 
 Coordinate scientific and clinical study activities for PROBIt, a multidisciplinary study of 
children’s brain development aimed at improving clinical practice via evidence-based 
research in the area of long-term neurobehavioral outcomes prediction in children with 
brain insults 
 Project management for all study phases (from planning and design, governance, 
recruitment strategies and participant enrollment, data collection, maintenance, 
anonymization, site files and secure storage, reporting to dissemination of results) 
 Lead submissions to Health Research Authority and support ethics requirements for all 
work packages: preparing and submitting documentation, amendments, new 
applications, annual reporting and adverse event reporting 
 In charge of critical communication and collaboration with academic, clinical and 
research organizations for study related activities and science communication 
 Manage the research staff, supervise and co-supervise students 
 Plan study activities and delivery, and support the Chief Investigator in all study 
administrative and research matters, as well as the PIs at each collaborating site 
 Liaise with and act as a key contact for all study stakeholders, including the funder 
(European Research Council), Scientific Steering Committee, collaborators, clinicians, 
research team and participating families 
 Maintain records of study budget, including invoicing and ensure accuracy; study audit 
documents and supervise purchase orders/expenditures 
 Carry systematic literature searches and review scientific databases, summarize 
findings, register reviews and prepare reports and submit outputs of the study 
 Support impact activities, including collating information and disseminate to academic 
and community stakeholders 
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Honorary research staff (2017 – present), Department of Neurophysiology, Birmingham 
Women’s and Children’s NHS Foundation Trust; Birmingham, United Kingdom 
 Support and coordinate research activities (scanning sessions and cognitive 
assessments) and study recruitment/enrolment 
 Act as key contact for the PROBIt study and coordinate medical data collection and 
transfer 
 
Clinical Trials Trainee / Postdoctoral Research Collaborator (2017 – present), Department of 
Medicine, Swiss Tropical and Public Health Institute; Basel, Switzerland 
 Conduct research on legal and regulatory frameworks impacting clinical trials in 
resource constrained settings 
 Support current projects on ethico-legal issues arising from dealing with high 
uncertainty in recruitment and informed consent procedures, with a focus on pediatric 
studies 
 Data mining of scientific databases and past STPH project repositories  
 Develop a database (knowledge pool) on research ethics review processes, from 
planning to approval and implementation, including customary practices regarding 
consent; Project focused on Sub-Saharan Africa and Central Asia 
 Collaborate on study recruitment and participant documentation design 
 Conduct systematic literature searches, register reviews and submit outputs for 
dissemination (manuscripts and scientific conferences) 
 
Research Assistant (2011 – 2016), University of Basel, Institute for Biomedical Ethics (IBMB); 
Basel, Switzerland 
PROJECTS 
(1) Communication and patient involvement in pediatric oncology care in Romania (a PhD 
project conducted in Romania and Switzerland; funded by the the Botnar Stiftung, 
Switzerland) 
The study explored parents’ and physicians’ experiences in communicating with minor 
patients about their cancer diagnosis, identified barriers to diagnosis disclosure and 
examined the different ways children and adolescents are supported or hindered to 
participate in their care. Qualitative interviews were employed for data collection. 
(2) Attitudes and motives concerning end-of-life decisions: Competency and autonomy of 
children and adolescents in pediatric oncology (prospective 3 years project funded by 
the Swiss National Science Foundation (SNSF), Switzerland ) 
The study investigated parents’ and oncologists’ attitudes and practices on minor 
patients’ involvement in care. Children’s and adolescents’ views on their inclusion 
during treatment for cancer were also examined. Data were collected in the German, 
French and Italian-speaking parts of Switzerland through quantitative surveys and 
qualitative interviews. 
RESPONSIBILITIES 
1. Conduct research in the area of pediatric oncology and ethics 
 Project management for all study phases (from planning, participant enrollment, data 
collection, maintenance, de-anonymization, secure storage, analysis to dissemination) 
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 Managed ethics approval – preparation of study documentation: writing informed 
consent documents, participant information sheets, and monitoring of all documents 
 Performed study monitoring and reporting, including to funding agencies and ethics 
committees 
 Designed and implemented a study in university hospitals in Romania (PhD project) 
 Co-investigator for a Swiss-wide study in 8 cantons (German, French and Italian); 
collaborated in study design and implementation 
 Conducted 28 one-on-one in-depth interviews with research subjects 
 Advised on building questionnaires, interview guides and participant information sheets 
and reviewed them 
 Developed and expanded collaborations with physicians/clinics; ensured 
communication with 11 clinical institutions, collaborating researchers and diverse 
organizations (funding agencies, compliance institutions) 
 Drafted/edited and translated reports, research and other documents from English to 
French 
 Disseminated research findings in scientific publications – 7 original articles – and 
presented findings at international conferences, professional meetings 
2. Advise on and support for diverse research studies 
 Advised on study design/protocols, ethics issues for projects in public health, fertility 
preservation, pediatric palliative care and prisoner health issues 
 Reviewed grant proposals and PhD projects 
 Performed peer-review of scientific manuscripts, conference abstracts, commentaries 
authored by colleagues 
 
COMMUNICATION AND RESEARCH ETHICS TRAINING 
1. Manage teaching activities  
 Developed and taught courses and one-day trainings in compliance, research ethics 
and clinical ethics (Medical Faculty, University of Basel) 
 Evaluated and commented on students’ research presentations on public health 
 Tutored students in the Medical and Science Faculties on research legal regulations for 
research with human subjects and ethical principles 
2. Coordinate courses and public lectures on research compliance and ethics 
 1 elective semester course, 2 lecture visits and workshops for Prof. Sana Loue (US) and 
Prof. Ezekiel Emanuel (former director of NIH Department of Bioethics, US) 
 Co-organization of the 27th European Conference on Philosophy of Medicine and 
Healthcare (ESPMH), (August 2013) 
 
NIH Fogarty International Fellow (August 2010 -  January 2012) 
Case Western Reserve University, School of Medicine; Cleveland, United States 
1. Research ethics 
 Participated in and observed daily activities of regulatory bodies (Institutional Review 
Boards and ethics committees’ meetings); drafted post-meeting reports 
 Revised, improved quality and reduced readability of informed consent documents and 
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participant recruitment tools 
 Performed critical methodological, ethical and legal analysis of clinical trials (focus on 
research in African countries) 
2. Clinical ethics expertise 
 Performed participatory observational work and shadowed medical round in various 
medical units within Case Medical Center network (100 hours) to train and gain 
expertise in clinical ethics 
 Participated in clinical case consultation as an observer and performed patient case 
analysis / drafted final reports 
 Compiled notes from medical rounds  and ethics committees meetings 
 
B. Legal and business sector 
Legal, Control and Administrative Support Officer for small and medium enterprises 
(December 2008 – July 2010) 
Raiffeisen Bank S.A., member of Raiffeisen Zentralbank Oesterreich (RZB); Romania 
 Coordinated communication and carried out credit approvals by preparing and 
ensuring documentation compliance with Risk, Control and Admin Departments’ 
regulations 
 Managed the department’s client portfolio by supporting and assisting the 
Relationship Manager in loan application processes 
 Offered legal advice and law interpretation to internal departments 
 
Junior Relationship Manager (March 2008 – December 2008) 
Raiffeisen Bank S.A., member of Raiffeisen Zentralbank Oesterreich (RZB); Romania 
 Trainee in banking operations, sales, financing and legal-financial analysis of 
documents for submitting loans applications to the Risk Department  
  
Education                    
2012 – 2016 Doctoral studies in medical sciences (PhD) 
Institute For Biomedical Ethics, University of Basel, Basel, Switzerland 
Supervisors: Prof. Bernice S Elger, MD; Tenzin Wangmo, PhD; Prof. Thomas 
Kühne, MD; Prof. Sana Loue, PhD 
2010 – 2011 
 
 
2008 – 2009 
 
 
2004 – 2008 
 
 
 
2004 – 2009 
MA in Bioethics 
Case Western Reserve University, School of Medicine, Department of 
Bioethics, United States 
MIB, International Commerce 
Faculty of Economics and Business Administration, Al. I. Cuza University, 
Romania 
Bachelor of Economics and Business Administration, specialization in 
International Economic Relations 
Faculty of Economics and Business Administration, Al. I. Cuza University, 
Romania 
Bachelor of Law 
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September 
2007 – 
February 2008 
Faculty of Law, Al. I. Cuza University, Romania 
Erasmus student in the Lifelong Learning Programme 
Faculty of Economics IQS, Ramon Llull University, Barcelona, Spain 
 
Relevant trainings, workshops and seminars                        
November 2015 
 
April 2015 
 
October 2014 
 
June 2014 
 
August 2013 
 
April 2013 
 
October 2012 
 
Zürich Intensive Ethics Course, University Hospitals Zürich, University of 
Zürich, Harvard Medical School, Zürich, Switzerland 
Research Methods in Bioethics – Data analysis, University of Basel, 
Switzerland 
ESO/SEMM Master in Ethical Counseling in Oncology, European School 
of Molecular Medicine, Milan, Italy 
Qualitative methods course for bioethicists. Summer School– University 
of Zürich, Zürich, Switzerland 
Summer School Lugano - Advanced Methods in the Social Sciences, 
University of Lugano, Lugano, Switzerland 
Advanced Research Methods in Bioethics – specialized topics, University 
of Basel, Basel, Switzerland 
Health Systems, Swiss Tropical Public Health Institute, Basel, Switzerland 
Consulting                                                             
2015 
 
Consultant for evaluation of participant/patient research documents with 
Center for Information and Study on Clinical Research Participation 
(CISCRP), US 
 
Professional Affiliations, Special Appointments, Grants                       
2017 – onward 
 
2012 – 2016 
2015 – 2016  
2015 
 
2010 – 2012 
 
2007 – 2008 
 
Member of the Editorial Board of the Journal of Immigrant and Minority 
Health,  Springer Science+Business Media New York 
Hemmi Stiftung, Basel, Switzerland 
Botnar Stiftung, University of Basel, Switzerland 
ANTELOPE career-program for young female researchers, University of 
Basel, Switzerland 
Fogarty Fellowship, International Research Ethics Training Program, 
Fogarty International Center, National Institutes of Health, US 
Erasmus scholarship, Erasmus LLP, Ramon Llull, Barcelona, Spain, 
awarded by the European Union 
 
Publications                                                       
A. Peer-reviewed articles 
1) Domnita O Badarau, Eva De Clercq, Bernice S Elger (2019). Continuous deep sedation 
and euthanasia in pediatrics. Does one really exclude the other for terminally ill 
patients? The Journal of Medicine and Philosophy 
2) Domnita O Badarau, Katharina M Ruhe, Thomas Kühne, Eva De Clercq, Anca Colita, 
Bernice S Elger, Tenzin Wangmo (2017). Decision making in pediatric oncology: Views of 
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parents and physicians in two European countries. AJOB Empirical Bioethics 
3) Domnita O Badarau, Eva De Clercq, Tenzin Wangmo, Monica Dragomir, Ingrid Miron, 
Thomas Kühne, Bernice S Elger (2016). Cancer care in Romania: challenges and pitfalls of 
children’s multifaceted involvement. Journal of Medical Ethics 
4) Katharina M Ruhe, Tenzin Wangmo, Eva De Clercq, Domnita O Badarau, Marc Ansari, 
Thomas Kühne, Felix Niggli, Bernice S Elger; Swiss Pediatric Oncology Group (2016). 
Putting patient participation into practice in pediatrics – Results from a qualitative study 
in pediatric oncology. European Journal of Pediatrics 
5) Tenzin Wangmo, Katharina M Ruhe, Domnita O Badarau, Thomas Kühne, Felix Niggli, 
Bernice S Elger; Swiss Pediatric Oncology Group (2016). Parents’ and patients’ 
experiences with pediatric oncology care in Switzerland – Satisfaction and some hurdles. 
Swiss Medical Weekly 
6) Katharina M Ruhe, Domnita O Badarau, Pierluigi Brazzola, Heinz Hengartner, Bernice S 
Elger, Tenzin Wangmo; Swiss Pediatric Oncology Group (2016). Participation in pediatric 
oncology: views of child and adolescent patients. Psycho-Oncology 
7) Domnita O Badarau, Tenzin Wangmo, Katharina M Ruhe, Ingrid Miron, Anca Colita, 
Monica Dragomir, Jan Schildmann, Bernice S Elger (2015). Parents’ challenges and 
physicians’ tasks in disclosing cancer to children. A qualitative interview study and 
reflections on professional duties in pediatric oncology. Pediatric Blood & Cancer 
8) Katharina M Ruhe, Tenzin Wangmo, Domnita O Badarau, Bernice S Elger, Felix Niggli 
(2015). Decision-making capacity of children and adolescents - suggestions for 
advancing the concept's implementation in pediatric healthcare. European Journal of 
Pediatrics 
9) Eva De Clercq, Domnita O Badarau, Katharina M Ruhe, Tenzin Wangmo (2014). Body 
matters: rethinking the ethical acceptability of non-beneficial clinical research with 
children. Medicine, Health Care and Philosophy 
10) Katharina M Ruhe, Domnita O Badarau, Bernice S Elger, Tenzin Wangmo (2014). End-of-
Life decision making in pediatrics: Literature review on children's and adolescents' 
participation. AJOB Empirical Bioethics 
B. Abstract(s) 
1) Domnita O Badarau, Anca Colita, Monica Dragomir, Bernice S Elger, Thomas Kühne, 
Ingrid Miron, Felix Niggli, Katharina M Ruhe, Tenzin Wangmo (2014). Decision-making 
for children following a cancer diagnosis – Preliminary findings from a qualitative study 
with parents and oncologists. Pediatric Blood & Cancer (Supplement S2) 
C. Book chapter(s) 
Domnita O Badarau, Beatrice G Ioan (2013). Forensic Epidemiology in the Romanian Legal 
System. In S. Loue (Ed.), Forensic Epidemiology in the Global Context (pp. 79-98): Springer 
New York 
D. Commentary and Encyclopedias 
1) Domnita O Badarau, Rebecca L Nast, David M Shaw (2014). The vulnerability of the 
individual benefit argument. American Journal of Bioethics 
2) Domnita O Badarau (2013). Declaration of Helsinki. In S. Loue (Ed.), Mental Health 
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Practitioner's Guide to HIV/AIDS. Springer New York 
3) Domnita O Badarau (2013). Disclosure Laws. In S. Loue (Ed.), Mental Health 
Practitioner's Guide to HIV/AIDS. Springer New York 
4) Domnita O Badarau (2013). Economic Impact. In S. Loue (Ed.), Mental Health 
Practitioner's Guide to HIV/AIDS. Springer New York 
5) Domnita O Badarau (2013). Human Trafficking. In S. Loue (Ed.), Mental Health 
Practitioner's Guide to HIV/AIDS. Springer New York 
6) Domnita O Badarau (2013). Informed Consent. In S. Loue (Ed.), Mental Health 
Practitioner's Guide to HIV/AIDS. Springer New York 
7) Domnita O Badarau (2013). World Trade Organization. In S. Loue (Ed.), Mental Health 
Practitioner's Guide to HIV/AIDS. Springer New York 
8) Domnita O Badarau (2012). Asylum. Encyclopedia of Immigrant Health, Springer  
Science+Business Media, LLC, USA 
9) Domnita O Badarau (2012). Brain Drain. Encyclopedia of Immigrant Health, Springer 
Science+Business Media, LLC, USA 
10) Domnita O Badarau (2012). Ghetto. Encyclopedia of Immigrant Health, Springer 
Science+Business Media, LLC, USA 
11) Domnita O Badarau (2012). Guest Worker. Encyclopedia of Immigrant Health, Springer 
Science+Business Media, LLC, USA 
12) Domnita O Badarau (2012). Hague Convention on Child Abduction. Encyclopedia of 
Immigrant Health, Springer Science+Business Media, LLC, USA 
13) Domnita O Badarau (2012). Labor. Encyclopedia of Immigrant Health, Springer 
Science+Business Media, LLC, USA 
 
Presentations                                                             
A. Invited oral presentations  
1) Domnita O Badarau (2016). What to consider when breaking bad news? Ethical 
challenges in communication in pediatric oncology, 12th International Bernd-Spiessl-
Symposium, University Hospitals Basel, Switzerland 
2) Domnita O Badarau (2015). Between finding their voice and giving children a voice. 
Parental struggles in pediatric oncology. Case Western Reserve University, School of 
Medicine, Department of Bioethics, Cleveland, US 
B. Oral presentations 
3) Katharina M Ruhe, Eva De Clercq, Domnita O Badarau, Bernice S Elger, Tenzin Wangmo 
(2015). Competency and autonomy of children and adolescents in pediatric oncology. 
SPOG Scientific Meeting, Lugano, Switzerland  
4) Katharina M Ruhe, Domnita O Badarau (2014). Competency and autonomy of children 
and adolescents in pediatric oncology. A study update. SPOG Scientific Meeting, Lugano, 
Switzerland 
5) Domnita O Badarau, Anca Colita, Katharina M Ruhe, Tenzin Wangmo, Bernice S Elger 
(2013). Competency and autonomy of children and adolescents in pediatric oncology 
decision-making. The 4th EBMT Training Course for Paediatricians and Paediatric Nurses 
on HSCT in Children and Adolescents: Interactive Educational EBMT PDs Course; 
ESH.EBMT, Bucharest, Romania 
CV D Oana Badarau 
 268 
6) Katharina M Ruhe, Domnita O Badarau, Tenzin Wangmo, Bernice S Elger (2013). 
Behandlungsentscheidungen in der pädiatrischen Onkologie und die Einbeziehung von 
Kindern und Jugendlichen – Vorläufige Ergebnisse einer qualitativen Studie mit 
Patienten und Eltern. Fachtagung Psychoonkologie, St. Gallen, Switzerland 
7) Katharina M Ruhe, Domnita O Badarau, Bernice S Elger, Tenzin Wangmo (2013). The 
inclusion of children in decision-making at the end-of-life: A review of the literature. 
European Association of Centers of Medical Ethics Annual Conference, Bochum, 
Germany 
8) Domnita O Badarau, Tenzin Wangmo, Katharina M Ruhe, Anca Colita, Bernice S Elger 
(2013). Is it ethically justifiable to involve children in non-therapeutic research? 
Bioethics, Medical Ethics & Health Law. Towards the 21st century, Naples, Italy 
C. Poster presentations  
9) Domnita O Badarau, Anca Colita, Monica Dragomir, Bernice S Elger, Thomas Kühne, 
Ingrid Miron, Felix Niggli, Katharina M Ruhe, Tenzin Wangmo (2014). Decision-making 
for children following a cancer diagnosis – Preliminary findings from a qualitative study 
with parents and oncologists. SIOP, Toronto, Canada 
10) Katharina M Ruhe, Domnita O Badarau, Bernice S Elger, Felix  Niggli, Thomas Kühne, 
Tenzin Wangmo (2013). Children’s and Adolescents’ Experiences in Pediatric Oncology 
Treatment Decision Making. 15th World Congress of Psycho-Oncology and Psychosocial 
Academy, Rotterdam, Netherlands 
11) Domnita O Badarau, Katharina M Ruhe, Tenzin Wangmo, Bernice S Elger (2013). Blurred 
lines in pediatric oncology. National Research Conference on Palliative Care, Swiss 
Academies of Arts and Sciences, Bern, Switzerland 
12) Katharina M Ruhe, Tenzin Wangmo, Domnita O Badarau, Bernice S Elger (2013). 
Physicians’ attitudes towards patient participation in decision making in the pediatric 
oncology setting and their assessment of competency-Preliminary findings from a 
qualitative study. European Cancer Conference, Amsterdam, Netherlands 
13) Domnita O Badarau, Bernice S Elger, Thomas Kühne, Tenzin Wangmo (2012). Acute and 
chronic pain management: An issue of concern in pediatric oncology. 80th Annual 
Meeting, Swiss Society of General Internal Medicine, Basel, Switzerland 
14) Tenzin Wangmo, Domnita O Badarau, Bernice Elger (2012). Children’s autonomy in 
making medical end-of-life decisions. Thinking Ahead – 11th World Congress of 
Bioethics, International Association of Bioethics. Rotterdam, The Netherlands 
 
Teaching                           
39429-01: 1h presentation on “Legal and ethical aspects of capacity in minor patients” as 
part of the Contemporary Debates in Bioethics lecture series on Reproductive 
ethics (Spring 2013) 
Course coordinator of the Contemporary Debates in Bioethics lecture series, IBMB, 
University of Basel (Spring 2012) 
Group seminar: Co-tutor for the Health, Personal Responsibility, Social 
Exclusion/Lebenszyklen, Medical School, University of Basel (Spring 2013) 
Small-group seminar: co-tutor in the Psychology-Ethics-Law (PoT Problem oriented 
Tutoring)/Psyche-Ethik-Recht (PER I), Medical School, University of Basel (Spring 
2012) 
30209-01: commentary on research presentation in the course Ethics in Biomedical and 
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Public Health Research, IBMB, University of Basel (Spring 2012) 
10423-01: Tutor for the Introduction to ethics/Grundlagen der Ethik, Bio- and 
Pharmacology Faculty, University of Basel (Spring 2012) 
Small-group seminar: organization and tutor in the Body, Subject, Environment/Körper, 
Subjekt, Umwelt block course, Medical School, University of Basel (Fall 2011) 
28724-01: 2h presentation as part of Biomedical Ethics seminar, IBMB, University of Basel 
(Fall 2011) 
 
Languages                                            
English - Proficient    German - Intermediate 
Spanish - Proficient   French - Intermediate  
Romanian - Native  Italian - Elementary 
 
RESEARCH INTERESTS                            
Research ethics and pediatric clinical trials, MRI pediatric research, pediatric ethics, parental 
experiences, child and adolescent participation in care, communication in pediatric 
oncology, decision making, (international) research ethics, cultural sensitivity 
 
Interests                                                                     
 Reviewer for international scientific journals (Journal of Immigrant and Minority Health, 
Journal of Pediatric Nursing, Journal of Empirical Research on Human Research Ethics). 
 French classes and visiting international development projects in in Burkina Faso, West 
Africa, in 2016-2017. 
 Volunteer with local Basel organization (OESA) for the Kid’s Playgroup at a center for 
asylum seekers, Switzerland; working with children from Congo, Syria, Afghanistan, Iraq. 
 Volunteer with regional group (NEOhcn) to serve disadvantaged communities in a city 
with diverse racial make-up, Cleveland, US. 
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